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ABSTRACT 
The cellular form of the prion protein (PrPC) has been widely investigated since its alternative folded 
isoform is the causative agent of prion disorders. PrPC is highly expressed in the nervous system, where it 
is involved in many physiological processes such as the maintenance of peripheral nervous system (PNS) 
myelination. A similar role in the central nervous system (CNS) is still controversial, since PrPC absence 
affects proliferation and maturation of oligodendrocyte precursor cells without affecting myelination. 
On the other hand, PrPC is involved in metal homeostasis and modulates oxidative stress, two processes 
influencing myelin formation and maintenance. In light of these considerations, we took advantage of 
wild-type (WT, Prnp+/+) and PrPC knock-out (KO, Prnp0/0) mice to  investigate PrPC role in CNS 
myelination. Myelin composition was examined in mouse brains at different developmental stages, from 
early postnatal days to aging, through cholesterol content measurement and through myelin protein 
and gene expression evaluation. Furthermore, peripheral myelin status was also investigated in the 
sciatic nerve (SN) in order to have a comparative analysis between the CNS and PNS myelin. Finally, an 
ex vivo model based on organotypic hippocampal cultures (OHC) was established to better investigate 
PrPC role in CNS myelin. 
Concerning the PNS, most of our results are consistent with the PNS myelin degeneration observed in 
literature. Accordingly, results show a 50% decrease in SN cholesterol content, a strong reduction of 
myelin genes transcription and an altered expression level of some myelin proteins during Prnp0/0 mouse 
aging. Moreover, some changes in the early postnatal period were also detected. Focusing on the CNS, a 
small reduction in cholesterol content was observed at postnatal day 1 and in aging brains of Prnp0/0 
mice, suggesting an alteration in CNS myelin status. Differently from PNS, CNS myelin proteins are 
slightly upregulated in Prnp0/0 brains during the whole life. In particular, in Prnp0/0 brains a higher 
amount of myelin proteolipid protein, myelin basic protein, myelin oligodendrocyte glycoprotein and 
the glycosylated form of myelin associated glycoprotein was detected. This myelin protein upregulation 
correlates with a higher gene expression in Prnp0/0 mouse brains. To better investigate PrPC role in CNS 
myelination, an ex vivo model based on OHC was established. In accordance with in vivo experiments, 
after 28 days in vitro the amount of myelin proteins and myelin gene expression is higher in Prnp0/0 than 
in Prnp+/+ OHC. Furthermore, the copper chelator cuprizone (CZ) was administered to OHC to investigate 
its effect in PrPC presence or absence. CZ treatment did not trigger the expected myelin degeneration. 
12 
 
Differently it induced an increase in myelin protein percentage particularly in Prnp+/+ OHC, while the 
effect on Prnp0/0 OHC was milder. Thus, different response of Prnp+/+ and Prnp0/0 OHC to CZ exposure 
denotes a distinct CNS susceptibility to this kind of stimulus in the presence or absence of PrPC. 
Altogether, these results support the hypothesis that PrPC is involved in CNS myelination, although in a 
different manner compared to the PNS. In fact, the differences observed in CNS lipid composition, 
protein expression and gene transcription are less pronounced compared to PNS, but are extended for 
the whole lifetime. Since electron microscopy on CNS myelinated regions did not show gross 
morphological changes between Prnp+/+ and Prnp0/0 mice, it is possible that myelin protein 
overexpression could be the result of a compensatory mechanism to prevent functional abnormalities. 
Furthermore, since PrPC plays neuroprotective roles, it is possible that it could protect myelin under 
stress conditions.  
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INTRODUCTION 
Neurodegenerative diseases are incurable and debilitating conditions leading to progressive loss of 
nerve cells and affecting movement (ataxia) or mental functions (dementia). With the global population 
aging, an ever-increasing number of people will be afflicted with neurodegenerative diseases. The World 
Health Organization predicted that neurodegenerative diseases will overtake cancer and become the 
second leading cause of death after cardiovascular disease by 2040. Because of their enormous social 
and economic implications, neurodegenerative diseases are considered a public health priority. Despite 
many efforts, the molecular mechanisms responsible for the pathophysiology of these disorders are still 
elusive. Several neurodegenerative diseases share common features, such as aberrant protein folding 
and aggregation, alterations in protein degradation pathways, mitochondrial dysfunction, compromised 
axonal transport processes and induction of cell death mechanisms (Jellinger 2010). Among them, 
oxidative or metabolic stress has an important role in the pathogenesis of neurodegenerative diseases 
(Bush 2000, Singh, Singh et al. 2010).  Altered metal-protein interactions were proposed to be the 
causative mechanism for certain disorders  like Alzheimer’s disease (AD), familial amyotrophic lateral 
sclerosis (fALS) Creutzfeldt-Jakob disease (CJD) (Bush 2000) (Table 1). These aberrant metal-protein 
interactions likely generate microanatomical stress, thus damaging the cell site where this event occurs.  
Table 1. List of the neurodegenerative diseases that share the same molecular pathogenic mechanism, where the abnormal 
metal ion interaction with a protein target is the common neurochemical denominator (Bush 2000).  
PRION DISEASES 
Among neurodegenerative diseases, prion disorders are biologically and pathologically interesting since 
they manifest as sporadic, genetic and infective diseases (Prusiner 2001). Prion diseases, also called 
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transmissible spongiform encephalopathies (TSE), are a group of rare, progressive and fatal 
neurodegenerative disorders affecting both humans and animals. TSE include bovine spongiform 
encephalopathy (BSE) in cattle, scrapie in ovine, chronic wasting disease (CWD) in deer, moose and elk, 
and Kuru, Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI) and Gerstmann, Sträussler and 
Scheinker syndrome (GSS) in humans (Table 2) (Aguzzi, Heikenwalder et al. 2004).   
 
Table 2. List of prion diseases of human and animals (Aguzzi, Heikenwalder et al. 2004) 
Although TSE affect primarily the nervous system, the clinical features can vary according to the 
different TSE forms. These differences regard the etiology, the incidence of the disease, the brain region 
affected by replicating prion deposits, the manifested clinical symptoms and the disease time-course 
(Prusiner 1992, Prusiner and DeArmond 1994). Despite these differences, all TSE share some 
pathological traits such as scrapie prion protein (PrPSc) deposition, synapse and dendritic spine loss, 
spongiform vacuolation, brain inflammation with diffused astrocytic gliosis and neuronal death (Figure 
1) (Soto and Satani 2011). 
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Figure 1. Multiple neurodegenerative pathways are implicated in TSEs (Soto and Satani 2011). Abnormalities in the brain of 
infected individuals include the accumulation of PrP
Sc
 deposits, synaptic damage and dendrite loss, spongiform degeneration, 
brain inflammation and neuronal death.  
PRION PARADIGM 
The term “prion” was introduced by Stanley B. Prusiner in 1982 and stands for “proteinaceous infectious 
particle”, to underline the exclusively proteinaceous property of this infective agent causing prion 
diseases (Prusiner 1982). While the scrapie agent was resistant to nucleic acid inactivation (Alper, Cramp 
et al. 1967), the infectivity of inoculated brain extracts was reduced after proteolytic treatments. 
Therefore, prion transmission and propagation occur without requiring nucleic acids. The so-called 
“protein-only hypothesis” challenged the central dogma of biology: even proteins and not only DNA and 
RNA could store and propagate biological information. The identification of the protein responsible for 
TSE revealed that this protein was encoded by an endogenous cellular gene (Prnp in mouse 
chromosome 2 or PRNP in human chromosome 20), whose translational product was called cellular 
prion protein (PrPC) (Oesch, Westaway et al. 1985). Prions are the product of posttranslational 
conformational changes converting PrPC into the disease-associated infectious form PrPSc. The two 
isoforms, PrPC and PrPSc, show different biochemical properties. While PrPC is mainly -helical folded 
(40% -helix, 3% -sheet), PrPSc is highly enriched in -sheet structures (30% -helix, 45% -sheet) 
(Caughey, Dong et al. 1991, Gasset, Baldwin et al. 1993). Genetic forms of TSE depend on mutations 
occurring in PrP encoding gene, which alter protein folding and stability promoting its conversion to the 
scrapie form. In infective forms of TSE, a preformed PrPSc-aggregate directly triggers the conversion of 
endogenous PrPC. In sporadic disease, PrPC tertiary structure is likely perturbed by environmental 
conditions favoring PrPSc formation. However, the biochemical and environmental events responsible 
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for sporadic TSE are still unclear (Prusiner 1991, Prusiner 1994, Caughey 2003, Budka, Head et al. 2011, 
Benetti and Legname 2015).  
PRION NEUROTOXICITY 
The mechanism underlying prions damage on CNS remains unknown. Given its accumulation in the brain 
and its ability to transmit fatal neurodegenerative conditions, PrPSc was generally assumed to be the 
neurotoxic specie, proposing a gain-of-toxic-function mechanism. However, PrPSc itself is not sufficient 
for the disease progression, but the presence of the cellular prion protein is also required. Accordingly, 
PrP KO mice inoculated with PrPSc did not show any neurotoxic effect (Bueler, Aguzzi et al. 1993). 
Besides, the accumulation of PrPSc within PrPC-expressing tissue grafted into the brains of PrPC-null mice 
does not damage the neighboring PrPC-null tissue (Brandner, Isenmann et al. 1996). It was observed that 
PrPC removal from cell membrane inhibited neurotoxicity (Chesebro, Trifilo et al. 2005). Interestingly, in 
vivo PrPC ablation during the neurotoxic phase of prion replication reversed prion pathology leading to a 
hypothetical switch off of PrPC expression as a cure of prion diseases (Mallucci, Dickinson et al. 2003). 
Recently, it has been suggested that prion replication is dissociated from neurotoxicity (Halliday, 
Radford et al. 2014). This hypothesis is supported by the discovery of subclinical states of prion 
infection, characterized by experimental animals that were asymptomatic carriers of infectivity, but 
never develop clinical disease throughout their lifespan (Hill and Collinge 2003). On the other hand, the 
lack of striking phenotypes and the absence of neurodegeneration and spongiform changes in the brain 
of PrP KO mice argue the loss-of-function hypothesis (Bueler, Fischer et al. 1992, Mallucci, Ratte et al. 
2002). Therefore, it is still under debate whether prion toxicity is due to a gain-of-function of oligomeric 
species, to a loss-of-function of PrPC or to a combination of the two. To answer these questions, PrPC 
physiological function needs to be understood. 
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THE CELLULAR PRION PROTEIN 
The cellular prion protein, PrPC, is an endogenously encoded protein with a molecular weight of 35-36 
kDa. As described in Figure 2, it is a sialoglycoprotein attached to the outer leaflet of the plasma 
membrane via a C-terminal GPI anchor (Stahl, Borchelt et al. 1990, Caughey and Baron 2006).  
Figure 2. Mature form of the cellular prion protein, PrP
C
. PrP
C
 is a GPI-anchored membrane protein, with a flexible, random 
coil N-terminus and a globular C-terminal domain. The N-terminal domain of PrP
C
 contains octapeptide repeats (in light blue), 
which can bind divalent cations such as copper ions. The C-terminal domain of PrP
C
 contains three alpha-helices (in pink) and an 
antiparallel β-pleated sheet formed by two β-strands (in yellow). PrP
C
 can be found non-, mono-, or diglycosylated forms 
(Caughey and Baron 2006). 
PrPC precursor protein contains two signal peptides: the N-terminal targets the protein to the 
endoplasmic reticulum (ER), while the C-terminal sequence is essential for the addition of the GPI 
moiety (Figure 3). Following the precursor protein proteolytic processing in the ER and Golgi, most of 
mammalian PrPC is exported to the cell surface as a mature protein of 208-209 amino acids (Stahl, 
Borchelt et al. 1987). Mature PrPC contains two domains: the unfolded N-terminal domain and the 
folded C-terminal domain. The N-terminal domain is unstructured and contains charateristic octapeptide 
repeats (OR) and two positively charged clusters, CC1 and CC2. The C-terminal domain presents three -
helices and two -sheets. It contains a disulfide bridge linking Cys178 and Cys213 (mouse numbering) 
and two glycosylation sites. PrPC can be expressed as un-, mono- or di-glycosylated form, depending on 
glycosylation level at Asn180 and Asn196 residues (Haraguchi, Fisher et al. 1989). N- and the C-terminal 
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domains are linked by a hydrophobic amino acidic stretch, also named hydrophobic core (HC) (Zahn, Liu 
et al. 2000) (Figure 3).  
Figure 3. Mouse prion protein scheme.This protein is anchored to the cell membrane by a glycosylphosphatidylinositol (GPI) 
anchor. The signal peptide for entry into the endoplasmic reticulum and the GPI signal peptide are cleaved before the protein 
reaches the cell surface. Glycosylation can occur on one, two or none of the Asn residues indicated. A hydrophobic region 
envelops a cleavage point (N-terminal cleavage) where the protein is cleaved during normal metabolic breakdown. A disulfide 
bridge links two regions of the protein that form separate -helices in the three dimensional structure of the protein. The 
complete octameric repeats can bind up to four copper atoms, most mammals also have an incomplete repeat located 
upstream of this (Brown 2001). 
The OR region confers to PrPC one of its most salient feature that is the ability to bind divalent cations as 
copper, zinc, nickel, iron and manganese (Stockel, Safar et al. 1998, Jackson, Murray et al. 2001, Singh, 
Das et al. 2010, Arena, La Mendola et al. 2012). The OR region is composed of four sequential repeats 
(PHGGGWGQ) between residues 59-90. Residues 51-58 constitute a nonarepeat lacking the histidine 
residue (PQGGGTWGQ) (Hornshaw, McDermott et al. 1995, Brown, Qin et al. 1997). The importance of 
copper binding for PrPC physiological function is supported by the high OR homology among different 
species (Vassallo and Herms 2003). Depending on copper concentration, PrPC binds copper differently, 
passing from a multi-His binding mode at low copper levels to a single-His, amide nitrogen bond at high 
copper levels (Chattopadhyay, Walter et al. 2005, Liu, Jiang et al. 2011). The OR region cooperatively 
binds up to four copper ions with affinity of 5-8 M (Whittal, Ball et al. 2000, Kramer, Kratzin et al. 
2001). These values are compatible with the physiological copper concentration released in the synaptic 
cleft during synaptic vesicle release (15 M) and during neuronal depolarization (100-300 M) (Hartter 
and Barnea 1988). Moreover, histidines at positions 96 and 111 create a fifth high affinity copper 
binding site (10-14 M), the so called “non-OR copper-binding site” (Jackson, Murray et al. 2001, Jones, 
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Abdelraheim et al. 2004). Both the low and high occupancy copper binding mode support the reduction 
of Cu(II) to Cu(I), thus conferring PrPC the important function in protecting neurons from oxidative stress 
(Liu, Jiang et al. 2011). Despite many studies trying to understand the physiological relevance of PrPC-Cu 
binding, a defined consensus is still elusive.  
PrPC EXPRESSION AND SUBCELLULAR LOCALIZATION 
PrPC is mostly expressed in the developing and in the mature nervous system, indicating a special 
relevance of this protein for neurons. However,  PrPC is also present in many non-neuronal tissues, such 
as blood lymphocytes, gastro-epithelial cells, heart, kidney and muscles (Horiuchi, Yamazaki et al. 1995, 
Fournier, Escaig-Haye et al. 1998). According to this expression pattern, PrPC function is not limited to 
the nervous tissue. In the CNS, PrPC expression has been described in postmitotic neurons and glial cells 
(Ford, Burton et al. 2002, Steele, Emsley et al. 2006), including oligodendrocyte precursor cells (OPC), 
mature oligodendrocytes and myelin (Radovanovic, Braun et al. 2005, Bribián, Fontana et al. 2012). PrPC 
expression starts from early embryonic stages and is developmentally regulated (Mobley, Neve et al. 
1988, Lazarini, Deslys et al. 1991, Manson, West et al. 1992, Sales, Hassig et al. 2002, Benvegnu, 
Poggiolini et al. 2010). In the mouse brain, PrPC expression increases from the initial postnatal weeks till 
the end the synaptogenesis and it reaches a plateau during adulthood. The protein levels may decrease 
with aging. The distribution and the expression level vary among distinct brain regions, cell types and 
neurochemical phenotypes (Linden, Martins et al. 2008, Benvegnu, Poggiolini et al. 2010). A detailed 
analysis of PrPC expression pattern revealed that the olfactory bulb and the hippocampus, which are 
both characterized by neuronal renewal also during adulthood, show the highest PrPC expression levels 
(Sales, Hassig et al. 2002). Starting from embryonic day 18.5 (E18.5) to adult life, the hippocampus is the 
region with the earliest and highest expression of PrPC. In particular, it is highly expressed in the stratum 
lacunosum moleculare, which contains a large number of synapses and afferent fibers (Figure 4) 
(Benvegnu, Poggiolini et al. 2010). High PrPC expression was also detected in specific white matter fiber 
tracts as the hippocampal fimbria and its anatomical continuation, the fornix, the stria terminalis and 
the fasciculus retroflexus.  
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Figure 4. PrP
C
 expression in the hippocampus during development. A,B: At P7 PrP
C
 (in red; A) is detected throughout the 
hippocampus, and in particular at high levels in the stratum lacunosum-molecolare (str l m), a synapse-dense region. No signal 
for PrPC is yet detected in the cortex. A merged image is shown in B (PrP
C
, in red; neurofilament, in green; nuclei signals in 
blue). C–H: PrP
C
 is specifically and highly expressed by the fimbria of the hippocampus and the stria terminalis at P7 (C,D). The 
fimbria of the hippocampus (Fi) and the stria terminalis (St) express high level of PrP
C
 also at embryonic stages (E18.5), and 
progressively increase the level of expression during postnatal development: P1 (F), P4 (G), and P7 (H). I,J: Higher magnification 
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of longitudinal (I) and coronal (J) section of the fimbria of the hippocampus and the stria terminalis, highlighting the net 
boundaries of PrP
C
 -expression between other brain regions and these structures. Scale bars ¼ 50 lm (Benvegnu, Poggiolini et 
al. 2010). 
Concerning PrPC subcellular localization, it is widely accepted that its expression is concentrated at 
synapses, both presynaptically and postsynaptically (Fournier, Escaig-Haye et al. 1998, Sales, Rodolfo et 
al. 1998, Herms, Tings et al. 1999, Haeberle, Ribaut-Barassin et al. 2000, Moya, Sales et al. 2000, Linden, 
Martins et al. 2008). Many lines of evidence suggest that different glycoforms of the prion protein 
determine its transport along the axon to the synaptic compartment (Rodolfo, Hassig et al. 1999). 
Diglycosylated PrPC is associated to detergent insoluble rafts (Naslavsky, Stein et al. 1997). These are 
specialized plasma membrane areas enriched in cholesterol, sphingolipids and proteins, functioning in 
membrane trafficking and signalling (Simons and Ikonen 1997). Both the presynaptic and postsynaptic 
sites are enriched in lipid rafts, which are likely to organize and maintain a precise localization of 
synaptic proteins, as for example ionotropic and metabotropic glutamate receptors (Sebastiao, Colino-
Oliveira et al. 2013).  
PrP KNOCK-OUT AND TRANSGENIC MICE 
To shed light on the physiological function of PrPC, an astonishing number of KO and transgenic mouse 
lines for the Prnp gene has been generated. The first generation of KO mice with disruptive 
modifications restricted to the open reading frame, namely Prnp0/0 (Zurich I) and Prnp-/- (Edimburgh) 
showed normal development as well as no pathological signs during their lifespan (Bueler, Fischer et al. 
1992, Manson, Clarke et al. 1994). Subsequently, another three KO lines were created, namely 
NgskPrnp-/- (Nagasaki), Rcm0 and Prnp-/-(Zurich II), which revealed ataxia, loss of Purkinje cells and 
cerebellar degeneration (Sakaguchi, Katamine et al. 1996, Moore, Lee et al. 1999, Rossi, Cozzio et al. 
2001). This discrepancy between the first and second generation lines of PrP KO mice was explained 
with the discovery of a novel gene, Prnd, encoding a protein called Doppel (Dpl), which is not usually 
expressed in the brain. Prnd gene, located 16 kb downstream to Prnp, resulted to be overexpressed in 
Ngsk, Rcm0 and ZurichII, but not in ZurichI and Edimburgh (Moore, Lee et al. 1999). The accidental 
deletion of a splice acceptor site to the third exon of Prnp led to the formation of chimeric Prnp-Prnd 
transcripts, with Prnd under the transcriptional control of Prnp promoter. Thus, Dpl ectopic expression 
in the brain caused cerebellar granule ataxia and degeneration that could be rescued by Prnp gene re-
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introduction (Nishida, Tremblay et al. 1999). This latter result showed PrPC acting as an antagonist of 
Dpl, counteracting its neurotoxic effects in vivo and in vitro (Didonna, Sussman et al. 2012).  
Additionally, murine models carrying PrPC deletion mutants have been created aiming at identifying 
functionally relevant domains within the protein (Figure 5).  
 
Figure 5. Murine PrP
C
 protein and transgenic mutant PrP. Schematic drawing of full-length murine PrP
C
, with sequence for the 
signal peptide (SP) and for the GPI anchor (MA). The left column denotes the individual mutants described in this thesis. The 
right columns indicate life expectancy of the animals, presence of cerebellar neurodegeneration, CNS demyelination, PNS 
demyelination, and references. All the mutants are to be intended as expressed in a Prnp
0/0
 genetic background. n.r. = not 
reported; ** = CNS demyelination of PrPΔ105-125 mice was revealed in a Prnp
+/0
 genetic background, due to the neonatal 
lethality of the mice expressing the transgene in a Prnp
0/0 
genetic background. 1 = (Shmerling, Hegyi et al. 1998); 2 = (Bremer, 
Baumann et al. 2010); 3 = (Baumann, Tolnay et al. 2007); 4 = (Baumann, Pahnke et al. 2009); 5 = (Chesebro, Trifilo et al. 2005); 6 
= (Li, Christensen et al. 2007). Modified from (Baumann, Tolnay et al. 2007). 
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Among these transgenic mutants, Prnp0/0 mice expressing PrPC lacking amino acid residues 32-121 or 32-
134 (PrP32-121 and PrP32-134) suffer from ataxia and cerebellar granule cell loss, as well as 
widespread gliosis and demyelination in the brain stem (Shmerling, Hegyi et al. 1998). Only gliosis and 
demyelination could be rescued by oligodendrocyte-specific PrPC expression, while neuron-specific PrPC 
expression could partially rescue cerebellar granule cell degeneration, but not demyelination 
(Radovanovic, Braun et al. 2005). Thus, PrPC expression is required in both neurons and glia to 
completely revert the degenerative phenotype. Additional observations showed that Prnp0/0 mice 
expressing PrPC lacking amino acid residues 32-93 (PrP32-93) within the OR region did not present 
pathological phenotypes. This fact hints at the central domain (CD, residues 94-134) as a key functional 
domain. The CD domain includes the positively charged CC2 cluster (residues 95-110) and the HC core 
(residues 112-134), (Figure 3, Figure 5). Therefore, other Prnp transgenic models have been created to 
analyze the different contributions of these two domains to the pathological phenotype. Mice entirely 
lacking the CD (PrP94-134) showed a drastic neuropathological phenotype with vacuolar degeneration, 
astrogliosis, extensive central and peripheral nervous system demyelination and death within 20-30 
days (Baumann, Tolnay et al. 2007). Despite the similar myelin damage, this model did not present the 
same cerebellar degeneration observed in PrP32-121 and PrP32-134 expressing mice. Furthermore, 
mice lacking residues 105-125 (referred to as CR) develop an even more dramatic phenotype, with 
severe neurodegeneration becoming lethal within the first post-natal week (Krebs, Wiebelitz et al. 
2007). Each of these phenotypes can be rescued co-expressing the WT PrPC in a dose-dependent 
manner according to the mutant PrP expression level and the severity of the pathology elicited 
(Baumann, Tolnay et al. 2007, Krebs, Wiebelitz et al. 2007). Moreover, other transgenic mice have been 
used to shed light on PrPC involvement in myelin homeostasis. Bremer et al. showed that Prnp0/0 mice 
display a late-onset chronic demyelinating polyneuropathy (CDP) in their PNS, (Bremer, Baumann et al. 
2010). Interestingly, mice expressing mutant PrP lacking the CC2 domain (PrPΔ94-110) did not develop 
CDP, while on the contrary mice expressing mutant PrP lacking the hydrophobic core (PrPΔHC) showed a 
reduced life expectancy (survival 80 ± 3.5 days), white-matter vacuolation and astrogliosis in cerebellum, 
brain stem and corpus callosum, and showed CDP (Bremer, Baumann et al. 2010). Thus, the hydrophobic 
core (HC), but not the charge cluster (CC2), of the central domain of PrPC is essential for myelin 
maintenance. However, the demyelinating phenotype in Prnp0/0 mice is mild and less severe than the 
demyelination-affecting mice expressing PrP mutants lacking the central domain. Indeed, while Prnp0/0 
mice show only PNS demyelination during aging, Prnp0/0 mice expressing the mutant with deletion of the 
central domain of PrP, i.e. PrPΔHC, PrPΔ32-121, PrPΔ32-134, show a more dramatic and lethal 
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demyelinating phenotype, with both central and peripheral demyelination, clinical manifestations 
ranging from partial hind limb paresis to ataxia, full tetraplegia, and reduced life expectancy (Shmerling, 
Hegyi et al. 1998, Baumann, Tolnay et al. 2007, Bremer, Baumann et al. 2010). Trying to explain the 
great phenotypical difference between demyelination in Prnp0/0 and PrPΔCD-expressing mice, Baumann 
and colleagues proposed a model in which PrPC and its deletion mutants can compete for a common 
ligand, maybe a receptor that regulates signal transduction. According to this scenario, a residual, basal 
activity of this receptor in Prnp0/0 mice may exist, whereas disruption of the CD may sequester the 
receptor in a dominant-negative state (Figure 6) (Steele, Lindquist et al. 2007). 
Figure 6. A model showing the effects of PrP
C
 deletion mutants. (A) Schematic diagram of WT PrP
C
 and its several deletion 
mutants. SP, signal peptide; octarepeats are indicated in blue; CC, charged cluster; HC, hydrophobic core; H1, H2, H3 Helix 1, 2 
and 3, respectively; GPI, GPI-anchor addition sequence (B). PrP (purple) consists of a globular C-terminal domain (hexagon) and 
a N-terminal flexible tail (arch) encompassing the octapeptide repeats (circle). The model rests on the following assumptions: 
(1) PrP activates a hitherto unidentified receptor (PrPR) which transmits myelin maintenance signal (flashes); (2) in the absence 
of PrP, PrPR exerts some residual activity, either constitutively or by recruiting a surrogate ligand; (3) the activity of PrP and its 
mutants requires homo- or heterodimerization, and induces dimerization of PrPR; and (4) PrP dimers containing PrPCD or 
PrPCD trap PrPR in an inactive dominant-negative state (from (Steele, Lindquist et al. 2007)). 
Finally, experiments on mice lacking the GPI anchor ( PrPGPI and PrPCDs) revealed that the proper 
expression and membrane anchoring of PrPC is necessary for both beneficial and deleterious effects 
elicited by PrPC and its variants, including the neurodegenerative effect of PrPSc. Despite the generation 
of all these KO and transgenic mice for PrPC, a general consensus on PrPC physiological function and 
mechanism of action is still missing. 
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PHYSIOLOGICAL FUNCTION OF PrPC 
The high Prnp sequence conservation between the mammalian species suggests that PrPC may retain 
some important physiological functions during evolution (Colby and Prusiner 2011). Even though PrnP0/0 
mice have normal lifespans without gross disturbancies under standard laboratory conditions, upon a 
deeper analysis many subtle phenotypic changes have been reported. PrPC has been implicated in 
oxidative stress potection, stress response, circadian rhythm, hippocampal neuronal function, spatial 
learning, synapse formation and functionality, brain copper and cuproenzyme level regulation, neurite 
outgrowth, maintenance of myelinated axons, phagocytosis and inflammatory response, 
haematopoietic-stem-cell renewal and neural-stem-cell differentiation (Caughey and Baron 2006, 
Aguzzi, Baumann et al. 2008). Figure 6 and Table 3 summarize some of the cellular processes in which 
PrPC is involved.  
Hereafter, some of the proposed PrPC functions will be described in detail, in accordance with the topic 
and the aim of this thesis. 
 
Figure 5. Physiological processes involving PrP
C
. Several processes in the nervous system have been influenced by PrP
C
. Neurite 
outgrowth, including growth of axons and dendrites, was observed to be reduced in neurons lacking PrP
C
. PrP
C 
has often been 
reported to promote neuronal survival, in particular following apoptotic or oxidative stress. Cerebellar granule cell apoptosis 
was observed in mice expressing toxic N-terminal deletion mutants of PrP. In addition, the latter transgenic mice show an 
impaired maintenance of myelinated axons in the white matter. Another site of PrP
C
 action might be the synapse, which is 
often affected in the first stage of prion diseases and whose formation was found to be reduced in neuronal cultures devoid of 
PrP
C
. Furthermore, electrophysiological studies indicate a role of PrP
C
 in synapse function, especially in neurotransmitter 
release (Aguzzi, Baumann et al. 2008).  
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Table 3. The cellular distribution and activities of PrP
C
 in cell types in which known or putative functions have been described 
(Caughey and Baron 2006).  
PrPC ROLE IN METAL HOMEOSTASIS 
As already mentioned, one of the most salient features of PrPC relies on its ability to bind divalent 
cations (in particular copper with the highest affinity, zinc, nickel, iron and manganese to a lesser extent) 
and to participate in their homeostasis.  
Biometals are essential for a wide range of functions in living organism, such as enzyme active site 
formation, electrochemical gradient formation, DNA replication, oxygen transport and 
oxidative/nitrosative stress regulation. Metal homeostasis is tightly regulated by highly interconnected 
and interdependent cellular pathways involving ion-specific transporters and metal-binding proteins. 
Hence, the impairment of an essential metal homeostasis may affect the metabolism of other species. 
Because of their chemistry, the distribution of physiological transition metals needs to be finely 
regulated to avoid dangerous effects, such as oxidative/nitrosative stress generation and abnormal 
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metal-protein interaction (Bush 2000, Valko, Morris et al. 2005, Bolognin, Messori et al. 2009, Rivera-
Mancia, Perez-Neri et al. 2010).  
It has been largely demonstrated that the brain requires high metal ion concentration because of its 
elevated oxidative metabolic rate (Bush 2000). Therefore, the brain must efficiently regulate metal 
amount, distribution and buffering system for its proper functioning. Metal ion deficiency and 
accumulation can both lead to neurological diseases (Lovell 2009). Importantly, the relative 
impermeability of the blood-brain barrier to fluctuating levels of plasma metal ions together with a 
proper energy production for the functioning of metal regulatory transport systems generally prevent 
detrimental effects of metal dysregulation in the CNS (Bush 2000). Many reports show the link between 
altered biometal homeostasis, especially copper, zinc, iron and manganese, and neurodegenerative 
pathologies, such as ALS, AD, Parkinson’s disease (PD) and prion diseases. Metals dysmetabolism can 
lead to protein aggregation, altering enzymatic activity, or catalyzing protein oxidation followed by 
protein damage and denaturation (Bush 2000). Despite many efforts have been done to disclose the role 
of metal homeostasis in neurodegeneration, it is not clear whether metal impairment could be an 
initiating/aggravating factor or a consequence of the neurodegenerative progression (Bolognin, Messori 
et al. 2009). Noteworthy, the aging is the dominant risk factor associated with neurodegeneration and it 
is characterized by an alteration of brain metal content and their topographical distribution (Tarohda, 
Yamamoto et al. 2004). Moreover, different neurodegenerative disorders are triggered by mutations in 
metal ion metabolism proteins. Two examples are Menkes’ and Wilson’s diseases that are caused by 
loss-of-function mutations in two copper transporters, affecting the proper distribution of this redox-
active metal ion (Dening 1991, Oder, Grimm et al. 1991, Vulpe, Levinson et al. 1993, Madsen and Gitlin 
2007). 
Besides its role in neurodegeneration, metal homeostasis has been implicated also in myelin formation 
and maintenance. In particular, copper and iron dysmetabolism may affect proper myelination (Morelli, 
Ravera et al. 2012, Aspli, Flaten et al. 2015). It has been observed that copper deficiency induced by a 
low copper diet in rats is associated with a substantial reduction in myelin content, suggesting that 
copper is essential for myelin formation and growth during critical periods in development (Zimmerman, 
Matthieu et al. 1976). Moreover, demyelination has been proven to occur in Menkes’ disease patients 
and in mice exposed to the copper chelator cuprizone (CZ) (Matsushima and Morell 2001, Liu, Chen et 
al. 2005, Skjørringe, Møller et al. 2012). Oligodendrocytes contain a huge amount of iron (Connor and 
Fine 1987). Since these cells are responsible for CNS myelin production, alterations in their functioning 
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are associated with hypomyelination (Beard and Connor 2003). Iron is directly involved in myelin 
production as a co-factor for cholesterol and lipid biosynthesis, and indirectly because of its requirement 
for oxidative metabolism (which occurs in oligodendrocytes at a higher rate than other brain cells) 
(Connor and Menzies 1996). A lack of iron bioavailability is associated with decreased amount and 
altered composition of myelin, together with oligodendrocyte maturation impairment. Given this strict 
connection between iron and myelination rate, a relationship between iron and multiple sclerosis (MS) 
was also hypothesized (Abo-Krysha and Rashed 2008).  
Considering the importance of metal-mediated molecular mechanisms, PrPC could be implied in some of 
these processes due to its ability to interact with biometals. In normal conditions, PrPC mediates copper 
and iron uptake (Brown 2003, Singh, Kong et al. 2009). PrPSc has a higher affinity for nickel, decreasing 
the binding of zinc and manganese (Jackson, Murray et al. 2001). Considering the strict interconnection 
among all metal metabolic pathways, it is likely that copper and iron uptake is impaired in prion diseases 
due to this shift in metal binding affinity of PrPSc.  
Since PrPC is implicated in the regulation of two important metals for myelination, its role in copper and 
iron regulation is described. 
As mentioned, PrPC-Cu interaction is well-known. Studies on neuroblastoma cells suggested that PrPC 
contributes to copper uptake since it binds extracellular copper ions and delivers them to the endocytic 
compartment, increasing antioxidant enzymes activity (Pauly and Harris 1998, Brown and Harris 2003, 
Rachidi, Vilette et al. 2003). The OR region plays a role in the reduction of Cu(II) to Cu(I) before 
transporting the metal across the endosomal membrane to the cytosol (Miura, Sasaki et al. 2005). PrPC 
may act as a copper uptake and delivery protein, although published results on copper content in the 
brain of WT, PrPC-null, PrPC overexpressing and scrapie infected mice are discordant (Singh, Das et al. 
2010). While some results showed no differences in copper content upon PrPC ablation (Waggoner, 
Drisaldi et al. 2000, Giese, Buchholz et al. 2005), others highlighted a reduced copper amount in the CNS 
of PrPC-null mice (Brown, Qin et al. 1997, Brown, Schmidt et al. 1998, Kralovicova, Fontaine et al. 2009, 
Singh, Kong et al. 2009). It has been proposed that PrPC acts as a buffer of Cu2+ ions released into 
synaptic cleft, protecting synapses from copper-dependent Fenton redox reactions (Vassallo and Herms 
2003). In the presynaptic bouton, PrPC has a role in the redistribution of released copper ions, 
contributing to  synaptosomal copper concentration maintenance. This likely occurs by transferring 
copper to membrane transporters such as copper transporter 1 (CTR1), having higher affinity than PrPC. 
A similar mechanism may occur in the postsynaptic bouton where PrPC is also expressed (Moya, Sales et 
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al. 2000) and copper ions are released from the trans-Golgi network (TGN) upon activation of glutamate 
ionotropic receptors (Schlief, Craig et al. 2005, Schlief, West et al. 2006). According to this hypothesis, 
copper content in Prnp0/0 mice may be unchanged since PrPC absence affects copper distribution without 
changing its overall content (Vassallo and Herms 2003).  
Conversely from PrPC-Cu interaction, no direct PrPC-Fe binding has been yet observed  (Singh, Das et al. 
2010). By using both in vitro models expressing PrPC mutants and Prnp0/0 mice, it has been shown that 
the prion protein has a fundamental role in iron metabolism (Singh, Kong et al. 2009, Singh, Mohan et al. 
2009). PrPC-null cells have a lower iron content as well as a lower saturation level of ferritin, the major 
iron storage protein. PrPC ablation prevents iron upatake as shown using in vitro cell models. On the 
contrary, cells overexpressing PrPC increase the intracellular iron pool, saturating ferritin molecules. In 
addition, Prnp0/0 mice showed a lower iron content in the brain, probably due to an impaired intestinal 
absorption. Re-establishing PrPC expression in PrPC-null mice the phenotype is reversed, indicating the 
specificity of PrPC functional role in iron homeostasis (Singh, Kong et al. 2009, Pushie, Pickering et al. 
2011). To date, it is not clear whether PrPC mediates iron uptake by using a novel pathway or by 
interacting with conventional iron uptake and transport pathways (Singh, Das et al. 2010). It has been 
proposed that it could interact with transferrin/transferrin receptor pathway or act as a ferric reductase, 
facilitating the transport of Fe(III) from endosomes to cytosolic ferritin (Singh, Mohan et al. 2009).  
Considering the important role of PrPC in modulating content and distribution of specific metals within 
the CNS, PrPC can regulate neurodegenerative disease progression (Pushie, Pickering et al. 2011). 
PrPC PROTECTIVE ROLE IN OXIDATIVE STRESS 
The protective role of PrPC against oxidative damages is widely accepted. Oxidative stress depends on 
alterations in reactive oxygen/nitrogen species formation and in antioxidant defenses. It leads to 
mitochondrial impairments, defects in the ubiquitin-proteasome system, protein oxidation and 
aggregation, lipid peroxidation and DNA damages (Milhavet and Lehmann 2002, Aguzzi, Baumann et al. 
2008, Didonna and Benetti 2015) (Figure 7). 
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Figure 7. Main intracellular pathways of oxidative stress. Increased production of ROS (O2
.-
 , OONO
-
 , OH
.
 ) leads to alterations 
of proteins, lipids, DNA and organelles. Calcium ions play an important role by regulating various enzymes such as protein 
kinase, phospholipases, proteases and endonucleases. The main anti-oxidant systems which tightly regulate the intracellular 
levels of ROS are represented by SODs and the glutathione system. ER, endoplasmic reticulum; Ca
2+
, calcium ions; CaMK, 
calmodulin kinase; NO, nitric oxide; NOS, nitric oxide synthase; O2
.-
 , superoxide ions; OONO
-
 , peroxynitrite; Cu/ZnSOD, copper–
zinc-dependent superoxide dismutase; MnSOD, manganese-dependent superoxide dismutase; H2O2, hydrogen peroxide; Fe
2+
, 
iron ions; Cu
1+
, copper ions; OH
.
, hydroxyl radical; GSH, glutathione; GSSG, disulfide glutathione; GPx, glutathione peroxidase; 
GR, glutathione reductase; Cat, catalase; ROS, reactive oxygen species (Milhavet and Lehmann 2002). 
The high presence of redox-active metals is one of the causes of oxidative stress in the brain (Avery 
2001). Increasing evidence suggested that PrPC improves resistance to oxidative stress, chelating free 
copper ions responsible for ROS generation (Brown, Clive et al. 2001). In vitro studies demonstrated that 
primary neuronal cells lacking PrPC were more susceptible to oxidative stress than WT cells (Brown, 
Schulz-Schaeffer et al. 1997, White, Collins et al. 1999, Rachidi, Vilette et al. 2003). In vivo observations 
reported reduced Cu/Zn superoxide dismutase (SOD) activity and high levels of oxidative damage to 
proteins and lipids in PrPC-deficient mice (Wong, Liu et al. 2001, Brown, Nicholas et al. 2002). Moreover, 
PrPC expression is increased in a variety of stress related conditions, including heat shock, hypoxia, 
ischemia and hypoglycemia, as well as in stroke models (Shyu, Kao et al. 2000, McLennan, Brennan et al. 
2004, Shyu, Lin et al. 2004, Shyu, Chen et al. 2005, Mitsios, Saka et al. 2007). While a knock-down of any 
SOD proteins triggers PrPC expression, shutting down PrPC increases extracellular-SOD expression and 
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SOD2 activity (Brown and Besinger 1998, Kralovicova, Fontaine et al. 2009). This connection between 
PrPC and SOD proteins indicates a common cell protection pathway. In vitro experiments revealed that 
PrPC has SOD-like activity with a dismutation constant rate similar to SOD2 (Brown, Wong et al. 1999, 
Brown, Clive et al. 2001, Cui, Daniels et al. 2003, Treiber, Pipkorn et al. 2007). SOD activity is dependent 
on Cu(II) incorporation and it probably involves Cu(II) reduction (Brown, Clive et al. 2001).  Given its 
localization at synapses, PrPC has been proposed to buffer Cu(II) ions in the synaptic cleft protecting 
neurons against toxic levels of this metal and acting as a synaptic SOD (Vassallo and Herms 2003). It 
should be also noted that PrPC is cleaved at the end of its Cu-binding OR through the action of ROS, a 
process termed -cleavage. -cleavage is considered an early and critical event in the mechanism by 
which PrPC protects cells against oxidative stress. PrP constructs lacking the OR fail the ROS-mediated -
cleavage, as occurs with PG14 and A116V mutations that are associated with human prion diseases 
(Watt, Taylor et al. 2005).  
In their review, Vassallo and Hermes proposed the activation of redox signaling upon Cu(II)-PrPC complex 
formation, modulating intracellular calcium content as secondary messenger (Vassallo and Herms 2003). 
Intracellular calcium is a critical component of the signaling pathways responsible for neuron structural 
and functional changes. The calcium signal usually corresponds to an elevation of the intracellular 
calcium concentration as a consequence of synaptic activity-induced depolarization. Indeed, in PrPC-null 
conditions, neuron calcium homeostasis is impaired (Krebs, Wiebelitz et al. 2007). Hence, PrPC may 
influence both neuron survival and synaptic physiology regulating calcium homeostasis (Vassallo and 
Herms 2003). The model proposed is reported in Figure 8. 
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Figure 8. Schematic representation of the physiological role of prion protein (PrP
C
) in copper homeostasis and redox 
signalling. Cu
2+
 ions released during neurotransmitter vesicles exocytosis are buffered by PrP
C
, and subsequently returned to 
the pre-synaptic cytosol. This can occur either by the transfer of copper to copper transporter proteins (CTR) within the 
membrane, or in case of high copper concentrations in the synaptic cleft, via PrP
C
-mediated endocytosis (◇represent an 
octarepeat; ◆represent an octarepeat bound to copper(II) ion). Further, copper-loaded PrPC may interact with ROS, including 
H2O2 and O2
•-
, triggering redox signalling and subsequently activation of Ca
2+
-dependent signalling cascade. Changes in the 
intracellular Ca
2+
 levels lead to a modulation of synaptic activity and neuroprotection. (from (Vassallo and Herms 2003)). 
PrPC AND SYNAPTIC FUNCTIONALITY 
PrPC localizes at synapses together with a plethora of ion channels, supporting the hypothesis that it is  
important for normal synaptic development and functionality (Moya, Sales et al. 2000, Kanaani, Prusiner 
et al. 2005). Some features of PrPC deficient mice such as alteration in circadian rhythm and impairment 
in spatial learning can be related to synaptic dysfunctions (Tobler, Gaus et al. 1996, Criado, Sanchez-
Alavez et al. 2005). Electrophysiology studies suggest a role for PrPC in the regulation of ion channels and 
neuronal excitability. A variety of abnormalities have been observed in the cerebellum and the 
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hippocampus of PrPC-null mice (Collinge, Whittington et al. 1994, Manson, Hope et al. 1995, Colling, 
Collinge et al. 1996, Carleton, Tremblay et al. 2001, Herms, Tings et al. 2001, Mallucci, Ratte et al. 2002, 
Maglio, Perez et al. 2004, Fuhrmann, Bittner et al. 2006, Prestori, Rossi et al. 2008, Lazzari, Peggion et al. 
2011, Caiati, Safiulina et al. 2013). Particular attention has been paied to PrPC modulation of glutamate 
excitatory receptors, as N-methyl-D-aspartate receptors (NMDARs) (Mallucci, Ratte et al. 2002, 
Khosravani, Zhang et al. 2008, You, Tsutsui et al. 2012). PrPC modulation of neuronal excitability has 
been shown to exert neuroprotection by preventing excitotoxicity (Spudich, Frigg et al. 2005, Rangel, 
Burgaya et al. 2007, Khosravani, Zhang et al. 2008). Excitotoxicity is a neuronal cell death pathway 
activated by the overactivation of glutamate receptors leading to massive calcium influx into cells (Dong, 
Saikumar et al. 2006). Calcium overload may increase the production of reactive oxigen and nitrogen 
species leading to cell death or damage (Nakamura and Lipton 2011). NMDARs overactivation is one of 
the mechanisms inducing excitotoxicity. For this reason, a precise modulation of NMDARs activity is 
essential for normal brain function. NMDARs are one of the major classes of ionotropic glutamate 
receptors mediating the excitatory synaptic transmission, plasticity and excitotoxicity in the brain. These 
glutamate-gated cation channels convert a chemical signal (glutamate released from presynaptic 
terminals) into an electric signal (excitatory post-synaptic potential) (Yashiro and Philpot 2008). These 
receptors are characterized by a voltage-sensitive block via extracellular Mg2+, a high Ca2+ permeability 
and an unusually slow activation/deactivation kinetics. NMDARs work as heteromers composed of two 
GluN1 subunits, retaining the binding of the co-agonist glycine required for NMDAR activation (Cull-
Candy, Brickley et al. 2001), and two other subunits among GluN2A-D and GluN3A-B (Moriyoshi, Masu 
et al. 1991, Sugihara, Moriyoshi et al. 1992, Das, Sasaki et al. 1998). The variety is also increased by the 
different splicing isoforms each subunit presents (Dingledine, Borges et al. 1999). According to the 
receptor composition, NMDARs differ in their localization, sensitivity to endogenous and exogenous 
ligands, permeation and block by divalent ions, kinetic properties, and interaction with intracellular 
proteins (Cull-Candy, Brickley et al. 2001). At least one type of GluN2 subunit retaining the glutamate 
binding site is required to form a functional receptor, while the GluN3 subunit does not form functional 
receptors alone, but can co-assemble with GluN1/GluN2 complexes (Das, Sasaki et al. 1998, Perez-
Otano, Schulteis et al. 2001). NMDARs are found both at synaptic and extrasynaptic sites including cell 
soma and dendritic shaft. The possibility that NMDARs subunit composition differs between synaptic 
and extrasynaptic sites is still controversial. It has been proposed that GluN2A-containing NMDARs 
occupy the central portion of synapses, while GluN2B-containing ones are preferentially targeted to 
peripheral portions of synapses or to extrasynaptic sites where they are activated by glutamate spillover 
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(Cull-Candy, Brickley et al. 2001). Since NMDAR modulation plays crucial roles in physiological processes 
(learning and memory) and in pathological conditions (ischemia, epilepsy, neurodegenerative diseases 
and neuropsychiatric disorders), several regulatory mechanisms have been identified (Collingridge 1987, 
Lipton and Rosenberg 1994, Aarts, Liu et al. 2002, Loftis and Janowsky 2003). Binding of the co-agonist 
glycine is responsible for NMDAR activation. High glycine concentrations with subsequent NMDAR 
overactivation lead to a dramatic slowing of receptor desensitization kinetics, with consequent toxic 
calcium overload into cells and excitotoxicity (Mayer, Vyklicky et al. 1989, Vyklický, Benveniste et al. 
1990). Activating phosphorylation can occur on serine and threonine residues by means of protein 
kinase A (PKA), protein kinase C (PKC) and Ca2+/calmodulin-dependent protein kinase II (CaMKII), while 
deactivating dephosphorylation occurs via Ca2+/calmodulin-dependent phosphatase calcineurin. Src and 
Fyn kinases can also activate NMDARs phosphorylating tyrosine residues (Dingledine, Borges et al. 1999). 
Other regulatory mechanisms involve glycosylation, covalent bound to lipids, as well as proteolytic 
degradation mainly mediated by calpain (Dingledine, Borges et al. 1999). Besides magnesium ions 
responsible for NMDAR voltage sensitivity, zinc ions modulate receptor activity by binding NMDAR 
outside the pore (Peters, Koh et al. 1987). Interestingly, copper released at the synaptic cleft emerged to 
be an important NMDAR modulator (Vlachova, Zemkova et al. 1996). Taking together these 
observations and searching for a possible mechanism of NMDAR modulation by PrPC, it has been 
proposed that PrPC protects neurons from excitotoxicity by inhibiting NMDAR currents in a copper 
dependent manner (Khosravani, Zhang et al. 2008, You, Tsutsui et al. 2012). Although researchers 
suggested that PrPC may regulate NMDARs decreasing glycine affinity (You, Tsutsui et al. 2012), favoring 
desensitization and avoiding calcium overload, others affirmed that copper-mediated regulation of 
NMDARs depends on nitric oxide (NO) (Schlief and Gitlin 2006). To this regard, NMDAR S-nitrosylation 
provides a link between copper and NO inhibitory roles (Lipton, Choi et al. 2002). S-nitrosylation is a 
chemical post-translational modification targeting protein cysteines. In NMDARs, S-nitrosylation is 
inhibitory and addresses two residues on GluN1 and three residues on GluN2A, including Cys399, which 
mediates the predominant inhibitory effect. Cysteine free thiols are subjected to electrophilic attack by 
NO+. Therefore, an electron acceptor, such as copper, is required for NO oxidation (Hess, Matsumoto et 
al. 2005). Copper released in the synaptic cleft is bound by metal-binding proteins such as PrPC, which 
binds copper with high affinity and sustains Cu(II) redox cycling (Brown, Qin et al. 1997, Liu, Jiang et al. 
2011). In vitro results have shown that PrPC-bound Cu(II) promotes NO oxidation and it is consequently 
reduced to Cu(I) (Bonomo, Pappalardo et al. 2008). Me and my colleagues proposed and demonstrated 
that PrPC exerts copper-dependent neuroprotection by mediating NMDAR S-nitrosylation (Gasperini, 
35 
 
Meneghetti et al. 2015). As shown in Figure 9, glutamate released from the presynaptic terminal 
activates NMDARs on the postsynaptic terminal. NMDAR activation triggers Na+ and Ca2+ influx, together 
with K+ efflux. In the intracellular compartment, Ca2+ activates different signaling cascades and, among 
these, it activates calmodulin (CaM). The Ca2+/CaM complex activates neuronal nitric oxide synthase 
(nNOS) resulting in NO release in the synaptic cleft.  Ca2+/CaM activates also the copper-transporting 
ATPase 1 (Atp7a) in the TGN permitting Cu2+ release into synaptic cleft. Released Cu2+ ions are bound by 
copper-binding proteins such as PrPC, highly expressed in lipid raft domains with NMDARs, and having 
high affinity for both Cu2+ and Cu+. Released NO can be oxidized by Cu-PrPC complex and react with 
extracellular cysteine thiols of NMDAR subunits GluN1 and GluN2A, leading to cysteine S-nitrosylation 
(SNO-Cys). Cu2+ bound to PrPC acts as electron acceptor allowing the S-nitrosylation reaction, thus 
inhibiting NMDAR activation by closing the channel and preventing excitotoxic effects.  
  
Figure 9. Mechanism of PrP
C
-mediated S-nitrosylation of NMDAR. Glutamate released from the presynaptic terminal activates 
NMDAR on the postsynaptic terminal. NMDAR activation triggers Na
+
 and Ca
2+
 influx, together with K
+
 efflux. In the intracellular 
compartment, Ca
2+
 ions bind different proteins, including calmodulin (CaM). The Ca
2+
/CaM complex activates, among others, 
neuronal nitric oxide synthase (nNOS) and copper-transporting ATPase 1 (Atp7a): nNOS activation results in NO release in the 
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synaptic cleft; Atp7a activation in the trans-Golgi network (TGN) results in Cu
2+
 release in the synaptic cleft. Released Cu
2+
 ions 
are immediately bound by copper-binding proteins: PrP
C
 is highly expressed in both presynaptic and postsynaptic terminals, 
and it can be included in lipid raft domains that also contain NMDARs, and it has high affinity for both Cu
2+
 and Cu
+
. Released 
NO can react with extracellular cysteines thiols of NMDAR subunits GluN1 and GluN2A, leading to cysteine S-nitrosylation (SNO-
Cys). The S-nitrosylation inhibits NMDAR activation by closing the channel. The chemical reaction between NO and the cysteine 
thiol requires the presence of an electron acceptor, often represented by Cu
2+
. According to this model, PrP
C
brings the Cu
2+
 ions 
that support the reaction of NO with thiols, leading to the S-nitrosylation of GluN1 and GluN2A, thus inhibiting NMDAR 
(Gasperini, Meneghetti et al. 2015).  
PrPC ROLE IN MYELINATION 
One of the most debated roles of PrPC concerns its involvement in CNS myelination. CNS white matter is 
mainly composed of myelinated axons. In some GSS cases, cerebellar and frontal white matter 
degeneration has been reported (Itoh, Yamada et al. 1994). Walis and colleagues showed vacuolation of 
myelinated fibers with splitting of myelin lamellae in myelin sheaths of rodents infected with human TSE 
(Waliś, Bratosiewicz et al. 2003). However, it was not investigated whether myelin degeneration was 
due to PrPC loss-of-function or it was a consequence of the pathological process. As already reported in 
the PrP KO and transgenic mice section, central and peripheral nervous system demyelination was 
observed in transgenic mice expressing the PrPC truncated Δ32-121, Δ32-134, Δ94-134, Δ111-134 and 
Δ105-125, hinting at the HC as essential for myelin maintenance (Shmerling, Hegyi et al. 1998, Baumann, 
Tolnay et al. 2007, Li, Christensen et al. 2007, Bremer, Baumann et al. 2010). Vacuolation and 
degeneration of CNS myelinated fibers was also described in Dpl overexpressing mice (Nishida, Tremblay 
et al. 1999). These degenerating phenotypes are fully reverted co-expressing full-length PrPC. It has been 
reported that PrPC is present in purified myelin fractions derived from brain homogenates and that 
oligodendrocytes-specific full length PrPC expression is necessary for CNS myelin maintenance 
(Radovanovic, Braun et al. 2005). Same authors hypothesized that oligodendrocyte-restricted PrPC may 
repress in trans the axonal pathology elicited by PrP mutants. A cellular signal might be transduced 
through PrPC from oligodendrocytes to axons, analogously to other GPI-anchored proteins playing a role 
in axon-myelin interactions. Alternatively, PrPC may instruct oligodendrocytes to release factors 
necessary for axonal survival (Wilkins, Majed et al. 2003). Surprisingly, Prnp0/0 mice presented a milder 
phenotype than PrP-mutant expressing mice, showing only PNS demyelination (Bremer, Baumann et al. 
2010). In the absence of PrPC there is an initial formation of morphologically normal PNS myelin 
followed by myelin disruption (Figure 10).  
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Figure 10. Ultrastructural alterations in Prnp
0/0 
SNs. Electron microscopy of SNs of 60-week-old WT (a) and Prnp
0/0 
(b) mice 
(both Balb/c). Cross-sections of WT nerves show normally myelinated nerve fibers and regular unmyelinated axons in Remak 
bundles (R). Cross-sections of Prnp
0/0
 nerves show thinly myelinated axons, surrounded by onion bulb formations (arrows). 
Modified from (Bremer, Baumann et al. 2010). 
PrPC expression in neurons, but not in Schwann cells, is required to prevent CDP in the PNS. Thus, 
neuronal PrPC in trans expression is required for the axon to Schwann cells communication (Bremer, 
Baumann et al. 2010). Bremer and colleagues suggested that PrPC cleavage may be linked to its 
myelinotrophic function. Indeed, PrPC is subjected to regulated proteolysis in late secretory 
compartments (Sunyach, Cisse et al. 2007), thus generating two distinct fragments, namely C1 and C2. 
C1 is generated by α-cleavage at amino acids 110–112, whereas C2 is derived by β-cleavage in the 
octarepeat region at position 96 (Mange, Beranger et al. 2004, Watt, Taylor et al. 2005).  Bremer and 
colleagues evidenced an association between the presence of CDP and lack of the C1 fragment in SNs, 
suggesting that alpha-cleavage is important for PrPC function in myelin physiology.  
The importance of PrPC in peripheral myelin maintenance during aging processes was also confirmed by 
a study by our group showing that PrPC positively influence the processing of neuregulin-1 and 3 (NRG1 
and NRG3) in the PNS of aged mice (Benvegnu, Gasperini et al. 2011). NRG proteolytic cleavage by 
different membrane proteases is crucial for myelin maintenance in the PNS. According to these findings, 
PrPC may exert its protective function through the modulation of β-secretase 1 (BACE1) (Parkin, Watt et 
al. 2007). Interestingly, correct PNS myelination was compromised in PrPC overexpressing mice 
(Westaway, DeArmond et al. 1994).  
Despite the expectations concerning PrPC involvement in CNS myelin maintenance, different studies 
failed to observe CNS myelin differences between WT and PrPC-null mice. Accordingly, Bremer and 
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colleagues did not detect myelin degeneration in optic nerve, corpus callosum or spinal cord of 60-
week-old Prnp0/0 mice (Figure 11) (Bremer, Baumann et al. 2010).  
Figure 11. Normal ultrastructure of Prnp
0/0 
CNS white matter at 60 weeks of age. Sixty-week old Prnp
0/0
 compared to WT mice 
were analyzed by electron microscopy. No morphological abnormalities were observed in corpus callosum, spinal cord white 
matter and optic nerve. Scale bar = 2 µm. Corpora callosa were analyzed in mixed B6/129Sv mice whereas spinal cords and 
optic nerves belonged to Balb/c mice (Bremer, Baumann et al. 2010). 
However, the authors did not exclude the possibility that subliminal myelin alterations might extend to 
central myelin in Prnp0/0 mice. In fact, motor deficits were detected in 3 to 8 months old Prnp0/0 mice, 
together with spongiform pathology in different CNS regions at 6 months of age (Nazor, Seward et al. 
2007). Vacuolar lesions were detected in particular in the corpus callosum, at the level of the 
hippocampus, in the medial globus pallidus, in the cerebellum and the inferior cerebellar peduncle and 
finally in the spinal trigeminal tract. Furthermore, no differences in the processing of NRG in the 
hippocampus of 1-year-old Prnp0/0 mice were observed (Benvegnu, Gasperini et al. 2011). Thus NRG 
cleavage modulation mediated by PrPC is important only for PNS myelin maintenance, but not for the 
CNS. In addition, it has been reported that PrPC absence increases OPC proliferation and delays their 
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maturation without affecting the final amount or quality of myelin (Bribián, Fontana et al. 2012). The 
expression of the myelin-associated glycoprotein (MAG), identifying mature myelinating 
oligodendrocytes, revealed no significant changes in the white matter of Prnp0/0 mice (Figure12). 
Accordingly, myelination was not affected and no significant differences were detected between the 
two genotypes in terms of the amount of total MAG or myelin basic protein (MBP) in adult cortical and 
spinal cord extracts. In agreement with previous findings by Bremer and colleagues, electron microscopy 
revealed no alterations to the myelin sheaths in the cortical white matter due to the loss of Prnp. On the 
basis of their observations, authors proposed that the increase in the OPC proliferation observed in the 
absence of PrPC may be compensated by extrinsic factors able to regulate the proper timing of OPC 
differentiation, ensuring adequate myelination and maintenance. Surplus OPC may be counterbalanced 
by cell death. In light of these controversial findings, PrPC role in CNS myelin formation and maintenance 
has not been clarified yet.  
 
Figure 12. Adult Prnp
0/0
 mice exhibit normal myelination in the CNS. (A-B) In situ hybridization of MAG in coronal sections 
from the brains of adult Prnp
+/+
 and Prnp
0/0
 mice. (C) Quantification of MAG-positive cells revealed no differences between 
genotypes in the corpus callosum or cingular cortex. Values represent the mean ± standard deviation and were analyzed using 
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the Student’s t test. (D-E) Western blots of brain extracts from Prnp
+/+
 and Prnp
0/0
 mice showing no differences in the 
expression of the MAG and MBP myelin proteins between genotypes in neocortex (D) and spinal cord (E). (F, H) Lower 
magnification electron microscopy photomicrograph of Prnp
+/+
 and Prnp
0/0
 mice. (G, I) Higher magnification of F and H, 
respectively, show no gross ultrastructural differences in the myelin sheaths of the corpus callosum. Abbreviations: CC: corpus 
callosum; CGC: cingulate cortex; NC: neocortex. H: hippocampus; Scale bars: A = 300 µm also applies to B; F: 2 µm also applies 
to H; G = 0.5 µm also applies to I. (Bribián, Fontana et al. 2012). 
MYELIN BIOLOGY 
Myelin is a spiral structure constituted by a greatly extended and modified plasma membrane 
enwrapping nerve axons (Baumann and Pham-Dinh 2001). Myelin membrane derives from Schwann 
cells in the PNS and from oligodendrocytes in the CNS. Its unique lipid-enriched composition makes the 
electrical insulation of axons possible. Myelin segmental structure allows the saltatory propagation of 
axon potentials and therefore the high-speed conduction and synchronization of afferent nerve 
impulses (Waxman 1997). Myelin maintains axon integrity by providing glial support, including glycolytic 
energy metabolites, neurotrophic factors and cargo-containing vesicles termed exosomes (Figure 13) 
(Nave 2010, Funfschilling, Supplie et al. 2012, Beirowski 2013, Fruhbeis, Frohlich et al. 2013, White and 
Krämer-Albers 2013). On the other hand, axonal contact, diameter, electrical activity and signaling are 
essential for a correct myelination, as reviewed in (Taveggia, Feltri et al. 2010, Hines, Ravanelli et al. 
2015).     
Figure 13. Hypothetical model summarizing impact of EG on axonal integrity by the mechanistic themes 
discussed. Preservation of healthy axons is controlled by the cooperative action of both the neuron and adjacent glia by 
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blocking endogenous axonal auto-destruction. Examples of neuronal mechanisms blocking this program(s) include somatic 
delivery of the putative axonal survival molecule Nmnat2 into axons, or the local translation of axonal maintenance factors such 
as Bcl-w. On the other hand, glia inhibit axonal death by transfer of metabolic substrates, neurotrophic factors, and vesicular 
shuttles (upper glia portion). This transfer is mediated by specific transport mechanisms represented by columns between glia 
and axon. Vertical lines embody adhesion mechanisms that ensure correct apposition and formation of nutritive channels 
between glia and axon. Under pathological conditions glia may also contribute to axonal auto-destruction by activating pro-
degenerative signaling, releasing toxic substances, and loosening contact to axons (lower glia portion). Note that the myelin 
membrane of EG is uncoiled in the illustration and myelination thus not represented (Beirowski 2013). 
Myelin presents a characteristic periodic structure of alternating electron-dense and -light layers, named 
major dense line and intraperiod line respectively. The major dense line is formed by the close 
apposition of the cytoplasmic surfaces of myelin membranes, while the apposition of the two outer 
leaflets forms the intraperiod line (Figure 14). Myelinated segments are separated by small 
unmyelinated gaps, Ranvier nodes, where sodium channels are highly concentrated and the membrane 
depolarization occurs. Within myelin segments, there are small regions of uncompacted membranes 
retaining small amount of cytoplasm (Schmidt-Lanterman clefts and paranodal loops). Myelin sheath is 
separated from the axonal membrane by an extracellular cleft, called periaxonal space. While in the PNS 
one myelinating Schwann cell forms only one myelin segment, in the CNS one oligodendrocyte can 
myelinate as many as 40 or more separate axons (Baumann and Pham-Dinh 2001, Hartline 2008, 
Aggarwal, Yurlova et al. 2011). 
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Figure 14. Myelinating glial cells, myelin structure, and composition in the peripheral nervous system (PNS) and in the CNS. In 
the PNS, the myelinating Schwann cell myelinates only one segment of axon (top left corner), whereas in the CNS (top right 
corner), the oligodendrocyte is able to myelinate several axons. The compact myelin is formed by the apposition of the external 
faces of the membrane of the myelinating cell, forming the “double intraperiodic line”; the apposition of the internal faces 
followed by the extrusion of the cytoplasm, form the “major dense line.” The myelin proteins are schematically described; they 
differ between PNS and CNS (Baumann and Pham-Dinh 2001). 
Myelin is a poorly hydrated structure containing only 40% water, in contrast to 80% in gray matter. 
Conversely from other cellular membranes, it consists of 70-85% lipids and only 15-30% proteins. There 
are no myelin-specific lipids, though myelin contains cholesterol, phospholipids and glycolipids in molar 
ratios ranging from 4:3:2 to 4:4:2. Cholesterol constitutes about 30% of total myelin lipids and it is 
essential for membrane stability. Among the other lipids, cerebroside, sulfatide, lecithin and 
sphingomyelin are present in myelin. Peripheral and central nervous system myelin lipids are 
qualitatively similar, but some quantitative differences are present. PNS myelin has less cerebroside and 
sulfatide, but more sphingomyelin than CNS. Differently from lipid composition, CNS and PNS present 
similarities and peculiarities in protein composition, as described in Figure 14. Some myelin proteins 
important for this thesis are here described, referring to (Campagnoni 1988, Baumann and Pham-Dinh 
2001, Aggarwal, Yurlova et al. 2011). Concerning CNS, myelin basic protein (MBP) and proteolipid 
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protein (PLP) represent the majority (80%) of the total myelin proteins. The Mbp gene, located on the 
mouse chromosome 18, is composed of 7 exons with at least 6 splice variants, encoding for 21.5, 18.5, 
17 and 14 kDa proteins. MBP is an extrinsic protein, localized exclusively at the cytoplasmic surface of 
the major dense line where it plays a role in membrane stability. It alone constitutes the 30% of CNS 
myelin proteins, while in the PNS it varies from 5 to 18% of the total proteins and it does not seem 
essential for correct myelin structure. Plp gene, located on mouse chromosome X, is composed by 7 
exons with 2 splice variants. PLP1 is a 30 kDa protein, while its isoform, DM20, present a 35 aminoacids 
deletion (Wight and Dobretsova 2004). The DM20 developmental expression precedes that of PLP1. 
Therefore, in adult brains DM20 is present at a much lower level compared to PLP1. In some reports, 
DM20 gene expression has been associated with remyelinating conditions in the adult brain (Mathisen, 
Kawczak et al. 2001). PLP is an integral membrane protein that stabilizes the intraperiod line. Both 
isoforms are highly acylated and extremely hydrophobic. PLP constitutes 50% of the total CNS myelin 
proteins, while in the PNS it is present in a small amount. Another protein that is shared between CNS 
and PNS is myelin associated glycoprotein (MAG). Its gene is located on mouse chromosome 7 and it is 
composed by 13 exons encoding two different splice variants: the 72 kDa long-MAG (L-MAG) and the 67 
kDa short-MAG (S-MAG). These proteins are usually found in the heavily glycosylated form, with an 
apparent molecular mass of 100 kDa. These transmembrane proteins are located in the periaxonal 
membrane of myelin sheats, where they are supposed to play a role in neuron-glia adhesion and in bi-
directional signaling. One of the CNS specific myelin proteins is myelin oligodendrocyte glycoprotein 
(MOG), encoded by a gene located on mouse chromosome 17. MOG is a 25 kDa protein presenting 
some glycosylation. It is a transmembrane protein localized in the outside surface of myelin sheats, 
where it may be involved in signal transduction. Differently from the CNS where the essential proteins 
are MBP and PLP, in the PNS myelin protein zero (MPZ or P0) constitutes more than 50% of the total 
myelin proteins. Mpz gene is located on mouse chromosome 1 and it encodes for a 30 kDa 
transmembrane protein that is subjected to post translational modifications, such as glycosylation, 
phosphorylation and acylation. MPZ stabilizes the intraperiod line, thus replacing the function of PLP 
which has very low expression levels in PNS. Expression of the correct amount of MPZ is apparently 
essential for normal myelin formation and maintenance. Recently, a novel 36 kDa isoform has been 
identified and named large-MPZ (L-MPZ) due to the presence of an additional domain at the C-terminus 
(Yamaguchi, Hayashi et al. 2012). This protein derives from the stop codon readthrough of MPZ mRNA 
and it has been identified both in physiological and pathological conditions. As MPZ, L-MPZ may retain a 
stuctural importance in myelin adhesion and compaction. Furthermore, many other proteins are 
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associated to myelin, such as enzymes and neurotransmitter receptors, making myelin a metabolically 
and signaling active structure. 
CNS MYELINATION, DEMYELINATION AND REMYELINATION 
In mouse, myelination predominantly occurs postnatally, starting at birth in the spinal cord and 
subsequently in the brain (Baumann and Pham-Dinh 2001). The process of myelin membrane formation 
and compaction is very rapid and many signaling mechanisms regulate the precise timing of 
oligodendrocyte differentiation and myelination, lipid and protein synthesis, displacement and 
organization (Baumann and Pham-Dinh 2001, Bradl and Lassmann 2010, Taveggia, Feltri et al. 2010). 
During development, myelinating glia and axons establish a continuous and reciprocal exchange of 
signals (Figure 15). While glial cells provide survival signals to neurons, define specific domains along the 
axon and determine the axon diameter, axons modulate proliferation, survival and differentiation of 
glia, thus controlling myelin formation (Bozzali and Wrabetz 2004, Simons and Trajkovic 2006, Salzer, 
Brophy et al. 2008). In addition, neuronal electrical activity promotes myelination, instructing nearby 
oligodendrocytes to initiate myelination (Malone, Gary et al. 2013, Hines, Ravanelli et al. 2015). 
45 
 
 
Figure 15. Axon to glia signaling pathways in myelination. Schematic representation of the main signaling pathways that 
regulate the onset of myelination during CNS development. The figure depicts an oligodendrocyte just before wrapping. The 
pathways shown are not comprehensive, but focus on signaling that converges on the glial cell nucleus. Regulatory feedback 
loops are not displayed. For some molecules, the localization shown is putative. Note that, as oligodendrocytes must integrate 
signals from multiple axons, with different calibers and electrical activities, a layer of local peri-axonal regulation is likely to be 
superimposed on nuclear regulation of myelination. Dashed lines indicate signals with uncertain targets. Abbreviations: Nrg: 
Neuregulin; EGF: Epidermal Growth Factor; IGF1: Insulin-like Growth Factor 1; Sema: Semaphorin; Fyn: Fyn kinase; GPR17: G 
protein-coupled receptor 17; P2: Purinergic Receptors 2; NICD: Notch-1 intracellular domain: PI3K: phosphatidylinositol-3 
kinase; Akt: serine/threonine-specific protein kinaseAkt/PKB; mTOR: mammalian target of rapamycin (mTOR) signaling 
complexes; HDAC: Histone deacetylase; YY1: YIN-YANG-1; Sox: SRY-box containing transcription factor; Zfp: zinc finger protein; 
MRF: Myelin gene regulatory factor; Tcf: T-cell factor 4 transcription factor; Hes: hairy and enhancer of split 5 transcription 
factor; Id: Inhibitor of differentiation transcription factor; β-cat: β-catenin; Wnt: Wingle wingless-related mouse mammary 
tumor virus integration site protein (Taveggia, Feltri et al. 2010). 
Once the myelinating phase is completed, the intricate signaling between enwrapping glia and axons 
continues in order to maintain a proper myelination. Observation that axonal damage follows myelin 
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damage in most myelin disorders, suggests that signals from myelin to axons might be altered by disease 
conditions (Beirowski 2013). In some cases, a simultaneous destruction of oligodendrocyte and myelin 
has been reported (Bradl and Lassmann 2010). Differently, in the Wallerian degeneration myelin 
degenerates as a consequence of primary axonal loss (Friese, Schattling et al. 2014). Thus, different 
degenerative mechanisms acting in pathological conditions may result in demyelination. Due to the 
combination of some peculiar features, oligodendrocytes and their myelin sheath are in general more 
susceptible to damage than other CNS cellular components. This peculiar vulnerability is due to the 
extremely high metabolic rate of oligodendrocytes. During myelination, oligodendrocytes consume large 
amounts of oxygen and adenosine triphosphate (ATP) in order to produce a large amount of membrane 
(McTigue and Tripathi 2008). This high cellular metabolism, together with accelerated ATP production, 
leads to ROS production that must be promptly metabolized to prevent cell damages. On the other 
hand, OPC and oligodendrocytes have the highest iron content among the cells of the brain (Thorburne 
and Juurlink 1996). Iron is directly involved in myelin production as a required co-factor for many myelin 
synthetic enzymes, as the ones involved in cholesterol and other lipid biosynthesis (Connor and Menzies 
1996). Iron is a transition metal that may participate in redox reactions leading to ROS production. 
Therefore, both these conditions make oligodendrocytes and myelin highly susceptible to oxidative 
stress, which is a common feature of many neurodegenerative diseases associated with demyelination 
(Bongarzone, Pasquini et al. 1995, Bizzozero, DeJesus et al. 2004, Encinas, Manganas et al. 2005, Morelli, 
Ravera et al. 2012). Furthermore, oligodendrocytes have only low concentrations of the anti-oxidative 
enzyme glutathione (Connor and Menzies 1996).  Several additional studies have shown that 
oligodendrocytes and myelin are vulnerable to glutamate excitotoxicity (Matute, Sanchez-Gomez et al. 
1997, McDonald, Althomsons et al. 1998) since they express both α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionate (AMPA)/kainite mainly in the soma and NMDA receptors in the myelin sheath. 
While in physiological conditions oligodendrocytes respond to glutamate released by electrically active 
axons, in pathological conditions NMDAR contribute to oligodendrocyte toxicity (McTigue and Tripathi 
2008, Wake, Lee et al. 2011). Finally, the capacity of endoplasmic reticulum (ER) to properly produce 
and fold proteins in a quick but precise manner is another factor influencing myelin amount and 
stability. Indeed, slight variations in the amount of one protein may result in the retention, misfolding 
and accumulation of many other proteins in the ER (Bauer, Bradl et al. 2002). 
After initial myelin damage, a remyelinating process can initiate, trying to form new myelin sheaths 
around axons (Franklin and Ffrench-Constant 2008, Bradl and Lassmann 2010). CNS remyelination is 
possible thanks to the generation of new mature oligodendrocytes from the adult, quiescent OPC pools. 
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Initially, OPC must switch from a quiescent to a regenerative state and they are subsequently recruited 
to demyelinated areas. The differentiation of OPC to remyelinating oligodendrocytes starts, with the 
expression of myelin genes and proteins, membrane wrapping and compaction. Although these 
processes resemble developmental myelination, some differences exist: first, remyelination is a slower 
process compared to developmental myelination, since adult OPC have a longer cell cycle time and a 
slower rate of migration. Secondly, signaling molecules and transcription factors seem to be different in 
these two processes. Lastly, remyelination results in a thinner and shorter myelin sheath than would be 
expected for a given axon diameter, meaning that the developmental correlation between axon 
diameter and myelin sheath thickness and length is lost during remyelination. Remyelination is a 
promising topic, since it provides a possible therapeutic target for demyelinating diseases. However, at 
later stages of the disease progression, remyelination largely fails leading to progressive 
neurodegeneration and disability (Franklin and Ffrench-Constant 2008). 
MODELS TO STUDY CNS MYELIN 
In the past years, many models have been established to study CNS myelination, demyelnation and 
remyelination. In vitro, in vivo and ex vivo models have been set up, each of them presenting some 
peculiarities.  
In vitro models based on OPC-neurons co-culture are simple, inexpensive and high throughput (Wang, 
Colognato et al. 2007, Watkins, Emery et al. 2008). However, they can only model myelination, but not 
remyelination (Zhang, Jarjour et al. 2011).  
Differently, myelination, demyelination and remyelination can be studied by using in vivo models based 
on experimental allergic encephalitis (EAE), viral-induced myelin damages and administration of toxins, 
among which the most common are lysolecithin (Lysophosphatidylcholine, LPC) and CZ (Blakemore and 
Franklin 2008, Furlan, Cuomo et al. 2009, van der Star, Vogel et al. 2012). Even if LPC mode of action is 
still debated, this toxin disrupts membranes, including myelin, by inserting into lipid bilayers which then 
form micellas (Gregson 1989). A precise dosage of this toxin allows damage to be specific to myelinating 
cells, sparing other cell types. Remyelinating processes start some weeks after the toxin source removal 
(van der Star, Vogel et al. 2012). Concerning CZ, oral administration of this copper chelating agent was 
widely used in myelin research since the 1960s (Carlton 1967, Hoffmann, Lindner et al. 2008, 
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Koutsoudaki, Skripuletz et al. 2009, Zendedel, Beyer et al. 2013). In adult mice, the administration of 0.2-
0.3% CZ containing diet for 5-6 weeks can induce an acute demyelination that may be reverted by a 
spontaneous and endogenous remyelination process once the normal diet is restored. Differently, CZ 
feeding for more than 12 weeks induces chronic demyelination with impaired spontaneous 
remyelinaion process (van der Star, Vogel et al. 2012). The way in which CZ induces demyelination is still 
unclear. However, it is known that CZ induces the death of mature myelinating oligodendrocytes, with 
concomitant microglia activation and astrocytosis (Norkute, Hieble et al. 2009, Bénardais, Kotsiari et al. 
2013). Figure 16 shows the cellular and molecular response during CZ-induced acute demyelination 
(Gudi, Gingele et al. 2014). Since no traces of CZ have been found in the brain of CZ-fed mice, the 
decrease in brain copper content might be caused by CZ-mediated interference with the intestinal 
absorption of this metal (Venturini 1973, Benetti, Ventura et al. 2010). Even though in vivo experiments 
are largely used to study myelination, these models are very low-throughput and expensive in terms of 
animals, time and money. 
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Figure 16. Cellular and molecular response in the medial corpus callosum during cuprizone-induced de- and remyelination. 
(A) Distribution of glial cells under normal conditions. (B) Weeks 1–3, “early demyelination.” Mature oligodendrocytes begin to 
undergo apoptosis already during the first week of cuprizone feeding. Microglia are highly motile cells. They may detect 
apoptotic oligodendrocytes and initiate together with astrocytes numerous inflammatory and probably also reparative 
processes. Various chemokines, cytokines, and growth factors, promoting attraction and activation of microglia and astrocytes 
but also migration of OPC are produced during the first week of cuprizone treatment. In the next 2 weeks of the “early 
demyelination” period inflammatory cytokines are already slightly up-regulated and maintain the inflammatory cycle by further 
promoting activation and proliferation of astrocytes and microglia but probably harming oligodendrocytes as well. 
Oligodendrocytes are almost completely depleted at week 3 of cuprizone treatment. (C) Weeks 3.5–5, “severe demyelination.” 
Activated microglia begin to clear myelin debris. Several matrix metalloproteinases (MMP), chemokines, cytokines, and growth 
factors produced by activated astrocytes and microglia are supporting phagocytosis and promoting proliferation of OPC. At 
week 5 nearly all axons in the medial corpus callosum are demyelinated. (D) Weeks 5–6 “early remyelination.” In this week the 
amount of activated microglia begins to decline. Astrocytes are still activated but change their morphology. OPC differentiate 
and begin to remyelinate nude axons (Gudi, Gingele et al. 2014). 
To overcome disadvantages of in vitro and in vivo models, ex vivo models based on organotypic cultures 
have been established. Myelination in such cultures was first examined in 1956 (Hild 1956). Since then, 
the technique was further developed to investigate different brain areas and organotypic cultures have 
been characterized and adapted to study myelination, demyelination and remyelination (Zhang, Jarjour 
et al. 2011). According to this characterization, organotypic culture myelination occurs readily and it is 
extensive by 10 days in vitro (DIV). After exposure to a demyelinating stimulus, remyelination process 
takes place since OPC are present in slice cultures. Thus organotypic cultures mimic in vivo processes 
and are a suitable model to study myelin status in different conditions. 
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AIM 
Prion disorders are a group of rare, fatal and progressive neurodegenerative disorders affecting both 
humans and animals. Among all neurodegenerative diseases, prion disorders are of prominent biological 
and pathological interest since they have genetic, sporadic and infectious origin. The infectious agent 
derives from PrPC, the endogenously encoded protein (Prusiner 2001). Upon conformational conversion, 
PrPC gives rise to the prion, or PrPSc, enriched in β-sheets and prone to aggregate (Caughey and 
Raymond 1991, Gasset, Baldwin et al. 1993). There is an ongoing debate about the nature of the 
neurotoxicity observed in prion diseases. According to the gain of toxic function hypothesis, the prion 
pathology is attributable to novel toxic properties acquired by PrPSc (Harris and True 2006, Westergard, 
Christensen et al. 2007, Linden, Martins et al. 2008, Winklhofer, Tatzelt et al. 2008). However, PrPSc 
alone is not sufficient to induce prion disease (Bueler, Aguzzi et al. 1993, Brandner, Isenmann et al. 1996, 
Hill and Collinge 2003). Therefore, it has been proposed that PrPC protective activity may be lost upon 
conversion to or contact with PrPSc. This PrPC loss-of-function would then cause neurodegeneration. 
Arguing against this second hypothesis, genetic ablation of Prnp expression has relatively little 
phenotypic effect and does not induce prion disease by itself. Both gain-of-function and loss-of-function 
may act to cause the disease. PrPSc toxic function may perturb PrPC protective function, exacerbating the 
pathology (Harris and True 2006, Westergard, Christensen et al. 2007, Linden, Martins et al. 2008, 
Winklhofer, Tatzelt et al. 2008). Understanding physiological function of PrPC may help to disclose 
pathological and disease-related phenotypes, as well as to propose new curative strategies. Despite 
many efforts have been done in the past years, PrPC physiological function has not been completely 
defined (Aguzzi, Baumann et al. 2008). To unveil PrPC function, several KO and transgenic mouse models 
have been generated. At a first look, PrPc-deficient mice develop normally but, at a deeper analysis, 
many subtle phenotypic changes have been reported. A striking property of PrPC is its ability to bind 
divalent cations such as copper (Stockel, Safar et al. 1998, Jackson, Murray et al. 2001, Singh, Das et al. 
2010). PrPC is able to support copper reduction from Cu(II) to Cu(I) (Liu, Jiang et al. 2011) and it may 
have superoxide dismutase activity, protecting cells from oxidative damage (Brown, Wong et al. 1999, 
Brown, Clive et al. 2001). PrPc and copper cooperatively protect neurons from excitotoxicity by 
mediating NMDAR inhibition through S-nitrosylation (Gasperini, Meneghetti et al. 2015). Other studies 
report a PrPc protective role against programmed cell death (Kuwahara, Takeuchi et al. 1999) and Bax-
mediated apoptosis (Bounhar, Zhang et al. 2001, Didonna, Sussman et al. 2012). PrPc is also a cell-
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surface receptor coupled to the tyrosine kinase Fyn for signal transduction (Mouillet-Richard, Ermonval 
et al. 2000, Aguzzi, Baumann et al. 2008), it plays a role in circadian rhythm, spatial learning, neurite 
outgrowth, phagocytosis and inflammatory response, hematopoietic-stem-cell renewal and neural-
stem-cell differentiation (Caughey and Baron 2006, Aguzzi, Baumann et al. 2008). Besides, PrPC is 
involved in the maintenance of PNS myelination as observed in PrPC-null mice that, after an initial 
formation of morphologically normal PNS myelin, show a long-term myelin maintenance disruption 
(Bremer, Baumann et al. 2010, Benvegnu, Gasperini et al. 2011). Neuronal PrPC expression is sufficient to 
prevent peripheral myelin degeneration, probably mediating axon to Schwann cells communication 
(Bremer, Baumann et al. 2010, Benvegnu, Gasperini et al. 2011). Differently, PrPC absence does not 
affect CNS myelin maintenance. Only the expression of PrPC mutants lacking the HC domain can trigger 
demyelination (Shmerling, Hegyi et al. 1998, Baumann, Tolnay et al. 2007, Li, Christensen et al. 2007, 
Bremer, Baumann et al. 2010). However, the possibility that subliminal myelin pathologies might extend 
to central myelin in Prnp0/0 mice was not excluded. Indeed, PrPC is involved in many processes that may 
influence myelin formation and maintenance. Firstly, its absence increases OPC proliferation and delays 
their maturation. Secondly, PrPC is involved in metal homeostasis and modulates oxidative stress. Both 
processes must be tightly regulated to prevent myelin structural or functional impairments (Zimmerman, 
Matthieu et al. 1976, Bongarzone, Pasquini et al. 1995, Matsushima and Morell 2001, Beard and Connor 
2003, Bizzozero, DeJesus et al. 2004, Encinas, Manganas et al. 2005, Liu, Chen et al. 2005, Morelli, 
Ravera et al. 2012, Skjørringe, Møller et al. 2012, Aspli, Flaten et al. 2015).  
In light of these considerations, this thesis is aimed to deeper investigate the role of PrPC in CNS 
myelination. Taking advantage from Prnp+/+ and Prnp0/0 mice, myelin composition was evaluated in 
mouse brains at different developmental stages, from early postnatal days to aging: neonatal (postnatal 
day 1 (P1)), early postnatal (P7), young (P14), end of the development-early adulthood (P30), adulthood 
(P90), late adulthood (P180), early aging (P365) and late aging (P450). In particular, cholesterol content 
and myelin-related proteins and genes were investigated in both Prnp+/+ and Prnp0/0 mice. Myelin 
morphology was investigated on corpus callosum by using transmission electron microscopy. The effects 
of PrPC absence on CNS myelin formation and maintenance was compared with those identified in the 
SN. To better investigate PrPC role in CNS myelin, an ex vivo model based on OHC was established and 
validated. This system showed a good correlation with in vivo observations for studying myelination-
demyelination-remyelination.  
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MATERIALS AND METHODS 
ANIMALS 
Inbred FVB/N Prnp+/+ and FVB Prnp0/0  male mice were used in these experiments. The FVB Prnp0/0 mice 
were obtained by backcrossing the original ZurichI Prnp0/0 mice (Bueler, Fischer et al. 1992) to FVB/N 
inbred mice for more than 20 generations (Lledo, Tremblay et al. 1996). All experiments were 
performed in accordance with European regulations [European Community Council Directive, November 
24, 1986 (86/609/EEC)] and were approved by the local authority veterinary service. All efforts were 
made to minimize animal suffering and to reduce the number of animals used. P1 to P14 animals were 
sacrificed by decapitation, while adult mice were killed by cervical dislocation. P180 and P365 mice used 
for electron microscopy studies were deeply anesthetized with CO2 and transcardially perfused. After 
the animal sacrifice, brains and SNs were extracted, immediately frozen in liquid nitrogen and stored at -
80 °C. Samples were collected at the following developmental stages: P1, P7, P14, P30, P90, P180, P365 
and P450. P1, P7 and P14 were considered developmental stages, P30 end of the development-early 
adulthood, P90 adulthood, P180 late adulthood, P365 early aging and P450 late aging. 
TISSUE HOMOGENIZATION AND MEMBRANE PURIFICATION 
Brains and SNs were homogenized in MES Buffer (25 mM pH 7.0, 2 mM EDTA, 5 mM NaF, 0.5 mM 
Na3VO4, proteases inhibitors cocktail (Inhibitor complete mini, Roche Diagnostics Corp., Mannheim, 
Germany)), (Sodero, Vriens et al. 2012). Samples were cleared by centrifugation (2000 g, 10 min, 4 °C) 
and supernatants were considered as total extracts. To purify the membrane fraction, part of the total 
extract was further centrifuged at 100000 g for 45 min at 4 °C (Optima Max Ultracentrifuge, Beckman 
Instruments). The resulting pellet was washed with MES Buffer and centrifuged again at 100000 g for 45 
min at 4 °C. The membrane containing pellet was re-suspended in MES Buffer and briefly sonicated. As 
control, a different method for membrane purification was also used. P30 mouse brains were 
homogenized in Isotonic Buffer (0.32 M sucrose, 0.5 mM MgSO4, 2 mM 2-Mercaptoethanol, 1 mM EDTA, 
10 mM Hepes-KOH pH 7.4, proteases inhibitors cocktail, 5 mM NaF, 0.5 mM Na3VO4). Samples were 
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further processed as described for MES Buffer and membrane pellet was re-suspended in 10 mM Hepes-
KOH pH 7.4, 1.5% SDS, proteases inhibitors cocktail, 5 mM NaF, 0,5 mM Na3VO4. Protein concentration 
was determined by bicinchoninic acid (BCA) assay (Sigma-Aldrich). 
ENZYMATIC CHOLESTEROL  
Brain and SN cholesterol level was assessed by fluorometric detection using a commercial available kit 
(Amplex Red Cholesterol Assay Kit, Molecular Probes, Invitrogen). Briefly, cholesteryl esters were 
hydrolyzed by cholesterol esterase into cholesterol, which was then oxidized using cholesterol oxidase 
to yield hydrogen peroxide and the corresponding ketone product. Hydrogen peroxide was then 
detected using 10-acetyl-3,7-dihydroxyphenoxazine. This compound, in the presence of horseradish 
peroxidase (HRP), reacts with hydrogen peroxide to produce highly fluorescent resorufin. Fluorescence 
was measured in a fluorescence microplate reader (SpectraMax M5, Molecular Devices) using excitation 
and emission wavelength of 544 nm and 590 nm respectively. The equivalent of 3 µg of total brain 
proteins and 0.5 µg of total SN proteins were loaded in the plate. As reference, a cholesterol standard 
curve was prepared with cholesterol concentration from 0 to 8 µg/ml. Background correction was 
applied by subtracting the value derived from the no-cholesterol control. 
PROTEIN EXPRESSION ANALYSIS 
Proteins expression was measured by Western blot (WB) in SN, brain and OHC. For each sample, the 
same protein amount (4-20 μg) was separated by SDS–PAGE in 12% polyacrylamide gels. On each gel, 
Prnp+/+ and Prnp0/0 samples were loaded, in order to compare them. Commonly, proteins were 
denaturated 15 min at 60 °C in loading buffer (10% glycerol, 50mM TrisHCl pH 6.8, 2% w/v SDS, 4M Urea, 
0.005% bromophenol blue). Proteins were transferred on nitrocellulose and after 1h in blocking solution 
membranes were incubated overnight at 4°C with the primary antibody. After incubation with the 
secondary antibody, membranes were developed with ECL detection reagent (GE Healthcare, Waukesha, 
WI, USA) and recorded by the digital imaging system Alliance 4.7 (UVITEC, Cambridge, UK). Bands 
quantification was performed with Uviband 15.0 software (UVITEC, Cambridge, UK). Each protein signal 
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was normalized against β-Actin for total homogenate samples or against Flotillin-1 for membrane 
samples. 
ANTIBODIES 
The following primary antibodies were used in TBST (Tris-Buffered Saline plus Tween 20) + 5% milk: anti-
β-Actin Peroxidase (AC-15) 1:10000 (A3854, Sigma-Aldrich); anti-Flotillin-1 (18) 1:1000 (610821, BD 
Biosciences), anti-Myelin PLP 1:1000 (AB28486, Abcam), anti-MAG 1:1000 (AB89780, Abcam), anti-MOG 
1:1000 (AB32760), anti-MPZ 1:10000 (AB31851, Abcam). The following primary antibody was used in 
TBST + 5% bovine serum albumin (BSA): anti-MBP 1:500 (AB980, Millipore). 
RNA EXTRACTION AND TEAL TIME PCR 
To check the expression of myelin-related genes, mRNA was extracted from brains and SNs of four 
Prnp+/+ and four Prnp0/0 mice at P30, P180 and P365. Besides, mRNA was extracted from 4 independent 
sets of Prnp+/+ and Prnp0/0 OHC after 28 DIV, where each set was composed of around 20 or more 
hippocampal slices. Frozen samples were homogenized in TRIzol reagent (15596018, Invitrogen) and 
total RNA was extracted following the TRIzol reagent manufacturer's instructions. To limit genomic DNA 
contamination, samples were treated with RNase free DNase set (79254, Qiagen, Germantown, MD, 
USA) and purified using the RNeasy mini kit (74104, Qiagen). RNA quantification was performed using a 
NanoDrop 2000 spectrophotometer (Thermo Scientific). RNA quality was assessed by observing on 1% 
agarose gel the two characteristic bands corresponding respectively to 28S and 18S rRNA. RNA was 
retrotranscribed by using SuperScriptIII RT (18080, Invitrogen) and oligodT primer (5′-GCT GTC AAC GAT 
ACG CTA CGT AAC GGC ATG ACA GTG(T)24-3′). In parallel, for each sample a negative control was carried 
along by omission of the reverse transcriptase (RT-) to check the presence of genomic contamination. All 
the primer sequences reported in Table 4 were tested by PCR and analyzed on a 2% agarose gel to verify 
their specificity for the genes of interest. Quantitative real time PCR was performed adding 2 ng RNA 
equivalent to the reaction mix including 2× iQ™ SYBR® Green Supermix (Bio-Rad Laboratories, Inc.) and 
400 nM of the corresponding forward and reverse primer (Sigma) on an iQ5 Multicolor Real-Time PCR 
Detection System (Bio-Rad Laboratories, Inc.). After initial denaturation for 3 min at 95°C, 40 cycles were 
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performed at 95°C for 15 sec and 60°C for 1 min. The expression of the gene of interest was normalized 
to housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and β-actin, and the initial 
amount of the template of each sample was determined as relative expression versus housekeeping 
gene chosen as reference. The relative expression of each sample was calculated by the formula 2exp-
∆∆Ct (User Bulletin 2 of the ABI Prism 7700 Sequence Detection System) (Livak and Schmittgen 2001). 
Housekeeping gene expression is not modified under the present experimental conditions (data not 
shown).  
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Table 4. Primer list for qRT-PCR experiments. 
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ELECTRON MICROSCOPY 
P180 and P365 Prnp+/+ and Prnp0/0 mice were transcardially perfused with saline solution followed by 4% 
paraformaldehyde (PFA) in in 0.12 M phosphate buffer (PB). Brains were removed and fixed with 4% PFA 
and 2% glutaraldehyde in 0.12 M PB. Tissues were post-fixed with 1% osmium tetroxide and embedded 
in Epon (Fluka). Semithin and ultrathin sections were obtained as described in (Quattrini, Previtali et al. 
1996). Ultrathin sections (70–90 nm thick) were stained with uranile acetate and lead citrate and 
examined by electron microscopy. 
ORGANOTYPIC HIPPOCAMPAL CULTURES PREPARATION 
As an ex vivo model of myelination, roller-tube OHC preparation protocol was set up based on 
Gahwiler’s protocol (Gahwiler, Capogna et al. 1997). Briefly, P5 mice were sacrificed and hippocampi 
were dissected in aseptic condition in dissection medium (Gey’s balanced salt solution, 5.6 mM D-
Glucose (G8270, Sigma-Aldrich), 1 mM kynurenic acid (K3375, Sigma-Aldrich)). Hippocampi were sliced 
by means of a tissue chopper into 300 μm thick sections. After rinsing in dissection medium for 40 min 
at 4 °C, slices showing an intact hippocampal cytoarchitecture were selected and singularly attached to a 
coverslip by embedding in a chicken plasma (P3266, Sigma-Aldrich) and thrombin (112374, Merck KGaA, 
Darmstadt, Germany) cloth. After 45 min at room temperature (RT), coverslips were placed into flat-
sided tubes (NUNC) with a medium composed by 50% basal medium Eagle (BME, 41010026, Gibco, 
Carlsbad, CA, U.S.), 25% horse serum (26050-088, Gibco), 25% Hank’s balanced salt solution (24020141, 
Gibco), 5.6mM D-Glucose, 2mM L-Glutamine (25030-032, Gibco). OHC were maintained at 37 °C in slow 
rotation (ten revolutions per hour) up to 28 DIV, when they were collected, immediately frozen in liquid 
nitrogen and stored at -80 °C. 
ORGANOTYPIC HIPPOCAMPAL CULTURES CUPRIZONE TREATMENT 
The copper chelator CZ (14690, Sigma-Aldrich) was freshly dissolved 1 mM in OHC medium with 0.25% 
ethanol and filter-sterilized. The proper dissolution of CZ was monitored by adding copper sulfate 
(C2284, Sigma-Aldrich) to CZ-containing medium and recording the CZ[Cu(II)] complex absorption at 
59 
 
600 nm (Benetti, Ventura et al. 2010). After 14 DIV, OHC were exposed to CZ-containing medium or to 
control medium (OHC medium with 0.25% ethanol) for 7 days. At 21 DIV, the same treatment was 
repeated with freshly prepared CZ-containing or control medium. Control and CZ-treated OHC were 
collected at 28 DIV, immediately frozen in liquid nitrogen and stored at -80 °C.  
MTS CELL VIABILITY ASSAY  
To evaluate the effect of CZ treatment on cell viability, the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay was performed on OHC after 14 days 
of 1 mM CZ exposure. The MTS assay was set up according to manufacturer instruction, with a few 
modifications necessary for roller-tube OHC. MTS powder was dissolved in phosphate-buffered saline 
(PBS) to 2 mg/ml to produce a clear golden-yellow solution. PES (phenazine ethosulfate) powder was 
dissolved in MTS solution to 0.21 mg/ml. Finally pH was adjusted to 6.0 to 6.5 using 1N HCl. The solution 
was filter-sterilized through a 0.2 μm filter into a sterile, light protected container. After 14 days of 1 
mM CZ exposure, OHC were washed with PBS and incubated with 0.33 mg/ml MTS in OHC medium for 3 
h at 37 °C. OHC medium containing the soluble formazan product produced by viable cells was collected 
and 200 µl were placed in a 96-well plate. Absorbance values were measured at 490 and 650 nm. The 
650 nm absorbance value was used as background, hence subtracted to the 490 nm signal. Cell viability 
was expressed as percentage of the control OHC value that was considered to be 100% viable and 
compared by t-Test. After MTS assay, OHC were washed one time with PBS, collected and immediately 
frozen in liquid nitrogen. OHC were stored at -80 °C for further use. 
STATISTICAL ANALYSES 
All the results concerning mouse SN and brain were compared between Prnp+/+ and Prnp0/0 samples 
performing the Student’s t-Test setting two-tailed distribution and two-sample unequal variance. For 
OHC experiments, 20 or more OHC slices of the same genotype and treatment were pulled together to 
be analyzed in one experimental replicate. Each pull was analyzed multiple times (technical replicates) 
during the same experimental replicate. The results of these technical replicates were compared 
between Prnp+/+ and Prnp0/0 samples performing the Student’s t-Test setting two-tailed distribution and 
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two-sample unequal variance. Finally, the results of different experimental replicates were compared by 
performeing the paired Student’s t-Test setting two-tailed distribution.   
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RESULTS 
ANALYSIS OF PERIPHERAL NERVOUS SYSTEM MYELINATION IN 
Prnp+/+ AND Prnp0/0 MICE 
PrPC has been reported to be essential for the maintenance of peripheral nervous system myelination 
(Bremer, Baumann et al. 2010, Benvegnù, Gasperini et al. 2011). Therefore some experiments were 
performed in order to confirm the occurrence of peripheral demyelination in our aged Prnp0/0 mice. 
Cholesterol quantification, myelin protein content and gene expression analysis were carried out in 
Prnp+/+ and Prnp0/0 mouse SN. Measurements were done at different developmental stages to monitor 
PNS myelin status from early postnatal days to aging. 
SCIATIC NERVE CHOLESTEROL CONTENT  
Cholesterol is the only integral myelin component essential for the development of both CNS and PNS 
myelin (Saher, Quintes et al. 2011). Considering this, cholesterol content was measured as a marker of 
myelin status in Prnp+/+ and Prnp0/0 mouse SN from early postnatal days to aging. Results are expressed 
as the ratio between Prnp0/0 and Prnp+/+ cholesterol content. In PrPC-null SN, cholesterol is increased at 
P7 and P14 of about 20% and 10% respectively compared to WT animals (Figure 17). During aging (P365 
and P450), cholesterol decreases in Prnp0/0 SN of about 50% compared to Prnp+/+ mice. 
62 
 
 
Figure 17. SN cholesterol content at different ages. The graph shows the ratio between Prnp
0/0 
and Prnp
+/+
 mice. All error bars 
indicate SD. Sample size: n=4; 3 right limb and 3 left limb SNs are considered n=1 at P7; right limb and left limb SNs are 
considered n=1 from P14 to P450; *p<0.05, **p<0.01. 
MYELIN PROTEIN EXPRESSION ANALYSIS IN SCIATIC NERVES 
Expression levels of myelin proteins were analyzed in PNS of both Prnp+/+ and Prnp0/0 mice at the 
different developmental stages. PLP, MBP, MAG and MPZ were analyzed in total SN homogenates. 
Representative images of bands obtained from WB experiments are shown in Figure 18. β-Actin was 
used as housekeeping protein for normalizing myelin protein contents. Results are expressed as the 
ratio between Prnp0/0 and Prnp+/+ protein content. 
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Figure 18. PNS myelin proteins. Representative WB images of PLP, MBP, MAG, MPZ and L-MPZ proteins from Prnp
+/+ 
and 
Prnp
0/0 
total SN homogenates. The constant level of β-Actin is also shown. 
Compared to Prnp+/+ mice, in Prnp0/0 SN PLP expression is lower at P30 and P365 (Figure19A), while MBP 
decreases in the early post-natal days till P30 and during aging (P365 and P450), (Figure 19B). In PrPC-
null SN, the expression level of glycosylated MAG is similar to WT SN at all developmental stages (Figure 
19C). Differently, in the absence of PrPC, non-glycosylated MAG is considerably increased starting from 3 
months of age (Figure 19C). MPZ shows an increasing trend in aged Prnp0/0 SN, with significant 
difference at P365 (Figure 19D). Its isoform L-MPZ is reduced in P7 Prnp0/0 SN and it has a decreasing 
trend during aging, with significant difference at P450. 
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Figure 19. PNS myelin protein expression levels. The graphs show the ratio between Prnp
0/0
 and Prnp
+/+ 
protein content. For 
each protein, the optical density value was normalized on the housekeeping protein β-Actin. All error bars indicate SD. (A) PLP. 
(B) MBP. (C) Glycosylated and non-glycosylated MAG. (D) MPZ and L-MPZ. Sample size: n=4, 3 right limb and 3 left limb SNs are 
considered n=1 at P7; right limb and left limb SNs are considered n=1 from P30 to P450; *p<0.05, **p<0.01. 
65 
 
TRANSCRIPTIONAL ANALYSIS OF MYELIN GENES IN THE PNS 
To investigate the transcriptional regulation of myelin proteins, qRT-PCR experiments were performed 
on SN total RNA extracted from P30, P180 and P365 Prnp+/+ and Prnp0/0 mice. The following transcripts 
were analyzed: Plp1 and its splice variant Dm20, Mbp, S-Mag and L-Mag and finally Mpz. Results were 
normalized on the housekeeping gene β-actin whose expression level is not different in Prnp+/+ and 
Prnp0/0 samples (data not shown). The non-template control (NTC) did not give any amplification result, 
as well as the RT- reactions. Results are expressed as ΔΔCt relative quantification of Prnp0/0 versus 
Prnp+/+ samples and the fold change is reported. At P30, Plp1, S-Mag and Mpz do not present differences 
between Prnp+/+ and Prnp0/0 samples (Figure 20). On the contrary, Dm20, Mbp and L-Mag are 
significantly decreased in Prnp0/0 SN. At P180, Prnp0/0 SN shows a decreased transcription level of Plp1, 
Dm20 and Mbp. A decreasing trend is visible also for S-Mag, L-Mag and Mpz, though differences are not 
statistically significant due to the high sample variability. At P365, all analyzed genes present a 
decreased transcriptional level compared to WT samples, except for L-Mag which does not show any 
statistically significant difference. 
 
Figure 20. Myelin gene transcription in Prnp
0/0
 and Prnp
+/+
 SN measured by qRT-PCR. Plp1, Dm20, Mbp, S-Mag, L-Mag and 
Mpz transcripts were analyzed at P30, P180 and P365. The results were normalized on the housekeeping gene β-actin and are 
represented as ΔΔCt relative quantification of Prnp
0/0 
versus Prnp
+/+
 samples. All error bars indicate SD. The fold change values, 
calculated by the formula 2exp
-ΔΔCt
, are reported on the top of each column. Sample size: n=4, right limb and left limb SNs are 
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considered n=1 from P30 to P450; 3 right limb and 3 left limb SNs are considered n=1 at P7; *p<0.05, **p<0.01, ***p<0.001, 
*****p<0.00001. 
ANALYSIS OF CENTRAL NERVOUS SYSTEM MYELINATION IN 
Prnp+/+ AND Prnp0/0 MICE 
While the role of PrPC in the maintenance of PNS myelination has already been proved, a similar role in 
the CNS is still controversial. Prnp0/0 mice do not show any gross myelin disturbance, though PrPC 
absence affects proliferation and maturation of oligodendrocyte precursor cells (Bribián, Fontana et al. 
2012).  PrPC also modulates two important processes in myelin formation and maintenance as metal 
homeostasis and oxidative stress (Brown and Sassoon 2002). In this work the role of PrPC in CNS 
myelination was investigated using Prnp+/+ and Prnp0/0 mouse brain. Similarly to PNS, cholesterol content, 
myelin protein and gene expression analysis were also carried out in the brain. To monitor CNS myelin 
status from early postnatal days to aging, measurements were done at the different developmental 
stages previously described. 
BRAIN CHOLESTEROL MEASUREMENT 
As for the PNS, cholesterol is essential for myelin membrane stability also in CNS. It represents about 
30% of the total myelin lipids and approximately 70% of brain cholesterol is associated to myelin sheaths 
(Baumann and Pham-Dinh 2001). Therefore, cholesterol content was used as a marker of myelin status 
in Prnp+/+ and Prnp0/0 mouse brain from early postnatal days to aging. Results are expressed as the ratio 
between Prnp0/0 and Prnp+/+ cholesterol content. Figure 21 shows a 15% reduction in Prnp0/0 brain 
cholesterol at P1 and a not significant slight reduction at P7. Starting from P180, a cholesterol 
decreasing trend is observed in Prnp0/0 brains, with significant difference only at P365 (10% cholesterol 
reduction compared to Prnp+/+ brains). 
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Figure 21. Brain cholesterol content at different ages. The graph shows the ratio between Prnp
0/0 
and Prnp
+/+
 mice. All error 
bars indicate SD. Sample size: n=6 at P1 and P7; n=4 from P30 to P450; *p<0.05, **p<0.01. 
MYELIN PROTEIN EXPRESSION ANALYSIS IN THE BRAIN 
The expression levels of the most important proteins for CNS myelination were analyzed in Prnp+/+ and 
Prnp0/0 brains at different ages. In particular the following proteins were investigated: PLP, MBP, MAG 
and MOG.  
Noteworthy, protein expression analysis of total brain homogenates prepared in MES buffer did not 
reveal significant differences between Prnp+/+ and Prnp0/0 mice, showing high sample variability (data 
not shown).  
Since myelin is composed of membranes enwrapping axons, membrane extracts were used for analyzing 
myelin proteins in Prnp+/+ and Prnp0/0 samples. Figure 22 shows representative images of bands obtained 
from WB experiments with membrane extracts, including the housekeeping protein Flotillin-1. 
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Figure 22. CNS myelin proteins. Representative WB images of PLP, MBP, MAG and MOG proteins from Prnp
+/+ 
and Prnp
0/0 
brain 
membrane extracts.  The constant level of Flotillin-1 is also represented. 
In PrPC-null membrane extracts, PLP is increased at all ages (Figure 23A) and MBP is increased at P1 and 
P365 (Figure 23B). In the absence of PrPC, the level of MOG protein increases at all the ages except at 
P90 (Figure 23C). Conversely from PNS, non-glycosylated MAG is not altered in PrPC-null brains, while 
the glycosylated form is increased at all ages except at P90 (Figure 23D). Although the non-glycosylated 
MAG has a low expression level, it is increased only in P7 Prnp0/0 mice compared to WT controls (Figure 
23D). 
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Figure 23. CNS myelin protein expression levels. The graphs show the ratio between Prnp
0/0
 and Prnp
+/+ 
protein content 
measured in brain membrane-enriched fractions. For each protein, the optical density value was normalized on the 
housekeeping protein Flotillin-1. All error bars indicate SD. (A) PLP. (B) MBP. (C) MOG. (D) Glycosylated and non-glycosylated 
MAG. Sample size: n=4; *p<0.05, **p<0.01, ***p<0.001. 
To exclude the dependence of these results on the membrane extraction protocol, another method 
based on Isotonic Buffer was applied. To reduce the number of required animals, this control 
experiment was performed only using P30 mice. PLP, MBP and MAG  were measured and images of 
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bands obtained from WB experiments are shown in Figure 24A, including the housekeeping protein 
Flotillin-1. As previously described, PLP is higher in PrPC-null brain than in WT mice (Figure 24B). MBP 
and MAG follow the same increasing trend, but the difference is not statistically significant due to the 
high sample variability (p=0.199 and p=0.066 respectively) (Figure 24B). 
 
Figure 24. CNS myelin protein expression in P30 membrane fractions extracted in Isotonic Buffer. (A) Representative Western 
blot images of PLP, MBP and MAG in Prnp
+/+ 
and Prnp
0/0 
brain membrane extracted in Isotonic Buffer. The housekeeping protein 
Flotillin-1 is also shown. (B) PLP, MBP and MAG quantification represented as a ratio between Prnp
0/0
 and Prnp
+/+ 
protein 
content measured in Isotonic Buffer brain membrane-enriched fractions. For each protein, the optical density value was 
normalized on the housekeeping protein Flotillin-1. All error bars indicate SD. Sample size: n=4; **p<0.01. 
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TRANSCRIPTIONAL ANALYSIS OF GENES INVOLVED IN CNS 
MYELINATION 
Prnp0/0 mice showed a general myelin protein overexpression compared to Prnp+/+. To investigate the 
role of transcription on myelin protein overexpression, qRT-PCR experiments were performed on total 
RNA extracted from P30, P180 and P365 Prnp+/+ and Prnp0/0 mouse brains. The following transcripts 
were analyzed: Plp1 and its splice variant Dm20, Mbp, Mog, S-Mag and L-Mag. Results were normalized 
on two housekeeping genes (β-actin and Gapdh) whose expression levels are not different in Prnp+/+ and 
Prnp0/0 samples (data not shown). The NTC did not give any amplification result, as well as the RT-
reactions. Concerning P30 brains, all analyzed myelin-related genes are significantly increased in Prnp0/0, 
normalizing versus either β-actin (Figure 25A) or Gapdh (Figure25B). Similar results were obtained at 
P180, though Plp1 shows significance only versus Gapdh (Figure 25B). At P365 all myelin-related genes 
are increased in their transcriptional level, except Mbp and L-Mag that show significance only versus β-
actin (Figure 25A) but not Gapdh (Figure 25B). Interestingly, Dm20 has the highest fold change between 
Prnp+/+ and Prnp0/0 mice at all the ages (Figure 25A-B). Despite these results suggest that the myelin 
protein overexpression is due to transcriptional upregulation, they do not exclude an increase of 
oligodendrocytes population compared to WT. 
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Figure 25. Myelin gene transcription in Prnp
0/0
 and Prnp
+/+
 brain measured by qRT-PCR. Plp1, Dm20, Mbp, Mog, S-Mag and L-
Mag  transcripts were analyzed at P30, P180 and P365. The results were normalized on the housekeeping gene β-actin (A) and 
Gapdh (B). The graphs show the ΔΔCt relative quantification of Prnp
0/0 
versus Prnp
+/+
 samples. All error bars indicate SD. The 
fold change values, calculated by the formula 2exp
-ΔΔCt
, are reported in the lower part of each graph. Sample size: n=4; *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, *****p<0.00001. 
To test this hypothesis, qRT-PCR experiments were performed on the same brain RNA samples in order 
to investigate the oligodendrocyte and neuronal population. The following transcripts were analyzed: 
NG2 (neural/glial antigen 2) as oligodendrocyte precursor cells indicator, Sox10 ((sex determining region 
Y)-box 10) as total oligodendrocyte marker, Tubb3 (βIII-tubulin) and NeuN (neuronal nuclei) as neuronal 
markers. At P30, no differences were detected between Prnp+/+ and Prnp0/0 brains, though NeuN 
presents a small increase in Prnp0/0 samples when normalized with Gapdh (Figure 26B). Concerning P180 
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brains, NG2, Sox10 and Tubb3 are over-expressed in Prnp0/0 brains only when normalized with Gapdh 
(Figure 26B). At P365, the only differentially transcribed gene is Tubb3 (Figure 26). These last results did 
not allow to clarify with certainty the influence of oligodendrocyte proliferation on myelin protein 
increase in PrPC-null mice. 
 
Figure 26. Oligodendrocyte and neuronal gene transcription in Prnp
0/0
 and Prnp
+/+
 brain measured by qRT-PCR. NG2, Sox10, 
Tubb3 and NeuN transcripts were analyzed at P30, P180 and P365. The results were normalized on the housekeeping gene β-
actin (A) and Gapdh (B). The graphs show the ΔΔCt relative quantification of Prnp
0/0 
versus Prnp
+/+
 samples. All error bars 
indicate SD. The fold change values, calculated by the formula 2exp
-ΔΔCt
, are reported in the lower part of each graph. Sample 
size: n=4; *p<0.05, **p<0.01. 
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ELECTRON MICROSCOPY ANALYSIS OF CNS MYELIN 
In the literature, no differences on CNS myelin structure and morphology have been associated to the 
absence of PrPC (Bremer, Baumann et al. 2010, Bribián, Fontana et al. 2012). To further investigate the 
observed differences between PrP KO and WT brains, transmission electron microscopy was performed 
on P180 (Figure 27A-F) and P365 (Figure 27G-L) Prnp+/+ and Prnp0/0 corpus callosum samples. 
Micrographs revealed that Prnp0/0 mice exhibit normal myelination in the CNS, inferring that the subtle 
changes observed in CNS myelin protein expression and gene transcription do not affect myelin 
structure. 
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Figure 27. Adult Prnp
0/0
 mice exhibit normal myelination in the CNS. Electron microscopy of P180 and P365 Prnp
+/+
 and Prnp
0/0 
corpus callosum. (A, B, D, E, G, H, J, K) Lower magnification electron microscopy photomicrograph of Prnp+/+ and Prnp0/0 mice. 
Scale bars: 2µm. (C, F, I, L) Higher magnification electron microscopy photomicrograph show no gross ultrastructural 
differences in the myelin sheaths of the corpus callosum. Scale bars: 1 µm. 
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ORGANOTYPIC HIPPOCAMPAL SLICE CULTURES AS AN EX VIVO 
MODEL FOR MYELINATION 
To better investigate the role of PrPC in CNS myelination, an ex vivo model based on OHC was 
established. Myelination of organotypic cultures was reported to occur readily and to be extensive by 10 
DIV (Zhang, Jarjour et al. 2011). Therefore, Prnp+/+ and Prnp0/0 OHC were prepared and let in culture for 
up to 28 DIV to resemble the P30 mouse brain in vivo. To confirm the occurrence of myelination in OHC 
and validate the system, myelin protein and gene expression was evaluated.   
MYELIN PROTEIN EXPRESSION ANALYSIS IN OHC 
To analyze the OHC myelin protein expression, membrane proteins were purified from around 40-50 
Prnp+/+ and 40-50 Prnp0/0 OHC slices. Membrane extraction was necessary for avoiding interferences 
with proteins composing the clot. OHC membrane proteins were analyzed by WB and three 
independent experimental replicates (Exp.1, Exp.2 and Exp.3) were performed. PLP, MBP and MAG 
expression levels were quantified and normalized versus Flotillin-1 and results are reported in Figure 
28A. T-Test performed within each experimental replicate shows a significant increase in PLP, MBP and 
MAG expression levels in Prnp0/0 OHC compared to Prnp+/+ OHC (Figure 28A). A significant increase in the 
PLP expression level was also observed considering all the three experimental replicates. No statistical 
significance is observed for MBP and MAG due to the high sample variability, though an increasing trend 
in Prnp0/0 OHC is still present (Figure 28A). Additional experiments are required to improve the statistics. 
Figure 28B shows representative images of WB bands obtained from one experiment (Exp.1), while 
Figure 28C reports quantification results of PLP, MBP and MAG represented as a ratio between Prnp0/0 
and  Prnp+/+ OHC in the same replicate. The amount of analyzed myelin proteins is visibly higher in 
Prnp0/0 than in Prnp+/+ OHC. Taken together, results show the correlation between PrPC-null 28 DIV OHC 
and in vivo P30 mouse brains. Thus, OHC are a suitable ex vivo model to study PrPC role in CNS 
myelination.  
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Figure 28. Myelin protein expression in 28 DIV Prnp
+/+
 and Prnp
0/0
 OHC. Membrane proteins were purified in order to get rid 
of the proteins composing the OHC covering clot. (A) Table representing PLP, MBP and MAG expression levels in three 
independent replicates of the experiment (Exp.1, Exp.2 and Exp.3). PLP, MBP and MAG optical density values were normalized 
versus Flotillin-1 and are reported as a ratio between Prnp
0/0 
and Prnp
+/+
 OHC. For each experimental replicate, SD derived from 
the technical replicates is shown. Furthermore, this table reports the p values calculated with the t-Test (for each individual 
experimental replica, in blue) or with the paired t-Test (considering all the replicates together). (B) Representative images of 
PLP, MBP and MAG WB bands obtained in Exp.1. The housekeeping protein Flotillin-1 is also reported. (C) PLP, MBP and MAG 
protein content represented as a ratio between Prnp
0/0
 and Prnp
+/+ 
OHC in Exp.1. For each protein, the optical density value was 
normalized on the housekeeping protein. All error bars indicate SD. *p<0.05, **p<0.01. 
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TRANSCRIPTIONAL ANALYSIS OF MYELIN GENES IN OHC 
To understand molecular mechanisms underlying myelin protein overexpression in Prnp0/0 OHC, qRT-
PCR experiments were performed on total RNA extracted from 28 DIV Prnp+/+ and Prnp0/0 OHC. The 
following transcripts were analyzed: Plp1, Dm20, Mbp, Mog, S-Mag and L-Mag. Four independent 
experiments were performed, each one comparing one set of around 20 or more Prnp+/+ and Prnp0/0 
hippocampal slices. Table 5 reports the ΔCt values of WT and PrPC-null OHC for each analyzed gene and 
for each experimental replicate. The results were normalized on two housekeeping genes (β-actin and 
Gapdh) whose expression levels are not different in Prnp+/+ and Prnp0/0 samples (data not shown). The 
NTC did not give any amplification result, as well as the RT- reactions. The resulting p value was 
calculated applying paired t-Test and it indicates that all transcripts are increased in Prnp0/0 than in 
Prnp+/+ OHC at 28 DIV when normalizing versus Gapdh. When normalizing versus β-actin, myelin genes 
show a tendency to increase in Prnp0/0 OHC without being statistically significant. The correlation 
between protein overexpression and gene upregulation is also confirmed using OHC, as previously 
observed in mouse brains. Also in OHC Dm20 has the highest fold change (Figure 29A-B). This further 
confirms the suitability of OHC system as a model to study the role of PrPC in CNS. 
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Table 5. Transcriptional analysis of myelin genes in 28 DIV Prnp
+/+
 and Prnp
0/0 
OHC. Table reporting the ΔCt values of WT and 
PrP
C
-null OHC for each analyzed gene (Plp1, Dm20, Mbp, Mog, S-Mag and L-Mag) and for each replicate of the experiment, 
normalized versus the housekeeping gene β-actin or Gapdh. The resulting p values calculated with the paired t-Test formula are 
also reported (blue). Sample size: in Exp.1, Exp.3 and Exp.4 a pull of around 20 Prnp
+/+
 and 20 Prnp
0/0 
OHC slices was used; in 
Exp.2 a pull of around 70 Prnp
+/+
 and 70 Prnp
0/0 
OHC slices was used. 
Figure 29. Example of myelin gene transcription results in Prnp
0/0
 and Prnp
+/+
 28 DIV OHC measured by qRT-PCR in Exp.2 
replicate. Plp1, Dm20, Mbp, Mog, S-Mag and L-Mag transcripts were analyzed and the results were normalized on the 
housekeeping gene β-actin (A) and Gapdh (B). The graphs show the ΔΔCt relative quantification of Prnp
0/0 
versus Prnp
+/+
 
samples. All error bars indicate SD derived from technical replicates. The fold change values, calculated by the formula 2exp
-ΔΔCt
, 
are reported in the lower part of each graph. Sample size: pull of around 70 Prnp
+/+
 and 70 Prnp
0/0 
OHC slices; *p<0.05, 
**p<0.01, ***p<0.001. 
Since myelin protein overexpression in PrPC-null OHC could be due to an increase of oligodendrocytes, 
qRT-PCR experiments on oligodendrocytic (NG2 and Sox10) and neuronal (Tubb3 and NeuN) markers 
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were performed. Table 6 reports ΔCt values of WT and PrPC-null OHC, normalized on β-actin and Gapdh. 
For each considered gene, the p value was calculated with the paired t-Test. It indicates that no 
statistical significance was found between Prnp+/+ and Prnp0/0 OHC in the entire experimental set. The 
absence of oligodendrocyte transcriptional difference in OHC suggests that no alterations in 
oligodendrocyte proliferation occur in Prnp0/0 OHC. Alternatively, oligodendrocyte proliferation could 
occur in PrPC-null OHC without affecting gene transcription. 
 
Table 6. Transcriptional analysis of oligodendrocytes and neuronal genes in 28 DIV Prnp
+/+
 and Prnp
0/0 
OHC. Table reporting 
the ΔCt values of WT and PrP
C
-null OHC for each analyzed gene (NG2, Sox10, Tubb3, NeuN) and for each replicate of the 
experiment, normalized versus the housekeeping gene β-actin or Gapdh. The resulting p values calculated with the paired t-Test 
formula are also reported. Sample size: in Exp.1, Exp.3 and Exp.4 a pull of around 20 Prnp
+/+
 and 20 Prnp
0/0 
OHC slices was used; 
in Exp.2 a pull of around 70 Prnp
+/+
 and 70 Prnp
0/0 
OHC slices was used. 
OHC TREATMENT WITH CUPRIZONE 
Once validated the OHC system as a suitable tool for studying the role of PrPC in CNS myelination, this ex 
vivo model was used to establish a myelination-demyelination-remyelination model. Prnp+/+ and Prnp0/0 
OHC were exposed to the well-known demyelinating agent CZ. This copper chelating agent is widely 
used in myelin research to induce demyelination in animal models. No information are available on its 
use for in vitro and ex vivo purposes.  After an initial period of myelination (14 DIV), Prnp+/+ and Prnp0/0 
OHC were exposed to 1 mM CZ-containing medium for 7 days. At 21 DIV, the same treatment was 
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repeated with freshly prepared CZ-containing medium. Control and CZ-treated OHC were collected at 28 
DIV and processed to analyze the effect of the treatment on myelin status.  
Firstly, myelin protein expression analysis was performed using membranes extracted from around 40 
Prnp+/+ and 40 Prnp0/0 OHC slices exposed to vehicle or CZ. OHC membrane proteins were processed 
through WB and PLP, MBP and MAG expression levels were quantified and normalized versus the 
housekeeping protein Flotillin-1. The results of one experimental replicate are reported in Figure 30A-C 
as the percentage of genotype-matched control. CZ-treated Prnp+/+ OHC show a significant increase of 
PLP, MBP and MAG proteins compared to controls. Concerning Prnp0/0 OHC, CZ treatment has a milder 
effect, triggering a significant increase in the expression level of PLP. Figure 30D shows representative 
images of PLP, MBP and MAG WB bands, together with the housekeeping protein Flotillin-1. A second 
replicate confirmed the results. These experiments show that CZ administration to OHC does not induce 
a decrease in the amount of myelin proteins. On the contrary this treatment induces myelin protein 
expression in WT OHC, while only a mild effect is observed in PrPC-null samples.  
 
Figure 30. Myelin protein expression in CTRL and CZ treated Prnp
+/+
 and Prnp
0/0
 OHC. Membrane proteins were purified in 
order to get rid of the proteins composing the OHC covering clot. Western blots were performed and PLP, MBP and MAG 
optical densities were normalized versus the housekeeping protein Flotillin-1. (A-C) Graphs showing the results as the 
percentage of each myelin protein in CZ exposed Prnp
+/+
 and Prnp
0/0 
OHC compared to their genotype-matched control. These 
results come from one single experimental replicate; sample size: pull of about 40 OCH slices for each genotype and for each 
condition. All error bars represent SD derived from the technical replicates. *p<0.05, ***p<0.001; *****p<0.00001. (A) PLP. (B) 
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MBP. (C) MAG. (D) Representative images of PLP, MBP and MAG WB bands in CTRL and CZ-treated Prnp
+/+
 and Prnp
0/0 
OHC. The 
housekeeping protein Flotillin-1 is also reported.  
To evaluate the effect of prolonged CZ treatment on cell viability, MTS assay was performed on Prnp+/+ 
and Prnp0/0 OHC after 14 days exposure to 1 mM CZ. Results reported in Figure 31 reveal that CZ 
treatment does not affect Prnp0/0 OHC viability, while it increases viability in WT OHC. 
 
Figure 31. MTS assay on CTRL and CZ treated Prnp
+/+
 and Prnp
0/0
 OHC. The graph shows the cell viability percentage in Prnp
+/+
 
and Prnp
0/0
 OHC treated and not treated with 1 mM CZ for 14 DIV; all error bars indicate SD; N=10-11; *p<0.05. 
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DISCUSSION 
The cellular form of prion protein has been widely investigated since its misfolded isoform is the 
causative agent of prion disorders (Prusiner 1991). Although PrPC localizes mainly in the nervous system 
and particularly in the synaptic compartments (Moya, Sales et al. 2000, Kanaani, Prusiner et al. 2005, 
Benvegnu, Poggiolini et al. 2010), PrPC is expressed in most non-neuronal tissues, including blood 
lymphocytes, gastro-epithelial cells, heart, kidney, liver and muscles, prompting the involvement of this 
protein in various physiological processes (Horiuchi, Yamazaki et al. 1995, Fournier, Escaig-Haye et al. 
1998). It is known that PrPC structural features such as glycosylation sites, cysteines forming a disulfide 
bridge and a hydrophobic transmembrane region are perfectly conserved among different mammalian 
species. PrPC sequences responsible for secondary structure elements, N- and C-terminal processing of 
the precursor protein and attachment of the GPI membrane anchor are highly conserved, suggesting 
that PrPC may retain important physiological functions (van Rheede, Smolenaars et al. 2003, Colby and 
Prusiner 2011).  Little is known about PrPc normal cellular function and about the precise manner in 
which it exerts its pathogenicity. At a first look, PrPc-deficient mice develop normally but they display 
minor defects imputable to a higher sensitivity to various stress stimuli. Many PrPc functions rely on its 
ability to bind divalent cations and particularly copper with higher affinity (Stockel, Safar et al. 1998, 
Jackson, Murray et al. 2001, Singh, Das et al. 2010, Arena, La Mendola et al. 2012). Thus, PrPc is involved 
in metal homeostasis, protecting neurons from possible Fenton reactions produced by metal unbalance 
(Brown 2003). PrPc is a copper-binding protein that could protect neurons against oxidative damages 
through its superoxide dismutase activity, and contribute to synaptic homeostasis (Brown, Wong et al. 
1999, Brown, Clive et al. 2001). PrPc and copper cooperatively protect neurons from excitotoxicity by 
mediating NMDAR inhibition through S-nitrosylation (Gasperini, Meneghetti et al. 2015). Other studies 
report a PrPc protective role against programmed cell death (Kuwahara, Takeuchi et al. 1999) and Bax-
mediated apoptosis (Bounhar, Zhang et al. 2001, Didonna, Sussman et al. 2012). There is evidence that 
PrPc is a cell-surface receptor for signal transduction, coupled to the tyrosine kinase Fyn (Mouillet-
Richard, Ermonval et al. 2000). Considering the involvement of PrPc in all these protective functions and 
in many other cellular processes, it is clear that a full understanding of PrPc normal and physiological 
mode of action may help elucidating some of the pathological phenotypes observed in prion diseases. 
To date, the nature of the neurotoxicity observed in prion diseases is still an open debate. A first 
hypothesis concerns the gain of toxic function of the pathological isoform PrPSc. In this view, PrPSc 
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possesses novel toxic properties that are not related to the normal and physiological function of PrPC. 
Since PrPSc alone is not sufficient to induce prion diseases (Bueler, Aguzzi et al. 1993, Brandner, 
Isenmann et al. 1996, Hill and Collinge 2003), it has been proposed that PrPC protective activity may be 
lost upon conversion to or contact with PrPSc. This PrPC loss-of-function would then cause 
neurodegeneration. This may explain some familial prion diseases, in which the effect of PrP mutations 
affects thermodynamic stability and biochemical properties of PrP, leading to the loss of its function. On 
the other hand, genetic ablation of Prnp expression has relatively little phenotypic effect and does not 
induce prion diseases by itself. Thus, it is possible that these two hypotheses work together, meaning 
that PrPSc toxicity may perturb PrPC protective function, exacerbating the pathology. For instance, a PrPC 
cytoprotective activity that is dispensable under normal conditions may become essential in the disease 
state due to cellular stress, but may be lost due to PrPSc presence (Harris and True 2006, Westergard, 
Christensen et al. 2007, Linden, Martins et al. 2008, Winklhofer, Tatzelt et al. 2008). Understanding the 
normal function of PrPC may have important implications for possible future therapies of prion 
disorders. At present, most therapeutic approaches aim to inhibit PrPSc formation. Targeting the cellular 
pathways in which PrPC exerts its protective function may be an alternative strategy to modulate the 
disease progression. 
Among different physiological processes, PrPC is involved also in the maintenance of PNS myelination 
(Bremer, Baumann et al. 2010, Benvegnu, Gasperini et al. 2011). PrPC-null mice present an initial 
formation of morphologically normal PNS myelin, but long term myelin maintenance is disrupted as 
reported in Figure 10. In particular, neuronal PrPC expression is sufficient to prevent peripheral myelin 
degeneration, possibly mediating axon to Schwann cells communication. Different hypotheses try to 
explain this late peripheral demyelination occurring in the absence of PrPC. One is the age-related 
impairment in the correct PrPC cleavage in late secretory compartments, which is necessary to preserve 
intact peripheral myelin (Bremer, Baumann et al. 2010). Secondly, the NRG1 and NRG3 processing is 
altered in PrPC absence in the PNS of adult and aged mice (Benvegnu, Gasperini et al. 2011). PrPC may 
influence NRG cleavage by modulating BACE1 (Parkin, Watt et al. 2007). Differently, PrPC absence does 
not affect CNS myelin maintenance (Figure 11-12). Only the expression of PrPC mutants lacking the HC 
domain (Figure5), but not the complete absence of the protein can trigger demyelination. The fact that 
PrPC absence affects only PNS but not CNS myelin maintenance may rely on the different characteristics 
of these two myelin structures. Indeed PNS and CNS myelin differ one from the other in the kind of 
myelinating cells (Schwann cells or oligodendrocytes), lipid and protein composition, morphology (i.e., 
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presence or absence of the basal lamina) and signaling (Baumann and Pham-Dinh 2001, Taveggia, Feltri 
et al. 2010). This may explain why the function that PrPC fulfill is different from PNS to CNS myelin. 
However, the possibility that subliminal myelin pathologies might extend to central myelin in Prnp0/0 
mice has still not been excluded. Indeed, PrPC is involved in many processes that may influence myelin 
formation and maintenance. Firstly, its absence increases OPC proliferation and delays their maturation 
(Bribián, Fontana et al. 2012). Secondly, PrPC is involved in metal homeostasis and modulates oxidative 
stress. Both processes must be tightly regulated to prevent myelin structural or functional impairments 
(Zimmerman, Matthieu et al. 1976, Bongarzone, Pasquini et al. 1995, Matsushima and Morell 2001, 
Beard and Connor 2003, Bizzozero, DeJesus et al. 2004, Encinas, Manganas et al. 2005, Liu, Chen et al. 
2005, Morelli, Ravera et al. 2012, Skjørringe, Møller et al. 2012, Aspli, Flaten et al. 2015).  
In the first part of this work, the role of PrPC in CNS myelination was deeper investigated. Taking 
advantage from Prnp+/+ and Prnp0/0 mice, myelin composition was evaluated in mouse brains at different 
developmental stages, from early postnatal days to aging: neonatal (P1), early postnatal (P7), young 
(P14), end of the development-early adulthood (P30), adulthood (P90), late adulthood (P180), early 
aging (P365) and late aging (P450). Furthermore, peripheral myelin status was also investigated in the 
SN in order to have a comparative analysis between the CNS and PNS myelin.  
Myelin is composed of membranes with a peculiar lipid to protein composition. Differently from the 
other cellular membranes which present a higher amount of proteins respect to lipids, myelin is made of 
about 70-85% of lipids and only 15-30% of proteins (Baumann and Pham-Dinh 2001). As described 
above, myelin contains cholesterol, phospholipids and glycolipids in molar ratios ranging from 4:3:2 to 
4:4:2. Cholesterol alone constitute about 30% of the total myelin lipids (Saher, Quintes et al. 2011). In 
the nervous system, the majority of brain cholesterol accumulates between the perinatal period and 
adolescence when neurons become myelinated. After this developmental period, cholesterol 
metabolism in the adult has a low turnover, but it continues to be active (Orth and Bellosta 2012, Zhang 
and Liu 2015). In this project, cholesterol content was investigated in Prnp+/+ and Prnp0/0 mice as a 
marker of myelin status. As reported in Figure 17, cholesterol is higher in Prnp0/0  SN than in WT controls 
at early postnatal days P7 and P14. The higher SN cholesterol content at these developmental stages 
reflects either an increased rate of cholesterol synthesis or alterations during embryonic development. 
These changes are then compensated during the adulthood, when no differences in SN cholesterol 
content are observe between the two genotypes. During aging (P365 and P450), cholesterol content is 
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reduced in Prnp0/0 SN of about 50% compared to Prnp+/+ mice. This huge cholesterol depletion is 
consistent with PNS demyelination described in Prnp0/0 mice. Conversely from PNS, cholesterol content 
is reduced in Prnp0/0 brain at early postnatal stage P1. A non-statistically significant reduction is also 
visible at P7 (Figure 21).  As for PNS, these changes may be caused by metabolic alterations during the 
embryo development. During embryonic development and in the early postnatal period, CNS undergoes 
an enormous cellular expansion. A sufficient availability of cholesterol as well as a correct ratio of 
cholesterol and phospholipids is crucial for the physicochemical properties of cells within the CNS (Orth 
and Bellosta 2012). Therefore, compensatory mechanisms may promptly re-establish the correct 
cholesterol content to guarantee the correct myelination of Prnp0/0 brains. Similarly to PNS, a cholesterol 
decrease is observed during aging in Prnp0/0 brains, with a significant 10% reduction at P365. During 
aging, cholesterol reduction in Prnp0/0 brain appears subtle when compared to the 50% reduction 
observed in the SN. Since approximately 70% of brain cholesterol is associated to the myelin sheath, a 
slight decrease in cholesterol content may impair myelin functionality. Interestingly, PrPC absence may 
impair PNS cholesterol more than CNS due to the higher metabolic activity of peripheral nerve myelin 
compared to CNS one (Rawlins and Smith 1971). Alternatively, higher cholesterol depletion in Prnp0/0 SN 
might not be a cause, but simply the consequence of the peripheral myelin degenerative process. 
Concerning cholesterol and lipid metabolism, it is interesting to notice that iron is directly involved in 
cholesterol and other lipid biosynthesis, since it is a co-factor for many enzymes acting in these 
pathways (Connor and Menzies 1996). Since Prnp0/0 brain presents an altered iron content and 
distribution, myelin production or maintenance may be affected (Singh, Kong et al. 2009, Pushie, 
Pickering et al. 2011). 
Besides cholesterol measurement, the expression of myelin proteins was evaluated in the PNS and CNS 
of Prnp+/+ and Prnp0/0 mice from early postnatal days to aging. PLP and MBP have low expression levels 
in the PNS where they seem not essential for a correct myelin structure (Baumann and Pham-Dinh 2001). 
Compared to WT mice, in Prnp0/0 SN PLP expression is lower at P30 and P365 (Figure19A) and MBP 
decreases in the first developmental stages (P7 and P30) and during the aging (P365 and P450) (Figure 
19B). Although these proteins are not essential in the PNS, changes in their expression level during aging 
may correlate with the peripheral demyelination process. These results indicate an altered PNS myelin 
composition from postnatal stages up to the adulthood, before the appearance of morphological 
changes occurring during aging. In this work MAG was also analyzed in the SN. This protein is mostly 
found in its fully glycosylated form and it is involved in neuron-glia adhesion and in bi-directional 
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signaling. In PrPC-null SN, the glycosylated form of MAG is quite constant throughout the development, 
while the non-glycosylated form of MAG is considerably increased starting from 3 months of age (Figure 
19C). The absence of glycosylation may affect the interaction of the protein with myelin sheath or impair 
its signaling role. MPZ is the most important protein for PNS myelination, representing about 50% of 
total myelin proteins. It is essential for PNS myelination and it resembles PLP function in the CNS. MPZ 
expression is increased in aged Prnp0/0 SN, with significant difference at P365 (Figure 19D). This result 
apparently contrasts with the demyelination affecting the PNS of aged Prnp0/0 mice. It is possible that 
demyelination occurs without altering MPZ relative content in myelin, thus impeding a reduced 
detection in WB. Differently, its isoform L-MPZ is reduced in P7 Prnp0/0 SN and a decreasing trend is 
visible also during the aging, with significant difference at P450. Since very little is known about the 
function of L-MPZ isoform, it is not possible to speculate on the biological meaning of its decrease in 
early postnatal and aged Prnp0/0 SN (Yamaguchi, Hayashi et al. 2012). Moving to the CNS, myelin 
proteins show a general upregulation in Prnp0/0 brain at all the ages, except at P90 (Figure 23). More in 
detail, in PrPC-null brain membrane fractions, PLP is increased at all the ages (Figure 23A) and MBP is 
increased at P1 and P365 (Figure 23B). The level of MOG protein is higher at all ages except at P90 in 
PrPC-null mice than in WT (Figure 23C). The expression of the main MAG glycosylated form is increased 
at all stages except at P90 (Figure 23D). Conversely from PNS, the non-glycosylated form of MAG is 
poorly detectable and it rises with the aging (P365 and P450) in a similar way between WT and Prnp0/0 
mice. Although the non-glycosylated MAG has a very low expression level, it shows an increment in P7 
Prnp0/0 mice compared to WT. It must be noticed that myelin protein expression changes between 
Prnp+/+ and Prnp0/0 brains occur only in enriched membrane fractions. No changes were observed in total 
brain homogenates, indicating that these are subtle differences. A possible reason for explaining 
different sample preparation used to appreciate changes in SN and brains relies on tissue composition. 
While SN is indeed principally made of myelinated and unmyelinated axons, brain homogenate include 
white and grey matter. Thus the presence of subtle differences may be hidden by the complexity of 
brain protein composition. To exclude the dependence of these results on the membrane extraction 
protocol, another method was applied and the same protein overexpression trend was confirmed in 
Prnp0/0 brains (Figure 24). Myelin protein expression analysis does not allow a direct quantification of 
myelin content, but it indicates membrane composition of SN and brain. Taken together, these results 
show that PrPC absence alters myelin protein composition differently in peripheral and central nervous 
system. Changes in PrPC-null SN protein composition during aging are possibly related to myelin sheath 
degeneration, while subtle impairments are observed in Prnp0/0 CNS throughout the whole lifetime, with 
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the only exception of P90. Many possible causes can justify the observed general myelin protein 
overexpression in Prnp0/0 brain. Firstly, myelin protein increase may be related to alterations in the 
transcriptional regulation of related genes. Secondly, a different trafficking and tournover of myelin 
proteins can occur in Prnp0/0 brain, storing or arranging them in different membrane compartments. 
Thirdly, an increased oligodendrocyte number can account for this observation. 
In order to verify whether myelin protein amount correlates with the transcriptional level of the 
corresponding genes, a qRT-PCR analysis was performed on SN and brain total RNA extracted from P30, 
P180 and P365 Prnp+/+ and Prnp0/0 mice. At P365, Prnp0/0 SN presents a significant decrease in the 
transcription level of myelin-related genes compared to WT mice. These results are consistent with the 
PNS demyelination affecting Prnp0/0 mice. Concerning the CNS, a small but general increase of myelin 
gene expression was observed in Prnp0/0 brain at all ages (Figure 25). These data correlate with the 
myelin protein increment described before (Figure 23). As reported in Figure 25, the differences are 
characterized by a low fold change increment, confirming that PrPC absence induce subtle impairments 
in the CNS. Interestingly, in Prnp0/0 brains Dm20 has the highest fold changes. Dm20 expression 
precedes that of PLP1 during development. Differently, in adult brain DM20 protein is present at much 
lower level compared to PLP1. In some reports, Dm20 gene expression has been associated to 
remyelinating conditions in adult brain (Mathisen, Kawczak et al. 2001). Considering that demyelination 
does not occur in Prnp0/0 brains (Bremer, Baumann et al. 2010, Bribián, Fontana et al. 2012), Dm20 
transcriptional upregulation cannot be implicated in remyelinating processes, but more likely in 
reparative processes. The myelin protein and gene increment in Prnp0/0 brains could be due to an 
increment in oligodendrocyte number. To verify this hypothesis, qRT-PCR experiments were performed 
on the same brain RNA samples in order to investigate the oligodendrocyte and neuronal population. 
NG2 and Sox10 transcripts were analyzed as oligodendrocyte precursor cells and total oligodendrocyte 
marker, while Tubb3 and NeuN were used as neuronal markers. The transcription of these genes shows 
only some oscillations that were not maintained between different ages and that were not confirmed in 
both Gapdh and β-actin normalization (Figure 26). This hampered the possibility to clarify the 
contribution of oligodendrocyte proliferation on myelin protein increase in PrPC-null mice. Other 
techniques such as WB or immunofluorescence could be applied to better elucidate this question. 
To conclude the analysis of CNS myelin in Prnp+/+ and Prnp0/0 mice, an electron microscopy study was 
performed in the corpus callosum of P180 and P365 mice. Corpus callosum was chosen since it is the 
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myelin richest region in the brain. Evidence reported in literature showed that CNS myelin structure and 
morphology do not have alterations due to PrPC absence (Bremer, Baumann et al. 2010, Bribián, 
Fontana et al. 2012). Transmission electron microscopy measurements were done in order to unveil 
subtle differences between Prnp+/+ and Prnp0/0 myelin. As shown in Figure 27, Prnp0/0 mice exhibit 
normal CNS myelination. These qualitative observations indicate that the subtle changes observed in 
CNS myelin protein expression and gene transcription do not affect myelin structure and morphology in 
Prnp0/0 mice. Taken together, these results suggest that myelin protein overexpression could be due to a 
compensatory mechanism for preventing functional abnormalities in CNS myelin. It would be useful to 
study the oligodendrocyte lineage and myelin protein distribution in different membrane compartments. 
Once the characterization of peripheral and central nervous system myelin in Prnp+/+ and Prnp0/0 mice 
was completed, an ex vivo model based on OHC was established to better investigate PrPC role in CNS 
myelin. The first report describing organotypic cultures myelination was dated 1956 (Hild 1956). Later, 
since organotypic cultures can be maintained in vitro for a prolonged period of time compared to other 
dissociated cultures and considered that they preserve a pool of active OPC, this ex vivo technique was 
adapted as a model to study myelination, demyelination and remyelination (Zhang, Jarjour et al. 2011). 
The organotypic cultures myelination process was reported to occur readily and to be extensive by 10 
DIV (Zhang, Jarjour et al. 2011). Therefore, Prnp+/+ and Prnp0/0 OHC were prepared and let in culture for 
up to 28 DIV to reach a myelination rate similar to the in vivo P30 mouse brain. To confirm the 
occurrence of myelination in OHC and to verify whether this system reflects in vivo condition, myelin 
protein and gene expression was evaluated.  A significant increase in PLP was observed in Prnp0/0 OHC 
compared to Prnp+/+ OHC (Figure 28). MBP and MAG expression level was also found increased in PrPC-
null OHC compared to WT ones.  The transcriptional regulation of myelin related genes was analyzed by 
qRT-PCR on RNA extracted from 28 DIV Prnp+/+ and Prnp0/0 OHC. The statistical analysis of four 
experimental replicates (Table 5) indicates that the transcription of all the analyzed myelin genes is 
higher in Prnp0/0 than in Prnp+/+ OHC at 28 DIV when normalizing versus Gapdh. When normalizing versus 
β-actin, myelin genes show a tendency to increase in Prnp0/0 OHC, without being statistically significant. 
Therefore, myelin protein increment in PrPC-null OHC correlates with an increased gene expression, as it 
was previously observed in mouse brains. To verify the possibility that myelin protein over-expression 
observed in PrPC-null OHC could be due to an increment in oligodendrocytes number, oligodendrocyte 
and neuronal genes were analyzed by qRT-PCR. As shown in Table 6, no difference was found in NG2, 
Sox10, Tubb3 and NeuN between Prnp+/+ and Prnp0/0 OHC in the entire experimental set. The absence of 
oligodendrocyte genes transcriptional difference in OHC suggests that an increase in oligodendrocyte 
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proliferation and number does not explain myelin protein over-expression in Prnp0/0 OHC. Alternatively, 
oligodendrocyte proliferation could occur in PrPC-null OHC without affecting gene transcription. Taken 
together, myelin protein and gene expression results concerning OHC are consistent with previous in 
vivo observations in mouse brains. Therefore, OHC are a suitable model to study PrPC role in CNS, though 
large numbers of OHC are required to have reliable and confident results. Indeed, the variability among 
different sets of cultures is high and it can be overcome only by increasing sample size and experimental 
replicates.  
Once the OHC model was established, the effect of the presence or absence of PrPC on myelin was 
studied. Trying to establish a myelination-demyelination-remyelination model, Prnp+/+ and Prnp0/0 OHC 
were exposed to the copper chelator CZ, which is known to induce demyelination following oral 
administration in mice. However, no reports were already present concerning a similar use in in vitro or 
ex vivo cultures. Therefore, after 14 days in culture, necessary for the initial OHC myelination, Prnp+/+ 
and Prnp0/0 OHC were exposed to 1 mM CZ-containing medium for an overall period of 14 days. Myelin 
protein expression was analyzed by WB revealing that PLP, MBP and MAG protein percentage is 
significantly increased in Prnp+/+ OHC exposed to CZ, compared to controls (Figure 30). Concerning 
Prnp0/0 OHC, CZ treatment has a milder effect, triggering a significant increase in the expression level of 
PLP, but not of MBP and MAG. It is clear that CZ treatment does not induce a decrease in OHC myelin 
protein expression level as it would have been expected in case of demyelination (Praet, Guglielmetti et 
al. 2014). The effect of prolonged CZ treatment to cell viability was evaluated through the MTS assay. 
Prnp+/+ and Prnp0/0 OHC exposed to control and CZ conditions revealed that CZ treatment do not 
influence Prnp0/0 OHC viability, while it increases the viability of WT OHC. Two different hypotheses can 
explain the increase in Prnp0/0 OHC viability: firstly, CZ treatment may not be adequate to induce a 
sustained oligodendrocyte death and demyelination, thus promoting oligodendrocyte proliferation or 
reparative events following the toxic insult; secondly, the increase in viability percentage may be related 
to hormesis, a favorable biological response following low exposure to toxins or other stressors (Martins, 
Galluzzi et al. 2011). To discriminate between these two hypotheses, cell proliferation should be 
investigated during CZ exposure. One possible method could be the immunofluorescence-based 
detection of 5’-bromo-2’-deoxyuridine (BrdU) incorporation during CZ administration, in association 
with other neuronal and glial markers. The fact that CZ treatment is not inducing a decrease in OHC 
myelin protein expression, but an increase in myelin protein level, may have different reasons. First of 
all, it is possible that CZ does not act in culture. In fact, all the reports concerning CZ demyelinating role 
refer to in vivo experiments (Carlton 1967, Hoffmann, Lindner et al. 2008, Koutsoudaki, Skripuletz et al. 
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2009, Zendedel, Beyer et al. 2013). In vivo, CZ induces the death of mature myelinating oligodendrocytes, 
but its precise mechanism of action is still unclear (Norkute, Hieble et al. 2009, Bénardais, Kotsiari et al. 
2013). Since no traces of CZ have ever been found in the brain of CZ-fed mice, CZ may exert its 
myelinotoxic effect by interfering with copper intestinal absorption, thus  decreasing  the content of this 
metal also in the brain (Venturini 1973, Benetti, Ventura et al. 2010). Therefore, it is not obvious that CZ 
action in vitro is the same as in vivo. It is also possible that the effects observed in this thesis are due to 
CZ ability to chelate copper. Given the strict interconnection between copper and the homeostasis of 
other metals such as iron, it is possible that copper decrease may trigger a general metal dysregulation 
which can be sufficient to alter myelin status. This could also explain why CZ treatment acts strongly in 
WT OHC by increasing the myelin protein amount, while its effect is milder in PrPC-null samples. Since 
PrPC-null mice present a lower level of brain copper content per se, chelation of this metal ion may 
influence Prnp+/+ samples more than Prnp0/0 ones. A second possibility is that the dose and timing of CZ 
administration is not suitable to induce demyelination. While in mice CZ administration lasts at least 5-6 
weeks to induce demyelination, OHC are exposed to two consecutive CZ treatments of 7 days each. It is 
possible that CZ activity decreases during the 7 days in culture. Therefore, if CZ treatment is not enough 
strong or prolonged, OPC proliferation and myelin reparative processes may occur following the initial 
toxic stimulus. To better elucidate this point, it would be interesting to try other protocols for CZ 
administration to OHC. For example a daily OHC exposure to freshly dissolved CZ may give more insights 
concerning the suitability of the adopted protocol. Concluding, at the moment a suitable protocol to 
induce OHC demyelination has not yet been established. However, the observation of a different 
response of Prnp+/+ and Prnp0/0 OHC to CZ exposure denote a different CNS susceptibility to this kind of 
stimulus in the presence or absence of PrPC. 
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CONCLUSIONS AND PERSPECTIVES 
In this project, PrPC role in CNS myelination was investigated, taking advantage from Prnp+/+ and Prnp0/0 
mice. Myelin composition was examined in mouse brains at different developmental stages, from early 
postnatal days to aging, through cholesterol content measurement and through myelin protein and 
gene expression evaluation. Furthermore, peripheral myelin status was also investigated in the SN in 
order to have a comparative analysis between the CNS and PNS myelin. In the last part of the project, an 
ex vivo model based on OHC was established to better investigate PrPC role in CNS myelin.  
Concerning the PNS, most of our results are in line with the myelin degeneration observed in literature 
(Bremer, Baumann et al. 2010, Benvegnu, Gasperini et al. 2011). A 50% decrease in SN cholesterol 
content, a strong reduction of myelin genes transcription and an altered expression level of some myelin 
proteins were found during Prnp0/0 mouse aging. Moreover, some changes in the early postnatal period 
were also observed and these may be triggered by some alterations during embryonic development. 
Considering the CNS, the results obtained in this work are not discordant with the previous literature 
(Bremer, Baumann et al. 2010, Benvegnu, Gasperini et al. 2011, Bribián, Fontana et al. 2012). Since the 
fold change increase in myelin gene expression in Prnp0/0 brains is low and the increase in myelin protein 
level can be observed only in membrane-enriched fractions, it can be concluded that the differences 
induced by PrPC absence are subtle. In literature, a similar analysis of myelin protein has never been 
performed in membrane- or myelin-enriched fractions. Thus, such small differences were not noticed 
before. According to the previous literature, electron microscopy on CNS myelinated corpus callosum 
did not show gross morphological changes between Prnp+/+ and Prnp0/0 mice. It is possible that myelin 
protein overexpression could be the result of a compensatory mechanism to prevent functional 
abnormalities. Since myelin must be finely regulated and even small changes can impair the normal 
function, myelin reparative processes can be established to guarantee the maintenance of a correct 
morphology. This hypothesis could also relate to the observation that among all the analyzed myelin 
genes, DM20 isoform of PLP presents the highest increasing rate in Prnp0/0 brains. This isoform has been 
associated to remyelination. Further investigation of reparative mechanisms and signalling could 
elucidate this hypothesis. An increased number of oligodendrocyte may also account for the general 
myelin protein and genes overexpression in PrPC-null brains. According to Bribián and colleagues 
(Bribián, Fontana et al. 2012), PrPC absence increases OPC proliferation and delays their maturation, 
without affecting the final amount and quality of myelin. These authors hypothesize that 
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oligodendrocytes produced in excess undergo cell death to maintain a proper number of mature 
myelinating cells. However, their oligodendrocyte quantification is limited to 2-month-old mice, an age 
close to 3 months, when differences are scarcely detected also in this thesis. Therefore, it cannot be 
excluded with certainty that OPC increased proliferation may produce mature oligodendrocytes able to 
integrate themselves in the tissue cytoarchitecture being required for the maintenance of the correct 
myelin functionality. A quantitative and qualitative analysis of the oligodendrocyte lineage between 
Prnp+/+ and Prnp0/0 mice may be useful to confirm or exclude this hypothesis. Running against this 
hypothesis, an accurate electron microscopy analysis should be able to detect the occurrence of 
reparative phenomena. Furthermore, since the increase in myelin protein level in Prnp0/0 brains does not 
correspond necessarily to a myelin increase, it would be interesting to evaluate the myelin protein 
trafficking and localization in various cell membrane compartments, even different from myelin sheath. 
For example, it has been reported that PLP overexpression triggers its accumulation in endosomes-
lysosomes, together with cholesterol (Simons, Kramer et al. 2002). Therefore, immunofluorescence or 
WB on different cellular fractions may help investigating the localization of the myelin proteins, 
comparing Prnp0/0 with Prnp+/+ mice. 
As already discussed, PrPC plays numerous protective functions against different kind of stress 
conditions, such as oxidative and nitrosative stress and excitotoxicity. It is possible that PrPC 
cytoprotecting activity may be dispensable under normal conditions, but may become essential in 
stressful conditions or even in the disease state. According to this hypothesis, differences in CNS myelin 
status between Prnp0/0 and Prnp+/+ mice may be exacerbated in stress conditions. The particular 
combination of some peculiar features (high rate of ATP production, high iron content) renders 
oligodendrocytes, and consequently also myelin sheaths, more susceptible to damage than other CNS 
cellular components. In PrPC-null mice, and even more in prion diseases, PrPC loss of protective function 
may facilitate demyelinating processes. Since PrPC can modulate synaptic activity through its interaction 
with copper ions, its absence may increase excitotoxic effects, leading to cytosolic calcium accumulation. 
Calcium may be directly toxic for oligodendrocytes or may modulate different signalling pathways 
involved in myelination. The establishment of an ex vivo myelination model such as the OHC is 
important since it allows to investigate the CNS myelin response to different stimuli in the presence or 
absence of PrPC. Since OHC allow to investigate myelination, demyelination and remyelination, the 
different rate of occurrence of these processes might be evaluated between Prnp0/0 and Prnp+/+ mice. 
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Understanding PrPC physiological function in CNS myelin formation, maintenance and protection against 
toxic insults might be essential not only in the comprehension of some of the pathological phenotypes 
observed in prion diseases, but may also elucidate the PrPC protective role in other neurodegenerative 
conditions sharing elevated levels of oxidative and metabolic stress. 
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ORIGINAL RESEARCH COMMUNICATION
Prion Protein and Copper Cooperatively Protect Neurons
by Modulating NMDA Receptor Through S-nitrosylation
Lisa Gasperini,1 Elisa Meneghetti,1 Beatrice Pastore,1 Federico Benetti,1,* and Giuseppe Legname1,2
Abstract
Aims: Several neurodegenerative disorders show alterations in glutamatergic synapses and increased susceptibility to
excitotoxicity. Mounting evidence suggests a central role for the cellular prion protein (PrPC) in neuroprotection.
Therefore, the loss of PrPC function occurring in prion disorders may contribute to the disease progression and
neurodegeneration. Indeed, PrPCmodulatesN-methyl-d-aspartate receptors (NMDAR), thus preventing cell death. In
this study, we show that PrPC and copper cooperatively inhibit NMDAR through S-nitrosylation, a post-translational
modification resulting from the chemical reaction of nitric oxide (NO) with cysteines. Results: Comparing wild-type
Prnp (Prnp+/+) and PrPC knockout (Prnp0/0) mouse hippocampi, we found that GluN1 and GluN2A S-nitrosylation
decrease in Prnp0/0. Using organotypic hippocampal cultures, we found that copper chelation decreases NMDAR S-
nitrosylation in Prnp+/+ but not in Prnp0/0. This suggests that PrPC requires copper to support the chemical reaction
between NO and thiols. We explored PrPC-Cu neuroprotective role by evaluating neuron susceptibility to ex-
citotoxicity in Prnp+/+ and Prnp0/0 cultures. We found that (i) PrPC-Cu modulates GluN2A-containing NMDAR,
those inhibited by S-nitrosylation; (ii) PrPC and copper are interdependent to protect neurons from insults; (iii)
neuronal NO synthase inhibition affects susceptibility in wild-type but not in Prnp0/0, while (iv) the addition of a NO
donor enhances Prnp0/0 neurons survival. Innovation and Conclusions: Our results show that PrPC and copper
support NMDAR S-nitrosylation and cooperatively exert neuroprotection. In addition to NMDAR, PrPC may also
favor the S-nitrosylation of other proteins. Therefore, this mechanism may be investigated in the context of the
different cellular processes in which PrPC is involved. Antioxid. Redox Signal. 22, 772–784.
Introduction
The cellular prion protein (PrP
C) has been extensively
investigated since its isoform, the prion, was identified as
the causative agent of prion disorders (33). PrPC is widely ex-
pressed, reaching the highest levels in the nervous system (3, 12,
31). Comparing wild-type with PrPC-null mice (Prnp0/0) has
revealed that PrPC expression at synapses contributes to hippo-
campus synaptic function (6, 27, 28) and exerts neuroprotection
by modulating neuronal excitability (21, 34, 38). In particu-
lar, PrPC inhibits N-methyl-d-aspartate receptors (NMDAR)
and requires copper for this effect (21, 40). Interestingly, Ab
oligomers induce neurotoxicity by blocking PrPC-Cu modu-
lation of NMDAR (40). Impairments in NMDAR regulation
induce excitotoxicity, the neuronal cell death pathway trig-
gered by massive calcium influx (10). Calcium ions enter the
Innovation
A major cause of neurodegeneration is the disruption of
excitatory synapse regulation. Mounting evidence points to a
central neuroprotective role for the cellular prion protein
(PrPC), a key player in prion disorders andAlzheimer disease
(AD). Here, we describe a novel neuroprotective mechanism
mediated by PrPC, copper, and nitric oxide: copper-bound
PrPC modulates N-methyl-d-aspartate (NMDA)-type gluta-
mate receptors by promoting S-nitrosylation, inhibiting the
ionic channel. This mechanism is likely blocked in prion
disorders and AD, thereby leading to neuron loss. PrPC
function in protein S-nitrosylation may also guide the study
of the numerous cellular pathways in which PrPC is involved.
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cell through the NMDAR channel and bind several interactors,
for example, calmodulin (CaM). Calcium-bound CaM acti-
vates neuronal nitric oxide synthase (nNOS) and induces cop-
per-transporting ATPase 1 (Atp7a) translocation, thus leading
to nitric oxide (NO) production and copper release in the
synaptic cleft (22, 36). Copper and NO modulate the NMDAR
activity through a not clearly defined mechanism: NMDAR S-
nitrosylation provides a link between copper and NO inhibitory
roles (7, 23). S-nitrosylation is a chemical post-translational
modification targeting protein cysteines. In NMDAR, S-
nitrosylation is inhibitory and addresses two residues on GluN1
and three residues on GluN2A, including Cys399, which me-
diates the predominant inhibitory effect. Copper released in the
synaptic cleft is bound bymetal-binding proteins, such as PrPC,
which binds copper with high affinity and sustains Cu(II) redox
cycling (5, 8, 24). In vitro results have shown that PrPC-bound
Cu(II) promotes NO oxidation and is consequently reduced to
Cu(I) (4). As PrPC-Cu is involved in glypican-1 heparan sulfate
S-nitrosylation (29), the complex may also have a role in
NMDAR S-nitrosylation.
Here, we show that PrPC exerts copper-dependent neuro-
protection by mediating NMDAR S-nitrosylation. We define
PrPC-Cu direct involvement in NMDAR S-nitrosylation com-
paring GluN2A and GluN1 S-nitrosylation levels in Prnp+ /+
and Prnp0/0 hippocampi and cultures treated with a copper
chelator. PrPC neuroprotective function is characterized com-
paring excitotoxicity susceptibility in different Prnp+ /+ and
Prnp0/0 hippocampal areas. The copper/NO-dependence of
PrPC neuroprotective activity is assessed observing the effects of
copper chelation, NOS inhibition, and NO donation on neuronal
death in wild-type and Prnp0/0 cultures.We propose amodel for
this molecular mechanism based on the results presented here.
Results
PrPC is involved in NMDAR S-nitrosylation
The S-nitrosylation of NMDAR extracellular cysteines may
be a mechanism by which the PrPC-Cu complex inhibits ion
gating. To test this hypothesis, wemeasuredGluN2A andGluN1
S-nitrosylation levels in adult Prnp+ /+ and Prnp0/0 hippocampi.
To compare wild-type with PrPC-null samples, the Western
blotting signals corresponding to each S-nitrosylated protein
(i.e.,GluN2A, GluN1 and b-Actin) were normalized against the
respective input signals. Then, the obtained GluN2A and GluN1
ratio values were normalized against the corresponding b-actin
ratio value, as an internal control. The resulting values for
Prnp+ /+ and Prnp0/0 hippocampi were compared by the Mann–
Whitney test. In PrPC-null hippocampus, we detected lower
GluN2A (n=9, p=0.0004) and GluN1 (n=9, p=0.00203) S-
nitrosylation levels compared with those in the wild type (Fig.
1A, B). These findings show that in PrPC-null hippocampus
NMDAR S-nitrosylation is reduced. We confirmed these results
by using an additional S-nitrosylation-detection method (Sup-
plementary Materials and Methods and Supplementary Fig.
S1; Supplementary Data are available online at www.liebert
pub.com/ars). This observation suggests that PrPC is involved in
GluN2A and GluN1 S-nitrosylation and, possibly through this
mechanism, it can modulate the NMDAR activity.
To exclude that the results observed in Prnp0/0 hippocampus
aredue todifferent levels of eitherGluN2A-containingNMDAR
or nNOS at synapses, we performed a co-immunoprecipitation
(coIP) with the postsynaptic density protein 95 (PSD95). The
results revealed comparable GluN2A (direct PSD95 inter-
actor), GluN1 (indirect PSD95 interactor), and nNOS levels in
Prnp+ /+ and Prnp0/0 hippocampal synapses (Supplementary
Materials and Methods and Supplementary Fig. S2A–C).
Furthermore, to exclude that the results observed in Prnp0/0
hippocampus are due to altered NOS activity, first, we as-
sessed the similarity of b-actin S-nitrosylation levels (Fig. 1A)
and then measured both the consumption of NADPH, an es-
sential cofactor for NO production, and the conversion of
radiolabeled arginine to radiolabeled citrulline (Supplementary
Materials and Methods). Adult Prnp+ /+ and Prnp0/0 samples
exhibited comparable kinetics for NADPH consumption and
the same capability to convert arginine to citrulline (Supple-
mentary Fig. S3A, C). Taken together, these results suggest
that the decreased NMDAR S-nitrosylation in PrPC-null hip-
pocampus is not due to a reduction in the levels of NMDAR
and nNOS at synapses or alterations in NO production.
In the absence of PrPC, hippocampal neurons
are more susceptible to NMDAR-mediated excitotoxicity
Since Prnp0/0 hippocampus shows lower NMDAR S-
nitrosylation (Fig. 1 and Supplementary Fig. S1) but the same
protein level at synapses (Supplementary Fig. S2A, C), PrPC-
null neurons should be more susceptible to excitotoxic treat-
ment. To investigate the neuroprotective role of PrPC through
glutamate receptor inhibition, we carried out excitotoxicity
studies on Prnp+ /+ and Prnp0/0 organotypic hippocampal
FIG. 1. In adult Prnp0/0 hippocampus, the S-nitrosylation
ofGluN2AandGluN1NMDARsubunits is lower compared
to wild type. (A) Signals of S-nitrosylated fraction, controls
without either biotin or ascorbate and corresponding input of
GluN2A, GluN1, and b-actin resulting from the biotin switch
assay of Prnp+ /+ and Prnp0/0 hippocampus; controls without
either biotin or ascorbatewere doneusingPrnp+ /+ samples. (B)
Statistical analysis ofS-nitrosylatedGluN2AandGluN1signals
normalized on the corresponding input and on b-actin; all error
bars indicate SD; **p< 0.01; ***p< 0.001. NMDAR, N-
methyl-d-aspartate receptors.
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cultures (OHC) by analyzing specifically neuronal death in
Cornus Ammonis 1 (CA1), Cornus Ammonis 3 (CA3), and
dentate gyrus (DG). We exposed Prnp+ /+ and Prnp0/0 OHC to
two toxic treatments withNMDAas selectiveNMDARagonist:
5lM NMDA for 3 h (prolonged insult) and 10lM NMDA for
10min (acute insult). We chose these two protocols after
observing that they induce low neuronal cell death levels in
wild-type samples, hence they can clearly reveal a different
susceptibility of Prnp0/0 samples. Neuronal cell death was
evaluated as pyknotic nuclei percentage over the total number of
nuclei in CA1, CA3, and DG, respectively. The concomitant
staining with the anti-neuronal nuclei marker antibody (NeuN)
allowed us to localize the pyknotic event in neurons and clearly
distinguished glia cells. Figure 2A–M shows the different
FIG. 2. Wild-type and PrPC-null OHC show different regional susceptibility to NMDA treatment, under both pro-
longed and acute insult. Images from three hippocampal regions are reported in rows: (A–D)CA1, (E–H)CA3, and (I–L)DG.
The four different combinations of treatment and samples are reported in columns: (A, E, I)Prnp + / + control, (B, F, J)Prnp + /+
treated with 5 lM NMDA for 3 h, (C, G, K) Prnp0/0 control, and (D, H, L) Prnp0/0 treated with 5 lM NMDA for 3 h. NeuN
staining is displayed in green and DAPI in red. Confocal microscope fluorescence images were acquired using a 40· /1.30 NA
oil objective. Comparison of the neuronal pyknotic nuclei percentage induced by 5 lMNMDA for 3 h (M; n = 4 OHC, 5 slices
per treatment in each culture) and by 10lMNMDA for 10min (N; n = 5OHC, 5 slices per treatment in each culture), calculated
over the total nuclei number, betweenPrnp + / + (white bars) andPrnp0/0 (black bars) OHC in CA1, CA3, and DG; all error bars
indicate SD; *p < 0.05, **p < 0.01. CA1,Cornus Ammonis 1; CA3,Cornus Ammonis 3; DAPI, 4¢,6-diamidino-2-phenylindole;
DG, dentate gyrus; OHC, organotypic hippocampal cultures. To see this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars
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responses of Prnp+ /+ and Prnp0/0 OHC to the prolonged
treatment (n=4 OHC, 5 slices per treatment in each culture). In
CA1, the NMDA exposure significantly induced neuronal cell
death in both Prnp+ /+ ( p=0.03038) and Prnp0/0 (p=0.03038)
OHC (Fig. 2A–D, M), but at the same time, it revealed a higher
susceptibility of Prnp0/0 OHC ( p= 0.03038). The NMDA
treatment did not induce significant neuronal cell death in
wild-type CA3 and DG, whereas it yielded high toxicity for
both regions in PrPC-null cultures (CA3, p = 0.03038; DG,
p = 0.03038), highlighting a significant difference between
Prnp + / + and Prnp0/0 (CA3, p = 0.03038; DG, p = 0.01996)
(Fig. 2E–M). The same quantitative differences between
Prnp + / + and Prnp0/0 OHC were observed following the
acute treatment (Fig. 2N; n = 5 OHC, 5 slices per treat-
ment in each culture). In CA1, 10 lM NMDA for 10 min
induced neuronal cell death in both Prnp + / + ( p =
0.01996) and Prnp0/0 ( p = 0.01996) OHC, but it revealed
a higher susceptibility of Prnp0/0 compared with Prnp + / +
( p = 0.02157). In CA3, the acute treatment was toxic only
for Prnp0/0 OHC ( p = 0.03038), confirming their higher
susceptibility compared with Prnp + / + ( p = 0.01421). The
wild-type DG showed low levels of neuronal cell death in
response to the acute insult ( p = 0.02518), whereas the
same treatment caused a greater cell death percentage
( p = 0.01421) in Prnp0/0 DG, leading to a higher damage
compared to Prnp + / + ( p = 0.00507). The enhanced sus-
ceptibility of Prnp0/0 neurons to the excitotoxic stimulus
confirms findings previously reported in the literature,
obtained by stimulating neurons with kainate (34) and
NMDA (21).
To evaluate the early changes in neuronal cell viability, the
MTT (thiazolyl blue tetrazolium bromide) mitochondrial
toxicity assay was performed on Prnp + / + and Prnp0/0 OHC
after exposure to 5 lM NMDA for 3 h. Results revealed that
Prnp0/0 OHC are more susceptible to excitotoxicity also in
the early phases after insult (Supplementary Materials and
Methods and Supplementary Fig. S4).
The excitotoxic mechanism induced by NMDAR over-
activation is triggered by calcium ion influx into the neuronal
cell (10). To verify that the excitotoxicity observed was a
calcium-mediated effect, the same treatments were per-
formed adding a calcium chelator, ethylene glycol tetraacetic
acid (EGTA; n = 3 OHC, 4 slices per treatment in each cul-
ture). It should be noted that the treatment with 5 lM NMDA
was shortened to 1.5 h since calcium deprivation for 3 h re-
sulted to be toxic per se. As expected, adding EGTA to
NMDA abolished neuronal cell death in all the analyzed re-
gions and under both prolonged and acute insults (Fig. 3A–C
and Supplementary Fig. S5A–I; Prnp + /+ CA1: p = 0.03038
and p = 0.03038; Prnp0/0 CA1: p = 0.01996 and p = 0.03038;
Prnp0/0 CA3: p= 0.01894 and p = 0.0294; Prnp0/0 DG:
p = 0.01945 and p = 0.01996). Shortening the exposure time
FIG. 3. Neuronal cell death in-
duced by NMDA treatment is pre-
vented by calcium chelation and
NMDAR antagonist, unaltered by
AMPA/kainate receptor and
GluN2B-containing NMDAR an-
tagonists. Comparison of NMDA-
induced neuronal pyknotic nuclei
percentages between EGTA-trea-
ted Prnp + /+ and Prnp0/0 OHC in
the (A) CA1, (B) CA3, and (C)
DG; n = 3 OHC, 5 slices per treat-
ment in each culture. Comparison of
NMDA-induced neuronal pyknotic
nuclei percentages between
NMDAR inhibitors (AP5 and/or
CNQX)-treated Prnp + /+
and Prnp0/0 OHC in the (D) CA1,
(E) CA3, and (F) DG; n = 4 OHC,
5 slices per treatment in each cul-
ture. ComparisonofNMDA-induced
neuronal pyknotic nuclei percentages
between GluN2B inhibitor (ifenpro-
dil)-treated Prnp+ /+ and Prnp0/0
OHC in the (G) CA1, (H) CA3, and
(I) DG; n=4 OHC, 5 slices per
treatment in each culture. All error
bars indicate SD; *p<0.05. AMPA,
a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid;AP5, (2R)-
amino-5-phosphonovaleric acid;
CNQX, 6-cyano-7-nitroquinoxa-
line-2,3-dione; EGTA, ethylene
glycol tetraacetic acid. To see this
illustration in color, the reader is
referred to the web version of this
article at www.liebertpub.com/ars
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to 5 lM NMDA did not affect the differences between
Prnp + /+ and Prnp0/0 OHC.
Next, we assessed the primary involvement of NMDAR in
the neurotoxic mechanism (n= 4 OHC, 5 slices per treatment
in each culture). Adding the NMDAR blocker AP5 to 5 lM
NMDA for 3 h abolished cell death (Fig. 3D–F and Supple-
mentary Fig. S6A–F; Prnp + /+ CA1: p= 0.03038; Prnp0/0
CA1: p = 0.03038; Prnp0/0 CA3: p= 0.03038; Prnp0/0 DG:
p = 0.03038). In contrast, adding the a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)/kainate receptor
blocker 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) to
5 lM NMDA for 3 h did not diminish cell death in Prnp + /+
CA1, Prnp0/0 CA1, and Prnp0/0 CA3 (Fig. 3D, E and Sup-
plementary Fig. S6A–D). However, adding CNQX to NMDA
did reduce the pyknosis percentage inPrnp0/0 DG (p=0.03038),
suggesting a partial AMPA/kainate receptor involvement
(Fig. 3F and Supplementary Fig. S6E, F). Overall, despite the
AMPA/kainate receptor inhibition, the higher cell death
levels in PrPC-null were maintained, confirming a primary
involvement of NMDAR. To assess whether the neurotoxic
effect was mainly due to either GluN2A- or GluN2B-
containig NMDAR, we used ifenprodil, a selective inhibitor
of GluN2B. The excitotoxic condition applied was 10 lM
NMDA for 10min since ifenprodil has an aspecific toxic
effect if added to lower NMDA concentrations (20). In both
Prnp + /+ and Prnp0/0 OHC, ifenprodil did not reduce the cell
death levels observed with NMDA alone, suggesting that the
overactivation of GluN2B-containing receptor is not the
leading cause for neuronal death (Fig. 3G–I and Supple-
mentary Fig. S7). A major involvement of GluN2A-
containing receptor is therefore a more likely hypothesis.
Copper ions are required for PrPC
to support NMDAR S-nitrosylation
Copper ions are fundamental in the S-nitrosylation reac-
tion because their reduction from Cu(II) to Cu(I) allows for
the oxidation of NO and its ensuing reaction with cysteine
thiols (11, 17). Because PrPC-bound Cu(II) promotes NO
oxidation (4), PrPC is likely to promote NMDAR S-
nitrosylation through the copper ions it binds. To verify this
mechanism, we measured GluN2A and GluN1 S-nitrosylation
levels in Prnp+ /+ and Prnp0/0 OHC upon treatment with cu-
prizone (CZ), a selective copper chelator that binds Cu2+ .
Since Cu2+ promotes S-nitrosylation while Cu+ triggers de-
nitrosylation, CZ treatment specifically blocks S-nitrosylation
induction. CZ does not affect neuronal viability and
cannot cross plasma membranes (2); hence, it should not af-
fect cytoplasmic protein S-nitrosylation. Indeed, b-actin S-
nitrosylation levels were comparable among control and CZ-
treated wild-type and PrPC-null OHC, providing us with a
reliable internal control for the normalization of NMDAR S-
nitrosylation signal. Moreover, we used serum-free medium to
avoid copper content variability and thereby ensure uniform
copper chelation. In serum-freemedium, CZ binds copper ions
released in the synaptic cleft (36), thus affecting the copper-
mediated S-nitrosylation in the extracellular environment.
Prnp+ /+ and Prnp0/0 OHC were exposed to 20lM CZ for 3 h,
immediately frozen, and then processed for the detection of S-
nitrosylated proteins. As already observed in the hippocampus,
GluN2A and GluN1 S-nitrosylation was decreased in Prnp0/0
samples (Fig. 4A, B; n = 4 slice pools, p = 0.03038 and
p = 0.03038, respectively). Consistent with the hypothesized
mechanism, CZ addition reduced GluN2A and GluN1 S-
nitrosylation in Prnp+ /+ OHC ( p= 0.03038 and p= 0.03038,
respectively) but not inPrnp0/0 ones (Fig. 4A, B). Furthermore,
NMDAR S-nitrosylation levels in CZ-treated wild-type OHC
were not different from either control or CZ-treated Prnp0/0
samples. This result shows that CZ addition affects NMDARS-
nitrosylation only inwild type but not inPrnp0/0 OHC; hence, it
strongly suggests that the lower S-nitrosylation of NMDAR
subunits in Prnp0/0 samples is due to the lack of the PrPC-Cu
complex and that PrPC-bound copper ions favor the S-
nitrosylation of NMDAR. Residual GluN1 and GluN2A S-
nitrosylation is due to PrPC-independent mechanisms.
To rule out that the results observed inPrnp0/0 OHC are due
to different levels of GluN2A-containing NMDAR and nNOS
at synapses, we performed coIP assays with PSD95 using
hippocampi from postnatal day 20 (P20) mice. This age was
selected because it is close to the developmental stage of OHC
FIG. 4. Copper chelation de-
creases S-nitrosylation of GluN2A
and GluN1 in wild type but not in
Prnp0/0 OHC. (A) Signals of S-
nitrosylated fraction and corre-
sponding input of GluN2A, GluN1,
and b-actin resulting from the biotin
switch assay of Prnp+ /+ and Prnp0/0
OHC, treated and untreated with CZ;
adult wild-type hippocampus was
used as negative (- biotin) and posi-
tive control. (B)Statistical analysis of
S-nitrosylated GluN2A and GluN1
signals normalized on the corre-
sponding input and on b-actin; all
error bars indicate SD; sample size
n= 4; *p< 0.05, n.s., not statistically
significant difference. CZ, cuprizone.
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at the time of the treatment. The results revealed comparable
GluN2A,GluN1, and nNOS levels in P20Prnp+ /+ andPrnp0/0
hippocampal synapses (Supplementary Fig. S8A–C). Also, at
this developmental stage, we reasoned to exclude that the
results observed in Prnp0/0 OHC were due to different levels
of NOS activity. Like in the adult hippocampus, we observed
that b-actin S-nitrosylation levels were similar in control and
CZ-treated Prnp + /+ and Prnp0/0 OHC (Fig. 4A). Next, we
measured the consumption of NADPH and the conversion of
radiolabeled arginine to radiolabeled citrulline in P20 sam-
ples and found comparable results in Prnp + /+ and Prnp0/0
hippocampi (Supplementary Fig. S3B, C).
The neuroprotective function of PrPC
is copper-dependent
So far, we have shown that in Prnp0/0 mouse OHC,
NMDAR S-nitrosylation is not mediated by copper since it is
not lowered by CZ addition. However, CZ treatment de-
creases NMDAR S-nitrosylation in Prnp + / + mouse OHC to
the level detected in Prnp0/0 mouse OHC (Fig. 4). Since
extracellular cysteine S-nitrosylation inhibits NMDAR by
lowering the frequency of channel opening (23), we mea-
sured intracellular calcium [Ca2 + ]i waves in wild-type mouse
hippocampal neurons upon treatment with 20lM CZ, 5lM
NMDA, and 5lM NMDA + 20lM CZ (Supplementary
Materials and Methods). We found that both CZ and NMDA
triggered [Ca2 + ]i waves, but the addition of CZ to NMDA
induced a much higher [Ca2 + ]i increase (Supplementary Fig.
S9). These results indicate that copper chelation enhances
NMDAR channel opening. Consistent with this finding, it has
been reported that, upon copper chelation, wild-type hippo-
campal neurons exhibit nondesensitizing NMDAR currents
comparable to those registered in Prnp0/0 (40). Therefore, we
studied the neurotoxic effects of NMDA exposure in Prnp+ /+
and Prnp0/0 OHC in the presence of CZ (n= 4 OHC, 5 slices
per treatment in each culture). CZ treatment without NMDA
did not induce neuronal cell death in neither Prnp + / + nor
Prnp0/0 OHC (Supplementary Fig. S10A–F). Our results
confirm the neuroprotective function of PrPC through a
copper-dependent inhibition of NMDAR (Fig. 5). In
wild-type OHC CA1, copper chelation did not enhance sig-
nificantly the pyknosis, but it abolished the difference with
PrPC-null OHC CA1 (Fig. 5A, G). In wild-type OHC CA3
and DG, CZ addition to NMDA significantly increased
neuronal cell death (Fig. 5C, E, H, I; p = 0.01219, p=
0.02157). In contrast, in Prnp0/0 CA1 and DG, the copper
chelator did not alter the susceptibility of neurons to NMDA
(Fig. 5 B, F, G, I), whereas in Prnp0/0 CA3, it did decrease
neuronal cell death (Fig. 5D, H; p = 0.01219). This partial
neuroprotection exerted by CZ inPrnp0/0 CA3may be related
to a toxic effect triggered by copper ions released after
NMDAR activation in the absence of PrPC. These results
indicate that copper is neuroprotective in wild-type mouse
OHC; on the contrary, this effect is greatly reduced in PrPC-
null OHC, thus suggesting that PrPC and copper can con-
tribute to neuroprotection only if simultaneously present.
The neuroprotective function of PrPC is NO-dependent
Next, we verified the involvement of NO in PrPC neuro-
protective function. To this aim, we studied the neurotoxic
effect of NMDA exposure in Prnp + / + and Prnp0/0 OHC
in the presence of either Nx-nitro-l-arginine (NNA), which
blocks NO production by all NO synthase isoforms
(i.e., nNOS, endothelial NOS, and inducible NOS) or S-
nitrosoglutathione (GSNO), a NO donor (n= 4 OHC, 5 slices
per treatment in each culture). Both NNA and GSNO had no
toxic effect (Supplementary Fig. S10A–F). NOS inhibition by
NNA significantly enhanced cell death in all the analyzed re-
gions in wild-type hippocampal cultures (Fig. 6A, C, E, G–I;
p= 0.03038, p= 0.03038, p= 0.03038), while it had no effect in
PrPC-null OHC (Fig. 6B, D, F, G–I). GSNO addition to
NMDA significantly increased neuronal cell survival in all the
analyzed regions in PrPC-null OHC (Fig. 6B, D, F, G–I;
p= 0.01996, p= 0.03038, p= 0.03038) and also in wild-type
CA1 region (Fig. 6A, G; p= 0.03038).
These results indicate that NOS production of NO is nec-
essary to mediate PrPC neuroprotective function.
Discussion
Determining the function of PrPC is of utmost importance
to understand different neurodegeneration mechanisms, in
particular those underlying prion disorders and Alzheimer
disease (AD). In prion disorders, the loss of PrPC function
upon protein aggregation may contribute to the pathology
progression (1). PrPC has been found to play a role also in AD
(19), where it has been involved in pathological mechanisms
together with copper and NMDAR. Recent results indicate
that the interaction with Ab oligomers prevents the PrPC-Cu
complex-mediated inhibition of NMDAR, leading to over-
activation of the ion channel (40). Zamponi and colleagues
propose that PrPC bound to copper limits excessive NMDAR
activity by reducing the receptor affinity for glycine. In the
present work, we put forward an additional mechanism in
which PrPC-Cu modulates NMDAR together with NO. The
novelty of this study is represented by the description of the
functional interaction of PrPC, copper, and NO. The rele-
vance of copper, NO, and NMDAR overactivation in pro-
cesses that lead to synapse loss in AD is widely accepted (15).
In light of these premises, the mechanism we present here
may help our understanding of the pathological processes
involved in the progression of both AD and prion disorders.
Here, we argue that PrPC protects glutamatergic synapses
from excitotoxic insults by promoting NMDAR S-nitrosylation.
Figure 7 shows the proposed model for NMDAR inhibition by
PrPC. Glutamate released from the presynaptic terminal acti-
vates NMDAR with ensuing calcium influx. In the intracellular
compartment, calcium binds to CaM, and the Ca2+ /CaM com-
plex activates, among others, nNOS andAtp7a (22, 36); NO and
copper are thus released in the synaptic cleft. Because of PrPC
high affinity to copper ions (8) and high expression levels in
hippocampal synapses (31, 35), it is likely to bind copper re-
leased in the synaptic cleft. In thismilieu, PrPC-boundCu(II) can
oxidize NO to NO+ and be reduced to Cu(I) (4). This reaction
enables the electrophilic attack of NO+ on GluN2A and GluN1
extracellular cysteine thiol groups, resulting in the S-nitrosyla-
tion of NMDAR. coIP experiments of PrPC with NMDAR
subunits have yielded positive results (40), confirming the
proximity of PrPC and NMDAR subunits in lipid rafts (9, 32).
The experimental evidence we present here supports this mo-
lecular mechanism.
NMDAR regulation operated by NO reduces significantly
the neurotoxic effect induced by the overactivation of the
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NMDAR-coupled ionic channel and the ensuing excessive
calcium entry (30). S-nitrosylation diminishes the amplitude
of NMDAR-evoked currents by reducing the number of
channel openings (23). By comparing GluN2A and GluN1
S-nitrosylation levels in wild-type and PrPC-null mouse
hippocampi, we found that, in absence of PrPC, NMDAR S-
nitrosylation levels are decreased. S-nitrosylation can proceed
through different routes not involving copper (14), and PrPC-
Cu is not the only complex able to support the copper-mediated
reaction; otherwise, no S-nitrosylated NMDAR signal would
be detectable in PrPC-null samples. However, the extent of the
reduction observed is remarkable, indicating that PrPC-Cu is a
key player in this post-translational modification on NMDAR.
Since S-nitrosylation limits NMDAR overactivation, thus
staving off apoptosis, PrPC-null neurons should be more
susceptible to excitotoxicity. Consistent with this observation
and with results reported in the literature (21), we found that
PrPC ablation strongly impairs neuronal survival upon toxic
exposure to NMDA. By applying a pool of glutamate recep-
tors antagonists, we found that GluN2A-containing NMDAR
FIG. 5. Copper chelation
increases neuronal cell
death in Prnp1/1 OHC but
not in Prnp0/0. Images from
Prnp + /+ and Prnp0/0 OHC
areas are reported in rows:
(A) Prnp + / + CA1; (B)
Prnp0/0 CA1; (C) Prnp + /+
CA3; (D) Prnp0/0 CA3; (E)
Prnp + /+ DG; (F) Prnp0/0
DG. The different treatments
are reported in columns:
5 lM NMDA for 3 h, left
column; 5 lM NMDA + 20
lM CZ for 3 h, right column.
NeuN staining is displayed in
green and DAPI in red.
Confocal microscope fluo-
rescence images were ac-
quired using a 40 · /1.30 NA
oil objective. Graphs show
the comparison of the neu-
ronal pyknotic nuclei per-
centage, calculated over the
total nuclei number, between
Prnp + /+ and Prnp0/0 OHC in
CA1 (G), CA3 (H), and DG
(I); all error bars indicate
SD; sample size n = 4 OHC,
5 slices per treatment in each
culture; *p < 0.05, **p < 0.01.
To see this illustration in
color, the reader is referred to
the web version of this article
at www.liebertpub.com/ars
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were mainly responsible for increasing the cell death level in
PrPC-null neurons. These results contrast with the notion that
GluN2B-enriched extrasynaptic receptors may be key medi-
ators of neuron death (16). However, growing evidence sup-
ports an involvement of both GluN2A and GluN2B in
synaptic and extrasynaptic NMDAR-mediated excitotoxicity
(39, 41, 42). Therefore, it is plausible that a dysfunction in
GluN2A inhibition causes higher neuron death in PrPC-null
mouse OHC. Interestingly, GluN2A is the subunit containing
the cysteine residue that mediates the predominant inhibitory
effect of NO (7, 23). This regulation provides a clear link
between the increased neuron death level and the lower
NMDAR S-nitrosylation detected in PrPC-null mouse hip-
pocampus. In situ hybridization experiments have shown that
PrPC knockout mouse hippocampus has higher GluN2A
mRNA levels (27). However, we excluded the possibility that
the higher susceptibility of PrPC-null mouse OHC was due to
an overexpression of NMDAR at synapses, as we revealed
comparable levels of interaction between PSD95 and Glu-
N2A, and indirectly with GluN1, in wild-type and PrPC-null
mouse hippocampi.
By measuring GluN2A and GluN1 S-nitrosylation levels
in CZ-treated wild-type and PrPC-null mouse OHC by CZ
addition, we found that copper chelation lowers GluN2A and
GluN1 S-nitrosylation in wild-type cultures but not in PrPC-
null ones. The residual signal detected in wild-type upon
copper deprivation was not different from that in treated and
untreated PrPC knockout cultures.
In line with previously published electrophysiological re-
cordings of NMDAR currents (40), our results on S-
nitrosylation highlight that PrPC regulation of NMDAR
activity is copper dependent. Consistent with this fact, we
found that also the neuroprotective effect of PrPC requires
copper. These results convincingly indicate that in glutama-
tergic synapses, the neuroprotective action of PrPC depends
on copper ions and that, vice versa, the neuroprotective action
FIG. 6. NOS inhibition in-
creases neuronal cell death in
Prnp1/1 OHC but not in
Prnp0/0, while NO addition
enhances neuron survival
upon NMDA exposure. Ima-
ges from Prnp+ /+ and Prnp0/0
OHC areas are reported in
rows: (A) Prnp+ /+ CA1; (B)
Prnp0/0 CA1; (C) Prnp+ /+
CA3; (D) Prnp0/0 CA3; (E)
Prnp+ /+ DG; (F) Prnp0/0
DG. The different treatments
are reported in columns: 5lM
NMDA for 3 h, left column;
5lMNMDA+ 1mMNNA for
3 h, central column; 5lM
NMDA+20lMGSNOfor3 h,
right column. NeuN staining is
displayed in green and DAPI
in red. Confocal microscope
fluorescence images were ac-
quired using a 40· /1.30 NA
oil objective. Graphs show the
comparison of the neuronal
pyknotic nuclei percentage,
calculated over the total nuclei
number, between Prnp+ /+ and
Prnp0/0 OHC in CA1 (G), CA3
(H), and DG (I); all error bars
indicate SD; sample size n= 4
OHC, 5 slices per treatment in
each culture; *p<0.05. GSNO,
S-nitrosoglutathione; NNA,
Nx-nitro-L-arginine; NO, ni-
tric oxide. To see this illustra-
tion in color, the reader is
referred to the web version of
this article at www.liebertpub
.com/ars
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of copper relies on PrPC expression. This finding has relevant
implications in defining copper-mediated modulation of
NMDAR and the involvement of copper in neuroprotection,
as these functions are impaired in both AD and prion dis-
eases. Moreover, it is known that copper metabolism dys-
function is a primary cause of other pathologies, such as
Menkes’ disease (MD)—a disorder caused by a loss-of-
function mutation in the Atp7a-encoding gene that results in
altered copper trafficking (26). Indeed, hippocampal neurons
derived from a MD murine model have shown altered
NMDAR current and increased damage upon excitotoxic
stimulus (37). Strikingly, this phenotype is very similar to
that observed in PrPC-null models (21, 34, 38).
Our findings indicate that PrPC, copper, and NO regulate
NMDAR and impart neuroprotection through a common
mechanism that is likely to be lost in AD, MD, and prion
diseases, thus leading to synapse degeneration. In this mech-
anism, PrPC-bound copper ions act as electron acceptors in the
reaction between NO and NMDAR cysteine thiols. The ensu-
ing S-nitrosylation inhibits the receptor and reduces the neu-
rotoxic effect caused by its overactivation. This mechanism is
neuroprotective and crucial for normal synaptic functionality.
As in the case of NMDAR, PrPC-Cu may also promote the
S-nitrosylation of other membrane proteins. Indeed, inducing
protein S-nitrosylation may be an overarching function of
PrPC. The novel mechanism presented here may provide a
platform to investigate additional and previously unforeseen
cellular processes in which PrPC may be involved.
Materials and Methods
Animals
All experiments were performed in accordance with Eu-
ropean regulations (European Community Council Directive,
November 24, 1986 [86/609/EEC]). Experimental proce-
dures were notified to and approved by the Italian Ministry of
Health, Directorate General for Animal Health. All experi-
ments were approved by the local authority veterinary service
of Trieste, Italy, and by the Ethics Committee of the Scuola
Internazionale Superiore di Studi Avanzati (SISSA), Trieste.
All efforts were made to minimize animal suffering and to
reduce the number of animals used. Inbred FVB/N (Friend
virus B-type susceptibility-NIH) wild-type and FVB Prnp0/0
mice were used in these experiments. The FVB Prnp0/0 mice
were obtained from George A. Carlson, McLaughlin Re-
search Institute (Great Falls, MT) and were bred by back-
crossing with the original Prnp0/0 mice at least 20 times (25).
S-nitrosylated protein detection: biotin switch assay
The biotin switch assay was performed, as described by
Jaffrey and Snyder (18) with a few modifications. Mouse
FIG. 7. Mechanism of PrPC-mediated S-nitrosylation of NMDAR. Glutamate released from the presynaptic terminal
activates NMDAR on the postsynaptic terminal. NMDAR activation triggers Na + and Ca2 + influx, together with K+ efflux.
In the intracellular compartment, Ca2 + ions bind different proteins, including calmodulin (CaM). The Ca2 + /CaM complex
activates, among others, neuronal nitric oxide synthase (nNOS) and copper-transporting ATPase 1 (Atp7a): nNOS acti-
vation results in NO release in the synaptic cleft; Atp7a activation in the trans-Golgi network (TGN) results in Cu2 + release
in the synaptic cleft. Released Cu2 + ions are immediately bound by copper-binding proteins: PrPC is highly expressed in
both presynaptic and postsynaptic terminals, and it can be included in lipid raft domains that also contain NMDARs, and it
has high affintiy for both Cu2 + and Cu + . Released NO can react with extracellular cysteines thiols of NMDAR subunits
GluN1 and GluN2A, leading to cysteines S-nitrosylation (SNO-Cys). The S-nitrosylation inhibits NMDAR activation by
closing the channel. The chemical reaction between NO and the cystein thiol requires the presence of an electron acceptor,
often represented by Cu2 + . According to this model, PrPC brings the Cu2 + ions that support the reaction of NO with thiols,
leading to the S-nitrosylation of GluN1 and GluN2A, thus inhibiting NMDAR. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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hippocampal samples (age-matched samples from 6-, 10-,
and 12-month-old male animals) were dissected, immedi-
ately frozen in liquid nitrogen, and stored at - 80C. Each
hippocampus was homogenized in 400 ll HEN buffer:
250mM HEPES pH 7.5 (H3375; Sigma-Aldrich, St Louis,
MO), 1mM EDTA (E6758; Sigma-Aldrich), 0.1mM neo-
cuproine (N1501; Sigma-Aldrich), protease inhibitors cock-
tail (Roche Diagnostics Corp., Mannheim, Germany), and
centrifuged at 2000 g, 10min at 4C. To evaluate the role of
copper in NMDAR S-nitrosylation, Prnp+ /+ and Prnp0/0 OHC
were treated for 3 h with 20lM CZ (14690; Sigma-Aldrich)
from the 4mM stock in 50% ethanol, then immediately frozen.
For each experiment, at least 60 slices per group were collected
and homogenized in 100ll HEN buffer by sonication. Protein
concentration in the supernatant was determined by bicincho-
ninic acid assay and the same amount of proteins per sample
was used for the further steps of the protocol (1mg for hip-
pocampal samples and 0.7–1mg for OHC depending on the
lowest sample concentration in each experiment). All the re-
agents were used proportionally. Samples were diluted to
0.8lg/ll in HEN buffer+ 0.04% CHAPS (C9426; Sigma-
Aldrich) and incubated at 50C for 1 h in 4 volumes of blocking
solution: 9 volumes of HEN, 1 volume of 25% w/v SDS
(L3771; Sigma-Aldrich) in ddH2O, and 20mM S-methyl
thiomethanesulfonate (64306; Sigma-Aldrich) from the 2 M
stock solution in dimethylformamide. S-methyl thiomethane-
sulfonate was removed by acetone precipitation and the protein
pellet was resuspended in 100ll of HENS buffer (HEN+ 1%
SDS) per mg of starting proteins. To selectively and effi-
ciently reduce S-nitrosylated thiols, ascorbate (A4034; Sigma-
Aldrich), prepared as 180mM in ddH2O, was added to 30mM
final concentration in the samples, and the reaction was carried
out for 3 h at 25C (14). A negative control without ascorbate
was performed on Prnp+ /+ samples to check the efficiency of
thiols blockingwith S-methyl thiomethanesulfonate. Ascorbate
was removed by acetone precipitation and the protein pellet
was resuspended in 100ll of HENS buffer per mg of starting
proteins. EZ-Link HPDP-biotin (21341; Thermoscientific,
Waltham, MA) was used to bind free thiols, corresponding to
the previously S-nitrosylated residues. It was added 1:3 to the
samples from the 4mM stock in dimethylformamide. A neg-
ative control without biotin was performed on Prnp+ /+ sam-
ples to check the selective binding to the resin. After 1 h
incubation at 25C, HPDP-biotin was removed by dialysis in
HENS buffer. To purify biotinylated proteins, 2 volumes of
neutralization buffer (20mM HEPES pH 7.5, 100mM NaCl,
1mM EDTA, 0.5% Triton X-100 [X100; Sigma-Aldrich]) and
50ll of wet Immobilized NeutrAvidin Agarose (29200;
Thermoscientific) were added to the samples and incubated for
2 h at room temperature (RT). Resin was washed 5 times with
neutralization buffer adjusted to 600mM NaCl; biotinylated
proteins were eluted directly in SDS-PAGE sample buffer,
boiled, and processed for Western blot detection. For each
sample, 30lg of protein extract were loaded as input. The
following primary antibodies were used: anti-GluN1 1:500–
1:2000 (G8913; Sigma-Aldrich); anti-GluN2A 1:500–1:2000
(G9038; Sigma-Aldrich); monoclonal anti-PrP SHA31 1lg/
ml (A03213; BertinPharma,Montigny le Bretonneux, France);
anti-b-actin Peroxidase (AC-15) 1:10,000 (A3854; Sigma-
Aldrich). After incubation with the secondary antibody,
membranes were developed with the ECL detection reagent
(GE Healthcare, Waukesha, WI) and recorded by the digital
imaging system Alliance 4.7 (UVITEC, Cambridge, United
Kingdom). Band quantification was performed with Uviband
15.0 software (UVITEC) obtaining an optical density (OD)
value. To normalize OD values, the following formula was
applied: (NMDAR subunit S-nitrosylation/input)/(b-actin S-
nitrosylation/input). Basically, S-nitrosylation signals were
normalized on the corresponding input. Then, NMDAR sub-
unit values were normalized on b-actin value. Prnp+ /+ and
Prnp0/0 samples were compared by the Mann–Whitney test
setting F(x)< >G(x) as alternate hypothesis.
Organotypic hippocampal cultures
preparation and treatments
OHC preparation protocol was set up based on Gahwiler’s
protocol (13). Briefly, in aseptic condition, P5 mouse hip-
pocampus was dissected in the dissection medium (Gey’s
balanced salt solution, 5.6mM d-glucose [G8270; Sigma-
Aldrich], 1mM kynurenic acid [K3375; Sigma-Aldrich]) and
sliced by means of a tissue chopper into 300-lm-thick sec-
tions. After washing in the dissection medium for 40min at
4C, slices showing an intact hippocampal cytoarchitecture
were selected, singularly attached to a coverslip by embed-
ding in a chicken plasma (P3266; Sigma-Aldrich) and
thrombin clot (112374; Merck KGaA, Darmstadt, Germany)
and maintained at 10 rotations per hour at 37C in Nunc cell
culture tubes (156758; Thermoscientific) with a medium
composed of 50% basal medium Eagle (41010026; Gibco,
Carlsbad, CA), 25% horse serum (26050-088; Gibco), 25%
Hank’s balanced salt solution (24020141; Gibco), 5.6mM d-
glucose, 2mM l-glutamine (25030-032; Gibco). After 13
days in vitro, OHCwere treated in the serum-free medium, as
described in Supplementary Table S1. The drug stock solu-
tions were prepared as follows: 1mM NMDA (0114; Tocris
Biosciences, Missouri, United Kingdom) in ddH2O stored at
- 20C; 250mM EGTA (E4378; Sigma-Aldrich) in phos-
phate-buffered saline (PBS), pH 7.4, stored at RT; 40mM
CNQX (C239; Sigma-Aldrich) in dimethyl sulfoxide
(DMSO, D8418; Sigma-Aldrich) stored at - 20C; 10mM
(2R)-amino-5-phosphonovaleric acid (AP5, A5282; Sigma-
Aldrich) in ddH2O stored at - 20C; 5mM threo ifenprodil
hemitartrate (2892; Tocris Biosciences) in ddH2O stored at -
20C; 10mM GSNO (N4148; Sigma-Aldrich) in ddH2O
stored at - 20C; freshly prepared three NNA (N5501; Sig-
ma-Aldrich) in serum-free medium; freshly prepared 4mM
CZ in 50% ethanol. To induce excitotoxicity, OHC were
exposed either to 5 lMNMDA for 3 h or to 10 lMNMDA for
10min. Experiments with EGTA were performed using
2mM EGTA in combination with either 5 lM NMDA for
1.5 h (EGTA treatment for 3 h was toxic for OHC) or 10 lM
NMDA for 10min. Treatments with 5lM NMDA in com-
bination with either 50lM AP5 or 20 lM CNQX or 20 lM
GSNO or 1mMNNA or 20 lMCZwere incubated for 3 h. To
obtain a more complete inhibition, AP5, CNQX, and NNA
were preincubated for 30min before adding NMDA. Treat-
ments with NMDA and ifenprodil were carried out differ-
ently because of the toxic effect of ifenprodil when associated
to low NMDA concentrations (20). For this reason, OHC
were exposed to 10lM NMDA and 3 lM ifenprodil for
10min. To evaluate neuronal cell death, all the described
treatments were followed by a 24 h washout before proces-
sing OHC for immunofluorescence.
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Immunofluorescence
To evaluate neuronal cell death, slices were fixed in 4%
paraformaldehyde (P6148; Sigma-Aldrich) in PBS, pH 7.4,
O/N at 4C. To improve the nuclear staining, slices were
treated as follows: 3 · 5min washes in PBS with 1% Triton
X-100, 10min in 0.1N HCl at 4C, 10min in 0.2N HCl at
RT, 20min in 0.2N HCl at 37C, 12min in borate buffer pH
8.4 at RT, 3 · 5min washes in PBS with 1% Triton X-100.
Slices were incubated for 2 h at RT in the blocking solution
(1M glycin [G8898; Sigma-Aldrich], 5% normal goat serum
[005-000-121; Jackson ImmunoResearch] in PBS with 1%
Triton X-100) and O/N at 4Cwith anti-neuronal nuclei (NeuN)
cloneA60 antibody 1:500 (mab377;Millipore, Billerica,MA) in
the blocking solution. Afterwashingwith PBS and 1%TritonX-
100, slices were incubated with Alexa fluorophore-conjugated
secondary antibodies (1:500, R37120; Invitrogen, Carlsbad,
CA) and 4¢,6-diamidino-2-phenylindole (DAPI, 1:500) in the
blocking solution for 2 h at RT. Slices were washed in PBS,
rinsed in water, and mounted with VectaShield (Vector La-
boratories, Burlingame, CA).
Confocal microscopy, image analysis,
and statistics of OHC experiments
Immunofluorescence images were acquired on a Leica
DMIRE2 confocal microscope (Leica Microsystem GmbH,
Wetzlar, Germany) equipped with DIC and fluorescent op-
tics, diode laser 405 nm, and Ar/ArKr 488 nm lasers. The
fluorescence images (1024 · 1024 pixels) were acquired with
a 40 · /1.30 NA oil objective, additionally zoomed 1.5-fold,
with 200Hz acquisition speed. Stacks of z-sections with an
interval of 3 lm were sequentially scanned. CA1, CA3, and
DG were the regions selected for the analysis. A protocol
for automatic count of the total amount of nuclei was set up
for each hippocampal zone with the Volocity 5.4 3D imaging
software (PerkinElmer, Coventry, United Kingdom). The
same software was used to manually count the pyknotic nu-
clei. The dead cell count was performed as a blind analysis.
The CA1, CA3, and DG regions were clearly distinguishable
in OHC used in these experiments (Supplementary Fig.
S11A) and the staining protocol allowed for the exact iden-
tification of neuronal pyknotic nuclei (Supplementary Fig.
S11B). Pyknotic nuclei count results for Prnp + / + and Prnp0/0
OHC were compared by performing the Mann–Whitney test
setting F(x) < >G(x) as alternate hypothesis. Each culture
preparation (resulting from three to four mice dissection) was
considered as one sample (n = 1). In each culture, the average
pyknotic nuclei percentage among the hippocampal slices
(four to five slices) of the same treatment group was calcu-
lated, grouped with values obtained from other OHC of the
same genotype with the same treatment for a final sample size
of four (n= 4) and compared with the other treatments and
genotype by means of the Mann–Whitney test.
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Abbreviations Used
AD¼Alzheimer disease
AP5¼ (2R)-amino-5-phosphonovaleric acid
Atp7a¼ copper-transporting ATPase 1
CA1¼Cornus Ammonis 1
CA3¼Cornus Ammonis 3
CaM¼ calmodulin
CNQX¼ 6-cyano-7-nitroquinoxaline-2,3-dione
coIP¼ co-immunoprecipitation
CZ¼ cuprizone
DAPI¼ 4¢,6-diamidino-2-phenylindole
DG¼ dentate gyrus
DMSO¼ dimethyl sulfoxide
EGTA¼ ethylene glycol tetraacetic acid
GluN1¼NMDAR subunit GluN1
GluN2A¼NMDAR subunit GluN2A
GSNO¼ S-nitrosoglutathione
MD¼Menkes’ disease
MTT¼ 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
NeuN¼ anti-neuronal nuclei marker antibody
NMDA¼N-methyl-d-aspartate
NMDAR¼N-methyl-d-aspartate receptors
NNA¼Nx-nitro-l-arginine
nNOS¼ neuronal nitric oxide synthase
NO¼ nitric oxide
OD¼ optical density
OHC¼ organotypic hippocampal cultures
Prnp+=+, Prnp0=0¼ PrPC wild type, PrPC knockout
PrPC¼ cellular prion protein
PSD95¼ postsynaptic density protein 95
SNO-Cys¼ cysteine S-nitrosylation
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Supplementary Data
Supplementary Materials and Methods
Protein S-nitrosylation detection by SNOB1 reagent
To compare GluN2A and GluN1 S-nitrosylation levels in
Prnp+ /+ and Prnp0/0 hippocampi, we used the SNOB1 re-
agent (sc-361363; Santa Cruz Biotechnology, Dallas, TX).
Two Prnp+ /+ and two Prnp0/0 hippocampi were separately
homogenized in 1 ml phosphate-buffered saline (PBS)+ 0.5%
Triton X-100+ protease inhibitors and centrifuged for 10 min
at 5000 rpm at 4C. Protein concentration in the supernatant
was determined by bicinchoninic acid assay, and the same
amount of protein was used as input for the following steps.
Half of the protein extract was added to PBS+ 0.5% Triton up
to 1 ml and incubated with 0.5 mM SNOB1 for 30 min at 37C
in the dark according to the manufacturer’s instructions. The
second half of the sample was added to PBS+ 0.5% Triton up
to 1 ml and incubated with 0.5 mM biotin for 30 min at 37C in
the dark, as negative control. To purify SNOB1-bound pro-
teins, 50ll of wet Immobilized NeutrAvidin Agarose (29200;
Thermoscientific, Waltham, MA) were added to the samples
and incubated for 2 h at room temperature (RT). Resin was
washed five times PBS+ 0.5% Triton. Then, proteins were
eluted directly in SDS-PAGE sample buffer, boiled, and
processed for Western blot detection. For each sample, 30lg
of protein extract was loaded as input. The following primary
antibodies were used: anti-GluN1 1:500–1:2000 (G8913;
Sigma-Aldrich, St Louis, MO); anti-GluN2A 1:500–1:2000
(G9038; Sigma-Aldrich); anti-b-actin peroxidase (AC-15)
1:10,000 (A3854; Sigma-Aldrich). After incubation with the
secondary antibody, membranes were developed with the
ECL detection reagent (GE Healthcare, Waukesha, WI) and
recorded by the digital imaging system Alliance 4.7 (UVI-
TEC, Cambridge, United Kingdom). Band quantification was
performed with Uviband 15.0 software (UVITEC) obtaining
an optical density (OD) value. To normalize OD values, the
following formula was applied: (SNOB1-NMDAR subunit/
input)/(SNOB1-b-actin/input). Basically, S-nitrosylation sig-
nals were normalized on the corresponding input. Then, N-
methyl-d-aspartate receptors (NMDAR) subunit values were
normalized on b-actin value. Prnp+ /+ and Prnp0/0 samples
were compared by the Mann–Whitney test setting F(x)< >
G(x) as alternate hypothesis.
Co-immunoprecipitation
To compare GluN2A, GluN1, and neuronal nitric oxide
synthase (nNOS) synaptic levels in Prnp+ /+ and Prnp0/0 hip-
pocampi, we performed a co-immunoprecipitation (coIP) with
postsynaptic density protein 95 (PSD95). Samples from 6-, 10-,
and 12-month-old male mice were used to parallel the biotin
switch assay experiments, while postnatal day 20 (P20) mouse
hippocampi were used to parallel organotypic hippocampal
cultures (OHC) excitotoxicity studies. Samples were homog-
enized in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 0.5% CHAPS, 10% glycerol, protease inhibitor cock-
tail, 5 mM NaF (S7920; Sigma-Aldrich), 0.5 mM Na3VO4
(S6508; Sigma-Aldrich), protein concentration was evaluated
by the BCA assay to use the same amount of proteins in each
sample. For PSD95 coIP with GluN2A (direct interaction) and
GluN1 (indirect interaction), hippocampal protein extracts
were precleared by 30 min incubation at 4C with protein A/G
(1:2) resin (17-5138-01 and 17-0618-01; GE Healthcare,
Waukesha, WI). Then, the samples were incubated for 2.5 h at
4C with 2lg/ml of either anti-PSD95 antibody (ab2723;
Abcam, Cambridge, United Kingdom) or normal mouse IgG
(mIgG, 12-371; Millipore, Billerica, MA), followed by 2 h in-
cubation with protein A/G (1:2) resin. For nNOS coIP with
PSD95, hippocampal protein extracts were incubated O/N at
4C with 2lg/ml of either anti-nNOS antibody (4234; Cell
Signaling, Danvers, MA) or normal rabbit IgG (rIgG, 12-370;
Millipore), followed by 2 h incubation with protein A/G (1:2)
resin. Proteins eluted from the resin were processed for stan-
dard Western blot protocol and revealed with anti-GluN1
1:2000 (G8913; Sigma-Aldrich), anti-GluN2A 1:2000 (G9038;
Sigma-Aldrich), anti-nNOS, anti-PrP SHA31 1lg/ml
(A03213; BertinPharma, Montigny le Bretonneux, France),
and anti-PSD95 antibodies. After incubation with the second-
ary antibody, membranes were developed with the ECL de-
tection reagent (GE Healthcare) and recorded by Alliance 4.7
digital imaging system (UVITEC). Band quantification was
performed with Uviband 15.0 software (UVITEC) obtaining
an OD value. To normalize OD values, the following formula
was applied: (co-immunoprecipitated protein/input)/
(immunoprecipitated protein/input), that is, [GluN2A (or
GluN1) coIP/input]/[PSD95 IP/input] and (PSD95 coIP/in-
put)/(nNOS IP/input). Then, Prnp + / + and Prnp0/0 samples
were compared by the Mann–Whitney test setting F(x)< >
G(x) as alternate hypothesis.
NADPH consumption assay
To estimate Prnp + /+ and Prnp0/0 nNOS activity level, we
evaluated the kinetics of NADPH consumption. Samples
from 6-month-old and P20 male mice were used to parallel
the biotin switch assay experiments and OHC excitotoxicity
studies, respectively. Samples were homogenized in 30 mM
Tris-HCl, pH 7.5, and protease inhibitor cocktail and
centrifuged at 10,000 g; the supernatant was used for the
assay. The protein concentration was evaluated by the BCA
assay to use the same amount of proteins in each sample
(*1 mg). Five mM NADPH (481973; Millipore) was pre-
pared in ddH2O and added to each sample to 0.5 mM final
concentration. The kinetics of NADPH consumption was
evaluated by measuring the absorbance at 340 nm each
minute for 30 min. For each sample, the respective absor-
bance without NADPH addition was subtracted as blank to
avoid differences in tissue scattering.
NOS activity assay
To measure Prnp + / + and Prnp0/0 NOS activity level,
we used the NOS activity assay kit (Item Number 781001;
Cayman, Ann Arbor, MI). Samples from 6-month-old and
P20 male mice were used to parallel the biotin switch
assay experiments and OHC excitotoxicity studies, re-
spectively. We used the radiolabeled substrate [3H]Argi-
nine monohydrochloride (40–70 Ci/mmol, 1 lCi/ll [Item
No. NET1123001MC; Perkin Elmer, Waltham, MA]). The
assay was run according to the manufacturer’s instruc-
tions. Results are reported as counts per minute (cpm)
subtracted of the blank-corresponding cpm value. As
control of the specificity of the assay for the NOS activity,
we measured the conversion of radiolabeled arginine in
radiolabeled citrulline in the presence of the NOS blocker
Nx-nitro-l-arginine (NNA, N5501; Sigma-Aldrich).
MTT mitochondrial toxicity assay
To evaluate the early phase of change in neuronal cell via-
bility, the MTT (Thiazolyl Blue Tetrazolium Bromide) mito-
chondrial toxicity assay was performed on OHC after exposure
to an excitotoxic stimulus. The MTT assay was set up following
the protocol by Mazzone (1) with a few modifications. A 5 mg/
ml MTT (M5655; Sigma-Aldrich) stock solution was prepared
in PBS, pH 7.4. After 13 days in vitro, Prnp+ /+ and Prnp0/0
OHC were exposed to 5lM NMDA in serum-free medium for
3 h. After one wash, OHC were incubated with 0.5 mg/ml MTT
in serum-free medium for 2 h at 37C. To dissolve formazan
crystals, OHC were incubated overnight at 37C with 1 ml of
acidified isopropanol (0.04 N HCl in isopropanol). Absorbance
values were measured at 570 and 690 nm. The 690 nm absor-
bance value was used as background, hence subtracted to the
570 nm signal. Cell viability was expressed as percentage of the
control OHC value that was considered to be 100% viable and
compared by the Mann–Whitney test setting F(x)< >G(x) as
alternate hypothesis.
Primary cell culture preparation and measurement
of relative intracellular Ca2 + [Ca2+ ]i changes
after NMDA and cuprizone treatment
Primary cell cultures were prepared from wild-type
mouse hippocampal neurons. Hippocampi were dissected
from P1 rats in the presence of 100 lM kynurenic acid and
25 lM 2-amino-5-phosphonovaleric acid (Tocris Bios-
ciences, Missouri, United Kingdom). The isolated tissue
was quickly sliced and digested with trypsin in the presence
of DNAse. After stopping the digestion with trypsin inhib-
itor, cells were triturated in the dissection medium con-
taining DNAse. After centrifugation, the resuspended cell
pellet was distributed to 24-well Nunc cell culture mul-
tidishes previously coated with polyornithine (0.5 mg/ml)
and Matrigel (2% [w/v]; BD Biosciences, San Jose, CA),
each one containing 0.5 ml of modified minimal essential
medium supplemented with dialyzed fetal bovine serum
(Gibco, Carlsbad, CA). Two days after plating, the culture
medium was supplemented with 2.5 lM Arabinosylcytosine
(Sigma), which inhibits the growth of glial cells. The culture
medium was exchanged every 2–3 days. The experiments
were performed after 15 days in vitro. Primary culture
neurons were washed, exposed to Fluo-3 AM (F-1242; Life
Technologies, Carlsbad, CA), the dye indicator, for 60 min
at 37C, washed two times, equilibrated for 30 min at 22C,
and washed. [Ca2 + ]i levels were determined as described by
Tauskela et al. with a few modifications (2) by using tem-
perature-controlled plate reader (EnSpire; Perkin Elmer) to
measure fluorescence intensity (excitation wavelength
488 nm; emission wavelength 526 nm). Fluorescence in-
tensities were measured from 19 locations within each well
before the treatment and 0, 5, 10, and 15 min after the
treatment (control, 20 lM cuprizone [CZ], 5 lM NMDA,
5 lM NMDA + 20 lM CZ). The background intensity was
measured in cell-free plate with dye-free buffer. The fold
increase in [Ca2 + ]i levels was calculated by subtracting the
background intensity and normalizing on the resting con-
ditions in each well.
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Supplementary Table S1. Organotypic Hippocampal Culture Treatments
Drug Control Pretreatment Treatment
Washout
(h)
Excitotoxic stimulus
5 lM NMDA ddH2O — 10 min 24
10 lM NMDA ddH2O — 3 h 24
Calcium chelation
10 lM NMDA + 2 mM EGTA 10 lM NMDA; 2 mM EGTA;
PBS pH 7.4
— 10 min 24
5 lM NMDA + 2 mM EGTA 5 lM NMDA; 2 mM EGTA;
PBS pH 7.4
— 1.5 h 24
NMDA receptor inhibition
5 lM NMDA + 50 lM AP5 5 lM NMDA; 50 lM AP5;
ddH2O
30 min AP5 3 h 24
AMPA/kainate receptor inhibition
5 lM NMDA + 20 lM CNQX 5 lM NMDA; 20 lM CNQX;
0.002% DMSO
30 min CNQX;
30 min 0.002%
DMSO
3 h 24
GluN2B-containing NMDA receptor inhibition
10 lM NMDA + 3 lM ifenprodil 10 lM NMDA; 3 lM
ifenprodil; ddH2O
— 10 min 24
Copper chelation
5 lM NMDA + 20 lM CZ 5 lM NMDA; 20 lM CZ;
50% EtOH
— 3 h 24
nNOS inhibition
5 lM NMDA + 1 mM NNA 5 lM NMDA; 1 mM NNA 30 min 1 mM NNA 3 h 24
NO donor
5 lM NMDA + 20 lM GSNO 5 lM NMDA; 20 lM
GSNO; ddH2O
— 3 h 24
AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AP5, (2R)-amino-5-phosphonovaleric acid; CNQX, 6-cyano-7-
nitroquinoxaline-2,3-dione; CZ, cuprizone; DMSO, dimethyl sulfoxide; EGTA, ethylene glycol tetraacetic acid; EtOH, ethanol; GSNO,
S-nitrosoglutathione.; NMDA, N-methyl-d-aspartate; NNA, Nx-nitro-l-arginine; nNOS, neuronal nitric oxide synthase; NO, nitric oxide;
PBS, phosphate-buffered saline.
SUPPLEMENTARY FIG. S1. NMDAR subunit S-ni-
trosylation levels comparison in wild-type and PrPC
knockout hippocampi by SNOB1 reagent. (A) Im-
munoblot signals corresponding to SNOB1-bound GluN2A,
GluN1, and b-actin in Prnp + / + and Prnp0/0 hippocampi. (B)
Graph showing the quantification of the immunoblot signals
normalized according to the following formula: (SNOB1-
NMDAR subunit/input)/(SNOB1-b-actin/input); all error
bars indicate SD; n = 4; *p < 0.05. NMDAR, N-methyl-d-
aspartate receptors.
SUPPLEMENTARY FIG. S2. CoIP of GluN2A and
GluN1 with PSD95 and coIP of PSD95 with nNOS show
comparable levels in adultPrnp1/1 andPrnp0/0 hippocampi.
(A) coIP of GluN2A and GluN1 with PSD95. (B) coIP of
PSD95 with nNOS. (C) Graph showing the quantification of
the coIP signals normalized according to the following formu-
la: (co-immunoprecipitated protein/input)/(immunoprecipitated
protein/input); all error bars indicate SD; n = 3. coIP, co-
immunoprecipitation; nNOS, neuronal nitric oxide synthase;
PSD95, postsynaptic density protein 95.
SUPPLEMENTARY FIG. S3. NADPH consumption
assay and radiolabeled arginine conversion in citrulline
shows comparable NOS activity levels in Prnp1/1 and
Prnp0/0 mice. (A) NADPH consumption assay in P180
Prnp + / + and Prnp0/0 samples; (B) NADPH consumption
assay in P20 Prnp + /+ and Prnp0/0 samples; all error bars
indicate SD; n = 3; (C) radiolabeled citrulline level mea-
surements in P20 and 6-month-old Prnp + /+ and Prnp0/0
mouse samples; all error bars indicate SD; n = 4; black
columns correspond to Prnp + / + mice, white columns cor-
respond to Prnp0/0 mice, gray columns correspond to the
control with NNA. NNA, Nx-nitro-l-arginine.
SUPPLEMENTARY FIG. S4. The MTT assay con-
firms PrPC-null OHC higher susceptibility to ex-
citotoxicity compared with wild-type OHC in the early
phase after NMDA treatment. The graph shows the cell
viability percentage in Prnp + / + and Prnp0/0 OHC treated
and not treated with 5 lM NMDA for 3 h; all bars indicate
SD; n= 12; **p< 0.01. OHC, organotypic hippocampal
cultures.
SUPPLEMENTARY FIG. S5. Neuronal cell death induced by NMDA treatment is prevented by calcium chelation.
Images from Prnp + / + and Prnp0/0 OHC areas are reported in rows: (A) Prnp + /+ CA1; (B) Prnp0/0 CA1; (C) Prnp + /+ CA3;
(D) Prnp0/0 CA3; (E) Prnp + /+ DG; (F) Prnp0/0 DG. The different treatments are reported in columns: 2 mM EGTA for
1.5 h, first column; 5 lM NMDA for 1.5 h, second column; 5 lM NMDA + 2 mM EGTA for 1.5 h, third column; 10lM
NMDA for 10 min, fourth column; 10 lM NMDA + 2 mM EGTA for 10 min, fifth column. NeuN staining is displayed in
green and DAPI in red. Confocal microscope fluorescence images were acquired using a 40 · /1.30 NA oil objective.
Comparison of neuronal pyknotic nuclei percentages induced by 10lM NMDA for 10 min, between EGTA-treated Prnp + /+
and Prnp0/0 OHC in the (G) CA1, (H) CA3, and (I) DG; n = 4 OHC, 5 slices per treatment in each culture; all error bars
indicate SD; *p < 0.05. CA1, Cornus Ammonis 1; CA3, Cornus Ammonis 3; DAPI, 4¢,6-diamidino-2-phenylindole; DG,
dentate gyrus; EGTA, ethylene glycol tetraacetic acid.
SUPPLEMENTARY FIG. S6. Neuronal cell death induced by NMDA treatment is prevented by NMDAR antagonist
and unaltered by AMPA/kainate receptor antagonist. Images from Prnp+ /+ and Prnp0/0 OHC areas are reported in rows:
(A) Prnp+ /+ CA1; (B) Prnp0/0 CA1; (C) Prnp+ /+ CA3; (D) Prnp0/0 CA3; (E) Prnp+ /+ DG; (F) Prnp0/0 DG. The different
treatments are reported in columns: 0.002% DMSO for 3 h, first column; 50lM AP5 for 3 h, second column; 20lM CNQX for
3 h, third column; 5lM NMDA for 3 h, fourth column; 5lM NMDA+ 50lM AP5 for 3 h, fifth column; 5lM NMDA+ 20lM
CNQX for 3 h, sixth column. NeuN staining is displayed in green and DAPI in red. Confocal microscope fluorescence images
were acquired using a 40· /1.30 NA oil objective. AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AP5, (2R)-
amino-5-phosphonovaleric acid; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; DMSO, dimethyl sulfoxide.
SUPPLEMENTARY FIG. S7. Neuronal cell death in-
duced by NMDA treatment is unaltered by GluN2B-
containing NMDAR antagonist. Images from Prnp + / + and
Prnp0/0 OHC areas are reported in rows: (A) Prnp + / + CA1;
(B) Prnp0/0 CA1; (C) Prnp + / + CA3; (D) Prnp0/0 CA3; (E)
Prnp + /+ DG; (F) Prnp0/0 DG. The different treatments are
reported in columns: 3 lM Ifenprodil for 10 min, left col-
umn; 10 lM NMDA for 10 min, central column; 5 lM
NMDA + 3 lM Ifenprodil for 10 min, right column. NeuN
staining is displayed in green and DAPI in red. Confocal
microscope fluorescence images were acquired using a
40 · /1.30 NA oil objective.
SUPPLEMENTARY FIG. S8. CoIP of GluN2A and
GluN1 with PSD95 and coIP of PSD95 with nNOS show
comparable levels in P20 Prnp1/1 and Prnp0/0 hippocampi.
(A) coIP of GluN2A and GluN1 with PSD95. (B) coIP of
PSD95 with nNOS. (C) Graph showing the quantification of the
coIP signals normalized according to the following formula:
(co-immunoprecipitated protein/input)/(immunoprecipitated
protein/input); all error bars indicate SD; n=3.
SUPPLEMENTARY FIG. S9. Copper chelation in-
creases NMDA-induced [Ca21]i waves. The graph shows
fluorescence intensity subtracted of the background intensity
and normalized on resting condition measurements. The
dashed line indicates the untreated cell fluorescence.
SUPPLEMENTARY FIG. S10. Treatments with CZ, NNA, and GSNO do not affect neuron health. Images from
Prnp + /+ and Prnp0/0 OHC areas are reported in rows: (A) Prnp + /+ CA1; (B) Prnp0/0 CA1; (C) Prnp + /+ CA3; (D) Prnp0/0
CA3; (E) Prnp + /+ DG; (F) Prnp0/0 DG. The different treatments are reported in columns: control, first column; 20lM CZ
for 3 h, second column; 1 mM NNA for 3 h, third column; 20 lM GSNO for 3 h, fourth column. NeuN staining is displayed
in green and DAPI in red. Confocal microscope fluorescence images were acquired using a 40 · /1.30 NA oil objective. CZ,
cuprizone; GSNO, S-nitrosoglutathione.
SUPPLEMENTARY FIG. S11. Description of the OHC system. (A) OHC staining with DAPI (in red) and anti-NeuN
antibody (in green). Confocal microscope fluorescence images were acquired using a 10 · /0.30 NA dry objective. (B)
Example of discrimination between healthy and pyknotic neuronal nuclei. Neurons are indicated by white arrows, while glia
cells are indicated by dashed arrows. DAPI is displayed in red and anti-NeuN antibody staining in green. Confocal
microscope fluorescence images were acquired using a 63 · /1.40 NA oil objective.
